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“When you reach for the stars, you may not quite get 
one, but you won't come up with a handful of mud 
either.”  
-Leo Burnett 
 
 
"Simple vs. Complex Traits:  the real definition: 
Simple: things we have deluded ourselves into 
thinking we understand.  
Complex: things we're pretty sure we don't 
understand." 
-Eleanor Feingold 
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ABSTRACT 
Migraine with aura (MA) is a common headache disorder with a population prevalence of 
approximately 5%. This subtype of migraine is characterized by neurological, typically visual, 
symptoms that precede the headache. Twin and family studies have provided strong evidence 
of genetic factors in MA susceptibility and have shown that the mode of inheritance is most 
likely multifactorial. Furthermore, mutations in the CACNA1A and ATP1A2 genes have been 
shown to cause a rare monogenic subtype of MA, familial hemiplegic migraine (FHM). The 
FHM1 gene, CACNA1A, is particularly interesting since mutations in it can also cause another 
related neurological phenotype, episodic ataxia type 2 (EA-2), also under investigation in this 
thesis. 
 
This study aimed at identifying genetic loci and variants that are involved in the etiology of 
MA. We have collected almost 700 Finnish families segregating this disorder and performed a 
genome-wide scan in 50 of these families. Strong evidence of linkage to chromosomal area 
4q21-24 was obtained. Encouragingly, this finding has been subsequently replicated in the 
Icelandic population. The actual causative variant has, however, not yet been identified 
despite substantial efforts.  
 
In an alternative study approach, the role of certain candidate loci and genes previously 
associated with migraine has been investigated in our large family and patient samples. A 
susceptibility locus on chromosome 19p13 contains two migraine-associated genes, 
CACNA1A (the FHM1 gene) and INSR encoding an insulin receptor. In the present study, this 
susceptibility locus was studied in 72 Finnish MA families but no evidence of linkage was 
seen. Furthermore, the association of genetic variants in candidate genes MTHFR (coding for 
a methylenetetrahydrofolate reductase) and ESR1 (coding for an estrogen receptor) with 
migraine was studied in 898 unrelated MA patients and 900 healthy controls. The previously 
migraine-associated polymorphisms showed no association with MA while some nominal 
evidence of association between MA and five other ESR1 variants was seen.  
 
In addition, the first Finnish families with FHM and EA-2 phenotypes were identified and 
studied in this thesis. The FHM family was shown to have a novel missense mutation in the 
ATP1A2 gene whereas the EA-2 phenotype was caused by a splice site mutation in the 
CACNA1A gene.  
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INTRODUCTION 
The human brain performs all the necessary functions that make us who we are, ranging from 
sensing, locomotion, and emotion to learning and memory. The cellular and molecular 
networks needed for these functions are extremely complex and delicately controlled. 
Because of this complexity, the nervous system seems to be especially vulnerable to 
mutations and the number of neurological diseases caused by genetic defects is high. 
Migraine, a severe disabilitating headache disorder affecting approximately 15% of 
population, is one the most common neurological disorders (Rasmussen
 et al. 1991). 
Migraine with aura (MA), with a population prevalence of 5%, is characterized by 
neurological (typically visual) symptoms that precede the headache attacks (Russell
 et al. 
1995a). Familial hemiplegic migraine (FHM), on the other hand, is a rare dominantly 
inherited subtype of MA distinguished by the presence of unilateral motor aura symptoms 
(Headache Classification Committee of the International Headache Society 2004). 
Recent methodological advances and determination of the human genome sequence have 
facilitated the identification of mutations that cause diseases with Mendelian inheritance. 
However, the progress in understanding diseases with complex inheritance, where multiple 
genes and environmental factors contribute to the liability, has been relatively slow. Although 
twin and family studies have clearly shown that genetic factors have a major role in migraine 
susceptibility (Russell and Olesen 1995; Mulder et al. 2003), the underlying gene variants 
have not yet been identified. As a result, most that is known of the genetics of migraine comes 
from studies of the monogenic FHM. During the last decade, at least this migraine subtype 
has been added to the growing list of channelopathies, i.e. diseases caused by mutations in ion 
channel genes. The two genes implicated in this disease, CACNA1A coding for a voltage- 
gated Ca2+ channel and ATP1A2 coding for a Na+,K+-ATPase, are both involved in ion 
translocation (Ophoff
 et al. 1996a; De Fusco et al. 2003). In addition to FHM, CACNA1A 
mutations can also lead to another dominantly inherited neurological phenotype, episodic 
ataxia type 2 (EA-2) (Ophoff
 et al. 1996a). Recurrent attacks of generalized cerebellar 
incoordination lasting up to several hours are the main symptom of EA-2, although vertigo, 
nausea and migraine headaches are also often present.  
In this thesis, the genetics of these three related neurological disorders, the multifactorial 
(MA) and monogenic (FHM) forms of migraine, and EA-2, were investigated in Finnish 
families.  
REVIEW OF THE LITERATURE 
 
 10
REVIEW OF THE LITERATURE 
1 CURRENT STATUS OF HUMAN GENETIC RESEARCH 
During the first five years of the new millennium we human geneticists have seen a 
remarkable progress in our field. The completion of the human genome sequence in 2001 is 
naturally the biggest achievement (Lander et al. 2001; Venter et al. 2001). Gaps in the draft 
sequence were mostly filled by a finishing project, results of which were published last year 
(International Human Genome Sequencing Consortium 2004). The current sequence is 
estimated to cover 99% of the euchromatic genome with an overall error rate less than 
1/100,000 nucleotides (International Human Genome Sequencing Consortium 2004). 
However, the completion of the genome sequence has raised even more questions than 
answers. It is now realized that the next major goal is to characterize the variance within the 
genome and, indeed, millions of single nucleotide polymorphisms (SNPs) have been 
described and deposited in public databases (Sherry et al. 1999; Sachidanandam et al. 2001). 
Issues related to this goal are the initiation of the International HapMap Project, the aim of 
which is to determine linkage disequilibrium (LD) patterns across the human genome, and the 
rapid progress in SNP genotyping techniques (Syvänen 2001; The International HapMap 
Consortium 2003). 
As a result of the Human Genome Project, the predicted number of genes in the human 
genome has been constantly dropping and the current estimate is only around 20,000-25,000 
protein-coding genes (International Human Genome Sequencing Consortium 2004). 
Surprisingly, this number does not differ much from the number of identified genes in, for 
example, the roundworm Caenorhabditis elegans (The C. elegans Sequencing Consortium 
1998). Differential gene regulation and alternative splicing of gene transcripts are now widely 
accepted causes of the complexity needed to produce human-beings. Future research will thus 
likely focus more on the study of transcriptomes and proteomes instead of genomes. 
However, studies concerning the human genome can still surprise us. Large-scale copy 
number variations (insertions and deletions ranging in size from 100 kb to 2 Mb) that do not 
cause any apparent phenotype were shown to be much more common than previously thought 
(Iafrate et al. 2004; Sebat et al. 2004). Furthermore, a 900 kb inversion polymorphism in 
chromosome 17 with an impact on natural selection has been recently identified (Stefansson 
et al. 2005). 
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One of the main challenges of human genetics is to identify genetic factors underlying human 
diseases. Numerous genes for diseases with Mendelian inheritance have been identified using 
traditional genome-wide scanning and subsequent positional cloning. In August 2005, the 
Online Mendelian Inheritance in Man (OMIM) database (http://www.ncbi.nlm.nih.gov/ 
entrez/query.fcgi?db=OMIM) contained 1781 phenotypes that have a known molecular basis 
but the number of genes involved is somewhat lower due to allelic diseases. Identification of 
complex disease genes is, however, clearly more difficult than originally envisioned. It is 
hoped that establishing large multinational research projects in molecular epidemiology, such 
as the MORGAM project (Evans
 et al. 2005) and the GenomEUtwin (Peltonen 2003), will 
help in the understanding of complex diseases.  
2 SEARCHING FOR DISEASE GENES 
2.1 The gene-mapper’s toolbox 
2.1.1 Patients 
Individuals with the phenotype of interest are crucial for identifying disease genes. A careful 
and thorough diagnostic procedure is an essential prerequisite for a study to succeed. In 
general, extended families segregating the trait, parent-affected child trios, affected sib-pairs, 
or case-control samples can be collected. Each of these study designs has its advantages and 
pitfalls and typically a combination of some of these is utilized. Extended pedigrees are 
superior when searching for high-penetrance variants while case-control samples may 
possibly be better suited for identifying low-penetrance variants (Freimer and Sabatti 2004). 
2.1.2 Genetic markers 
In principle, any polymorphic feature with Mendelian inheritance can be used as a marker. 
Table 1 summarizes the types of genetic variation present in humans. The earliest genetic 
markers used were blood groups and the electrophoretic mobility variants of serum proteins 
(Strachan and Read 1996). Biallelic restriction fragment length polymorphisms (RFLPs) were 
the first deoxyribonucleic acid (DNA) markers (Botstein et al. 1980). Identification of the 
multiallelic variable number of tandem repeat (VNTR) markers that include minisatellites 
(moderately sized arrays of tandemly repeated DNA sequences) and microsatellites (typically 
di-, tri- or tetranucleotide repeats) made genetic mapping much easier (Nakamura et al. 1987; 
Weber and May 1989). Several microsatellite maps of the human genome have been 
published, the newest of which is the deCODE Genetics map containing precise information 
REVIEW OF THE LITERATURE 
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on 5136 microsatellites (Weissenbach et al. 1992; Gyapay et al. 1994; Dib et al. 1996; Kong 
et al. 2002). 
   Table 1. Genetic variation in humans (excluding chromosomal rearrangements). 
 Type of variation Size 
(repeat size) 
Predicted number in 
the human genome 
Variability Reference  
 SNPs 1 bp 11 million (MAF 1%)  Diallelic Kruglyak and Nickerson 
2001 
 
 Microsatellites <150 bp 
(1-13 bp) 
>600,000 
1 nt repeats 120,000  
2-4 nt repeats 280,000 
Multiallelic Lander et al. 2001  
 Small diallelic 
insertions/deletions 
1 bp - a few kb  >700,000 
(~85% 1-4 nt) 
Diallelic Bhangale et al. 2005  
 Transposable 
elements 
280 bp - 
a few kb 
>3 million; 
~2000 polymorphic  
Diallelic Bennett et al. 2004  
 Minisatellites 500 bp - 20 kb  
(10 - >100 bp) 
~6000;  
~4800 polymorphic 
Multiallelic Denoeud et al. 2003  
 Large-scale 
variation 
~8 kb - 1 Mb NA (639 identified) Di/multiallelic Database of Genomic 
Variants*  
 
 MAF = minor allele frequency; NA = information not available; * http://projects.tcag.ca/variation/  
 
SNPs are DNA variations in which one of the four nucleotides is substituted for another. In 
some cases, for example in the SNP databases, single nucleotide insertions and deletions are 
also considered to be SNPs. Since practically all SNPs are biallelic, the heterozygosity of 
these markers is lower than that of microsatellites. SNPs are, however, much more abundant 
than microsatellites. Two haploid human genomes are estimated to differ at 1 out of every 
1,331 base pairs (Sachidanandam et al. 2001). The total number of SNPs having minor allele 
frequencies of at least 1% (the traditional definition of polymorphism) has been approximated 
to be 11 million, which means one SNP per every 290 bp (Kruglyak and Nickerson 2001). 
Another advantage of SNPs is their lower mutation rate compared to microsatellites. On the 
other hand, a recent report on segmental genome duplications (defined as segments of >1 kb 
with >90% sequence similarity) comprising ~5% of the human genome has raised concern 
regarding the reliability of genotyping SNPs located in these duplicated areas (Fredman et al. 
2004).  
At the moment the public databases such as dbSNP (build 124; 
http://www.ncbi.nlm.nih.gov/projects/SNP/) and SNPper (http://snpper.chip.org/) contain 
slightly above 10 million SNPs, around half of which have been validated (Sherry et al. 1999; 
Riva and Kohane 2004). Progress in this field has been exceptionally rapid, since the SNP 
map published in 2001 contained only 1.4 million SNPs (Sachidanandam et al. 2001). This is 
mainly due to the development of high-throughput SNP genotyping techniques (Syvänen 
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2001), summarized in Table 2. Frequency information is, however, available for only 
500,000 of the SNPs in the dbSNP database. A pilot study performed in 2001 using three 
population samples showed that of the ~1200 SNPs studied, around half were found to be 
common (with minor allele frequency ≥ 20%) in any given population (Marth et al. 2001). 
 
Table 2. Examples of medium- to high-throughput SNP genotyping techniques (Syvänen 2001; Hirschhorn 
and Daly 2005; Syvänen 2005). 
 
 Method Description Throughput  
 SNaPshot (Applied Biosystems) PCR, primer extension & gel 
electrophoresis  
12 SNPs in 384 samples  
 MassEXTEND, MassArray 
(Sequenom) 
PCR, primer extension & mass 
spectrometry 
7-29 SNPs in 384 samples  
 TaqMan assay (Applied 
Biosystems) 
ASOH, 5’-exonuclease cleavage and 
FRET detection during real-time PCR 
1 SNP in 384 samples  
 Pyrosequencing (Biotage) PCR, primer extension & luminometric 
detection 
1 SNP* in 96 samples  
 Molecular Inversion Probe assay 
(Parallele Biosciences) 
Single base extension of a circularizable 
probe, generic PCR & tag array 
10,000 SNPs in 1 sample  
 Golden Gate assay (Illumina) Allele specific extension, ligation, generic 
PCR & tag array on beads 
1536 SNPs in 96 samples  
 GeneChip 10K/100K 
(Affymetrix) 
Generic PCR, ASOH to array 10,000-100,000# SNPs in 
1 sample 
 
 Perlegen “wafers” Long-range PCR, ASOH to array  ~1.5 million SNPs in 1 
sample (using 49 arrays) 
 
PCR = polymerase chain reaction; ASOH = allele specific oligonucletide hybridization; FRET = 
fluorescence resonance energy transfer; * several if within a ~50 bp distance; # two arrays  
 
 
2.1.3 Statistical methods 
2.1.3.1 Linkage analysis 
The aim of linkage analysis is to determine chromosomal locations for disease susceptibility 
loci by genotyping genetic markers in families with several affected individuals. When a 
chromosomal region is transmitted with the disease phenotype within families, this region is 
likely to contain the gene of interest. The basis for linkage analysis is the fact that loci located 
close to each other on the same chromosome are not usually separated by recombination but 
inherited together during meiosis (Strachan and Read 1996). The recombination fraction (θ) is 
a measure of the dependence in inheritance between two loci and approximates 0 if these loci 
are close to each other and 0.5 if the loci are inherited independently. A recombination 
fraction of 0.01 corresponds to a genetic distance of 1 cM which approximates 0.9 Mb 
(Gyapay et al. 1994). 
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For calculating linkage, a likelihood ratio test is applied. The LOD 
(logarithm of odds) score is the logarithm of a ratio of the 
likelihood of two loci being linked at a given θ and the likelihood 
that they are unlinked (θ = 0.5) (Morton 1955).  
In their classic paper, Lander and Kruglyak proposed standards for the interpretation of 
linkage results (1995). They determined that a genome-wide significance threshold of p = 
0.05 is achieved at a pointwise p-value of p = 4.9 x 10-5, the corresponding LOD score being 
3.3. They also suggested the use of terms “suggestive linkage” (p ≤ 1.7 x 10-3; LOD ≥ 1.86), 
that is statistical evidence of linkage expected to occur once at random in a genome scan, and 
“nominal linkage” (p ≤ 0.05; LOD ≥ 0.5875) (Lander and Kruglyak 1995; Nyholt 2000).  
Both parametric, i.e. model-based, and nonparametric, i.e. model-free, linkage analysis 
methods exist. In parametric analysis, performed with programs such as LINKAGE (Lathrop 
and Lalouel 1984), the pattern of inheritance has to be determined. Nonparametric methods 
are based on increased sharing of chromosomal segments between affected individuals 
without specifying the underlying genetic model. Affected sib-pair (ASP) analysis is a 
classical form of nonparametric linkage analysis (Penrose 1953). Programs developed for 
analyzing allele sharing between more distantly related individuals such as GENEHUNTER, 
GENEHUNTER-PLUS, ALLEGRO, SOLAR and MERLIN are widely used, powerful tools 
and some of them are also suitable for identifying loci that influence quantitative traits 
(Kruglyak et al. 1996; Kong and Cox 1997; Almasy and Blangero 1998; Gudbjartsson et al. 
2000; Abecasis et al. 2002). 
Since nonparametric methods do not require specification of the inheritance model, these 
methods are often regarded as more suitable for complex diseases. On the other hand, it has 
been shown that in many situations parametric and nonparametric methods are actually 
statistically equivalent since some assumptions have to be made anyway to reduce the 
complexity of the data (Göring and Terwilliger 2000; Hodge 2001). A well-known example is 
the equivalence of the mean test of ASP analysis and parametric linkage analysis assuming a 
recessive mode of inheritance (Knapp
 et al. 1994). Furthermore, the power of nonparametric 
methods is typically relatively low. It has been shown that even when the mode of inheritance 
is multifactorial, parametric analysis performed under a few different genetic assumptions 
with reduced penetrance is often more powerful than the use of nonparametric methods 
(Abreu et al. 1999). 
)5.0(
)(log)( 10 L
LZ θθ =
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2.1.3.2 Association analysis 
The goal of association analysis is to determine whether a trait and a particular allele of a 
marker co-occur nonrandomly (Ewens and Spielman 2001). If an allele increases 
susceptibility to a disease, it should be present at a higher frequency among affected 
individuals than among controls. This can be computed by comparing the observed allele or 
genotype frequency distributions in cases and controls using a standard χ2-test. In association 
studies, two competing hypothesis, namely H0: the allele occurs at equal frequencies in cases 
and controls and H1: the allele occurs at different frequencies, are evaluated. The statistical 
significance of the association is measured using a p-value, which is defined as the probability 
of obtaining a difference as large as observed by chance although it does not actually exist in 
the population. In other words, it is the risk of rejecting H0 when it is true (type I error). 
Typically, if a single test is performed, a p-value ≤ 0.05 is regarded as significant. Type II 
error (H0 is retained although it is false) is the major concern in replication studies. When the 
probability of type II error is low, the power of a study (the probability of rejecting H0 when it 
is false) is high. An experiment with 80% power to detect a true difference is commonly 
regarded as acceptable (Lalouel and Rohrwasser 2002). One of the much debated subjects is 
how the correction for multiple testing (many genotyped markers and subgroup analysis) 
should be performed. Bonferroni correction, i.e. multiplying the established p-value with the 
number of tests performed, is likely to be too conservative when the markers or phenotypes 
studied are not entirely independent (Nyholt 2001). Permutation testing can be used to 
empirically evaluate the probability of having observed a particular result by chance. In this 
method, the empirical distribution for the χ2-statistic under the H0 is defined by randomly re-
ordering (permuting) the case-control status for the individuals in the data set many times 
(Hirschhorn and Daly 2005). 
Unfortunately, the increased frequency of a particular allele among cases can not alone be 
used as proof of causality. The possibility of a spurious association due to an inadequate 
sample size or a poorly matched control group has to be kept in mind (Cardon and Bell 2001). 
Some investigators have suggested the use of so-called genomic control, i.e. evaluation of 
several unlinked genetic markers, to identify population stratification and also to correct for it 
if present (Pritchard and Rosenberg 1999). Although population admixture in Finland is 
thought to be minimal, some geographical factors have to be taken into account. The 
differences in neutral allele frequencies between western and eastern Finland can be quite 
dramatic and if the prevalence of the disease in question is higher in some area, a considerable 
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number of the cases might be collected from the more-susceptible population subgroup (Kere 
2001). 
Family-based controls are thought to be one answer to the population stratification problem. 
The transmission disequilibrium test (TDT) and haplotype relative risk (HRR) test were the 
first statistical methods developed based on this idea (Falk and Rubinstein 1987; Spielman et 
al. 1993). In both tests, parental alleles that are not transmitted to affected children serve as 
controls. Drawbacks of these methods are the need for collecting and genotyping trios and, in 
the case of the TDT, a loss of power due to the fact that only information from heterozygous 
parents can be used. Applying these methods for late onset diseases, where parental genotypes 
are typically not available, is also problematic, although methods using siblings as controls 
have been developed (Curtis 1997). Furthermore, programs for family-based tests of 
association (TRANSMIT, FBAT, Pseudomarker) are available and some of them can be used 
to test for association in the presence of linkage (Clayton 1999; Göring and Terwilliger 2000; 
Horvath et al. 2001). 
To summarize, there are two main differences between a linkage study and an association 
study: 1) In association analysis we are interested in the particular alleles of the markers 
studied while in linkage analysis the markers are only tools for locating the susceptibility 
region and the linked alleles can be different between families. 2) In linkage analysis co-
segregation of a trait and a locus is studied using families with several affected individuals but 
in association analysis unrelated patients can be used. However, the main principle of these 
methods (excluding the situation when the causal variant is directly studied) is basically the 
same – because of common ancestry, patients share alleles of markers located in the vicinity 
of the disease gene.  
2.1.4 Linkage disequilibrium and haplotype blocks 
Linkage disequilibrium, the co-occurrence of particular alleles at neighboring genetic markers 
more often than expected by chance, is an important tool in disease gene mapping. An allele 
showing association to a disease is not necessarily causative but can be only located close 
enough to be in LD with the actual susceptibility variant. Until recently, LD mapping has 
mainly been used for fine-mapping of previously identified susceptibility areas and thus 
restricting the critical chromosomal regions (Hästbacka et al. 1994; Horikawa et al. 2000; 
Hugot et al. 2001). Using genome-wide association mapping for disease gene localization 
has, however, raised a lot of interest (Risch and Merikangas 1996). In both approaches, the 
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central assumption is that although the causal variant is not necessarily directly genotyped 
because of practical and economic reasons, it is associated with some of the studied markers. 
However, this only holds if we assume that most affected individuals share the same mutant 
allele (Terwilliger and Weiss 1998). Using haplotypes instead of independent SNPs in 
association analyses may potentially lead to increased power in certain situations, such as in 
the presence of multiple disease-causing alleles (Morris and Kaplan 2002; Clark 2004). 
The strength of LD can be described using different statistics, the most commonly used being 
D’ and r2. Both are based on a pairwise-disequilibrium 
coefficient, D, which quantifies the difference between 
the observed and expected frequencies of the two-locus 
haplotype, the expected frequency calculated as the 
product of the allele frequencies. D’ is an absolute value 
of D determined by dividing D by the maximum value 
that D can attain, given the allele frequencies at the loci 
in question. The r2measure is calculated as D2 divided by 
the product of the allele frequencies. 
Both D’ and r2 equal 1 only if the two markers have not been separated by recombination. 
Furthermore, for r2 to equal 1 (known as perfect LD), the allele frequencies need to be 
identical (Zondervan and Cardon 2004). D’ has a tendency to overestimate the magnitude of 
LD especially in small samples and thus the r2 measure is possibly a more relevant measure 
for association studies (Ardlie et al. 2002; Wall and Pritchard 2003). The minimum r2 value of 
useful LD is thought to be r2 >1/3 but much higher D’ values are needed to indicate similarly 
useful levels of LD (Ardlie et al. 2002). 
Intense research efforts have recently been turned to investigating the extent of LD across the 
genome. It is already clear that patterns of LD vary extensively both from one genomic region 
to another and among populations, with European and Asian populations showing greater LD 
than African populations (Reich et al. 2001; Ardlie et al. 2002). The greater extent of LD in 
non-African populations is probably due to population bottleneck effects that have occurred 
during the migration of ancestral humans out of Africa (Wall and Pritchard 2003). When 
studying microsatellites, background LD can be detected over distances of ≥ 1 cM especially 
in population isolates (Laan and Pääbo 1997; Mohlke et al. 2001; Service et al. 2001; Varilo 
et al. 2003). In the case of SNPs, LD has been reported between markers separated >100 kb 
)()()()(
'
)()()(
2121
2
2
max
1111
BfBfAfAf
D
r
D
DD
BfAfBAfD
=
=
−=
REVIEW OF THE LITERATURE 
 
 18
(Ardlie et al. 2002). On the other hand, it is quite common that the expected inverse 
relationship between the degree of LD and physical distance does not hold; closely located 
markers are not necessarily in LD because of complex population demographic factors and 
the history of mutation events. The average extent of useful LD (defined as r2 >1/3) in 
northern European populations has been estimated to be 10-30 kb (Ardlie et al. 2002).  
Recent studies have suggested that the human genome can be partitioned into discrete blocks 
of limited haplotype diversity separated by possible recombination hot-spots that break the 
LD (Daly et al. 2001; Johnson et al. 2001; Patil et al. 2001; Gabriel et al. 2002). The size of 
most of the identified blocks is in the range of 5-20 kb (Wall and Pritchard 2003). However, 
in many regions the overall extent of LD seems to be limited, and many of the markers 
studied are not in the identified blocks (Gabriel et al. 2002). Furthermore, defining 
haploblocks and their boundaries is not straightforward and several methods for this have 
been proposed (Wall and Pritchard 2003). Three basic approaches are to: 1) make use of 
pairwise disequilibrium measures and define blocks as regions over which the average LD is 
above some predetermined threshold (Daly et al. 2001; Gabriel et al. 2002), 2) delineate 
blocks on the basis of limited haplotype-diversity within the blocks (Patil et al. 2001; Zhang 
et al. 2002) or 3) use a minimum-description-length principle based method that combines 
these two variables (Koivisto
 et al. 2003). 
Typically only a few (2-6) common haplotypes together constituting ~90 % of all the 
observed haplotypes are seen within a block (Gabriel et al. 2002). Haplotype tagging 
(ht)SNPs are defined as a minimal set of SNPs that allow all these common haplotypes to be 
distinguished (Johnson et al. 2001). A goal of the HapMap project is to characterize patterns 
of haplotype structure and LD across the human genome (The International HapMap 
Consortium 2003). Utilizing this information could possibly lead to ~3-fold average 
genotyping savings in western European populations (Goldstein et al. 2003; Ke et al. 2004). 
On the other hand, the DNA samples for the HapMap project have come from a relatively 
modest number of individuals (N=270) belonging to four populations (U.S. residents with 
northern and western European ancestry, Japanese, Han Chinese, and Yorubans from Nigeria) 
(The International HapMap Consortium 2003) and there is only limited evidence of the 
usefulness of this approach in other populations. 
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2.2 Identification of genes underlying complex diseases 
2.2.1 Challenges of complex disease studies 
Human disorders can be thought of as forming a continuum ranging from diseases that are 
primarily genetic (such as diseases of the Finnish disease heritage) to those that are primarily 
environmental (breaking a bone due to an accident). Diseases with complex inheritance are 
located somewhere in the middle of this continuum. Allelic heterogeneity (where the disease 
is caused by different variants within the same gene) and locus heterogeneity (disease caused 
by variants in genes at different chromosomal loci) can complicate the analysis of both 
monogenic and complex diseases. Furthermore, in polygenic inheritance, multiple genetic 
factors contribute to the phenotype (Sheffield et al. 1998; Thornton-Wells et al. 2004). A 
further subdivision can be made to situations where multiple alleles have a true additional 
effect (the phenotype is seen when a disease threshold is reached) and to those where a single 
major gene and additional modifier genes produce the phenotype. This interaction between 
genes, where the effect of one gene is altered or masked by another gene, is called epistasis 
and dealing with it in statistical analysis can be very demanding (Cordell 2002). Furthermore, 
based on twin studies, the contribution of genetic factors to susceptibility to complex diseases 
is typically below 60% (Boomsma
 et al. 2002). Thus environmental factors evidently have a 
significant role, which increases the complexity even further. 
Other factors that complicate the search for complex disease genes include phenocopies and 
the variability of disease phenotype within families (Thornton-Wells et al. 2004). 
Phenocopies are individuals who have the disease phenotype but different underlying genetic 
susceptibility factors. This can be a major problem especially when studying migraine or 
some other highly prevalent disease. Furthermore, migraine is a good example of a disease 
with phenotypic variability. The two common forms of migraine, migraine with and without 
aura, are both commonly present in the same families and the same patient can have both 
types of attacks (Blau 1995; Kallela
 et al. 2001b). 
The main difficulty in identifying genetic susceptibility factors for complex diseases is, 
however, the fact that an individual variant will in most cases have only a small effect on 
disease risk. To overcome this problem, many different study designs have been developed 
but the suitability and success of these depends dramatically on the assumptions that have 
been made. Thus, to be able to choose the most successful design, we should know what we 
are looking for. Key parameters are the number of genes involved, the frequency of the risk 
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alleles and the magnitude of the effect these alleles have on risk. There is continuous debate 
over the allelic structure of common diseases (Reich and Lander 2001; Pritchard and Cox 
2002; Smith and Lusis 2002). The common disease – common variant (CD-CV) hypothesis 
suggests that relatively common alleles with weak effect size could predispose to a disease 
and that each underlying locus contains only one or a few disease alleles (Lander 1996; 
Cargill et al. 1999; Reich and Lander 2001). An alternative viewpoint is that the allelic 
structure of complex diseases resemble that seen in monogenic diseases, i.e. multiple rare 
alleles with moderate to large effect size (Terwilliger and Weiss 1998; Smith and Lusis 2002). 
Most of the confirmed alleles associated with common diseases tend to support the CD-CV 
hypothesis, but this could be due to the fact that such genes are easier to identify (Lohmueller 
et al. 2003). Prototypical examples include the APOE ε4 allele in Alzheimer’s disease and the 
PPARγ Pro12Ala allele in type II diabetes (Corder et al. 1993; Altshuler et al. 2000).  
Another open question is the type of sequence variations we should expect to find behind 
complex diseases. Previously, mainly variations located in the coding sequences of genes 
(cSNPs) have been sought but recent studies have identified causal or at least strongly 
disease-associated polymorphisms in the regulatory regions of genes (Enattah et al. 2002; 
Pajukanta et al. 2004). From the large number of SNPs localized within the non-transcribed 
genomic regions, those in evolutionarily conserved (and thus also potentially functionally 
important) areas are more likely to be associated with diseases (Dermitzakis et al. 2005). The 
information provided by comparative genomics methods can be used to select and prioritize 
these SNPs. It is also worth mentioning that most of the identified cSNPs associated with 
complex diseases were recently shown to affect amino acids that are far less conserved than 
those causing Mendelian diseases and thus likely to have milder effects on protein function 
(Thomas and Kejariwal 2004). 
2.2.2 Study designs 
2.2.2.1 Candidate gene strategy 
Candidate gene studies are always hypothesis-driven. Genes are selected either on the basis of 
their location in a previously identified susceptibility region (positional candidates) or because 
of some evidence of their possible connection with the disease (functional candidates) (Tabor 
et al. 2002). The main drawback of this method is that in most cases the pathophysiology of 
the studied disease is still relatively poorly understood and thus selecting the most likely 
candidate among the 25,000 predicted human genes (International Human Genome 
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Sequencing Consortium 2004) can be extremely difficult. A population based (case-control) 
association study with multiple SNPs covering the selected gene(s) is the most common type 
of candidate gene study although family-based studies are also possible. Preferably, the gene 
should be resequenced in a group of cases and controls to find every variation within the gene. 
This is, however, quite expensive and still rarely done. Furthermore, in most cases only the 
coding sequence of the gene is sequenced (Hirschhorn and Daly 2005).  
2.2.2.2 Genome-wide scanning 
The aim of genome-wide scanning is to localize the disease gene by establishing statistically 
significant evidence of linkage or association. Since the whole genome is screened, no prior 
information about the location or the function of the gene is needed. The success of 
identifying complex disease genes by performing a genome-wide linkage analysis followed 
by traditional positional cloning has been limited. Signals are often weak and inconsistent: 
less than one third of the scans published until December 2000 showed significant evidence of 
linkage (Altmuller et al. 2001). However, this could mostly be due to the use of too sparse 
marker maps. In fact, it has been shown that dense re-genotyping of existing sample sets can 
add to the amount of information extracted considerably (Sawcer et al. 2004). Linkage 
analysis has been shown to be less powerful than association analysis for identifying common 
genetic variants with modest effects (<3-fold) on disease risk (Risch and Merikangas 1996; 
Risch 2000). Furthermore, the susceptibility regions identified by linkage analysis are often 
rather wide, typically exceeding 10 cM (Glazier et al. 2002). Once a susceptibility region has 
been identified, it must be restricted as much as possible by fine-mapping and looking for 
evidence of association (LD mapping). On the other hand, the advantage of linkage analysis is 
that allelic heterogeneity does not affect the results. 
Genome-wide association studies performed thus far have mainly been limited to population 
isolates, in which LD can be detected over long distances using microsatellites (Ophoff et al. 
2002). The proposal of using SNPs for genome-wide association screening in complex 
disease research was first made around a decade ago (Risch and Merikangas 1996; Collins et 
al. 1997) and the potential of this method has been evaluated in several recent reviews 
(Carlson et al. 2004; Hirschhorn and Daly 2005; Wang et al. 2005). The real breakthroughs 
have, however, thus far not occurred, but evidence of the efficacy of this method is now 
gradually mounting. As an example, a polymorphism causing age-related macular 
regeneration in a gene coding for complement factor H was recently identified by several 
groups, one of which performed a genome-wide association screen (Edwards
 et al. 2005; 
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Haines
 et al. 2005; Klein et al. 2005). On the other hand, this study design has also raised 
considerable controversy mainly because it is likely to succeed only if there is a single 
predominant disease allele at a given disease locus. This is because new mutations most likely 
arise on independent haplotypes and thus cancel out each other’s signals (Terwilliger and 
Weiss 1998; Slager et al. 2000; Weiss and Terwilliger 2000). 
Two approaches have been suggested for estimating the number of SNPs to be genotyped in a 
genome-wide association study. In direct association studies only functional variants 
including approximately 50,000 non-synonymous (resulting in amino acid change) SNPs plus 
an unknown number of regulatory SNPs would be tested (Risch and Merikangas 1996; 
Kruglyak and Nickerson 2001). Estimates of the htSNPs needed in an LD-based indirect 
approach vary from 170,000 to 500,000 in European populations (Gabriel
 et al. 2002; 
Goldstein
 et al. 2003; Carlson et al. 2004). The costs of large-scale genotyping are still a 
major limiting factor although pooling of samples has been suggested to be an effective way 
to reduce costs (Sham et al. 2002). However, the precise construction of the pools is 
demanding and requires multiple concentration determination steps, the detection power of 
pooled samples in the case of modest-risk alleles can be low and haplotype analysis of pooled 
data is complicated (Sham et al. 2002). Although genotyping of hundreds of thousands of 
SNPs might be feasible in the future, major challenges such as unrealistically large sample 
sizes needed due to the multiple testing problem are still faced (Risch and Merikangas 1996). 
2.2.3 Burden of proof 
Lack of reproducibility of published genetic associations has lately become a major concern. 
True variability between populations can explain some of this inconsistency and could be due 
to either different patterns of LD (when the causative variant is not directly studied), disease 
alleles that are specific to one ethnic group or different effect sizes because of modifying 
genetic or environmental factors (Colhoun et al. 2003). However, false positive and false 
negative studies are currently regarded as more likely explanations for these discrepancies 
(Colhoun et al. 2003). Multiple testing in modest sample sizes can easily produce associations 
significant at the 5% level by chance alone and preferential publication of positive results, the 
so-called publication bias, aggravates this effect. In addition, it has been shown that even if 
the association is true, the initial positive studies tend to overestimate the size of the genetic 
effect (Göring et al. 2001; Ioannidis et al. 2001). This winner’s curse effect can lead to a 
situation where subsequent replication attempts are underpowered and the results thus false 
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negatives (Colhoun et al. 2003). Other reasons for false negative results are variations in 
study design, for example testing of a slightly different phenotype or a nearby genetic variant. 
Replication of an association using an independent sample set is regarded as convincing 
evidence of a true finding, especially if the sample is large and population-based. Seeing an 
association both in a case-control setting and in a family based study increases the confidence 
further. However, associations can often be proven only by performing a meta-analysis where 
results of all published studies are combined (Ioannidis et al. 2001; Lohmueller et al. 2003). 
At the end, functional tests are needed to provide conclusive evidence of causality of the 
associated SNP in the disease pathogenesis. Using in vitro systems, the effect of SNPs on 
gene or protein expression and function can be tested. These effects can, however, be highly 
context dependent and seen only in certain cell types or experimental conditions and thus 
difficult to interpret. Producing transgenic animals with a similar phenotype as in humans is 
probably the most convincing evidence although these findings can also be hard to interpret 
(Glazier et al. 2002). 
2.2.4 Solutions and success stories 
Based on meta-analyses, the number of identified polymorphisms truly associated with 
complex diseases is below 50, but since this is a very rapidly moving target, the correct 
number is probably higher (Ioannidis et al. 2001; Lohmueller et al. 2003). The NOD2 gene 
underlying Crohn’s disease, a chronic inflammatory bowel disease, is commonly regarded as 
the first complex disease gene identified using positional cloning (Todd 2001). In 2001, five 
years after linkage to chromosome 16 had been established (Hugot
 et al. 1996), two 
independent groups showed an association of NOD2 variants with this disease (Hugot et al. 
2001; Ogura
 et al. 2001). NOD2 is also a good example of a complex disease gene that has 
been identified in spite of moderate allelic heterogeneity. In Table 3, some examples of 
genetic variants associated with complex diseases are listed. 
In spite of these successes, a typical situation in the complex disease field at the moment is 
that for any particular trait several whole-genome linkage analyses have been performed but 
most of the identified linkage signals are weak and found in only one study. Thus the number 
of consistently replicated loci is relatively small and in only a few of these have the gene and 
variant in question been conclusively identified. An excellent example is schizophrenia in 
which at least 18 susceptibility regions scattered over almost all chromosomes have been 
observed (O'Donovan et al. 2003). On the other hand, a recent meta-analysis of 20 
REVIEW OF THE LITERATURE 
 
 24
schizophrenia genome scans concluded that the linkage results are more consistent than has 
been previously recognized (Lewis
 et al. 2003). Furthermore, various association studies have 
also produced promising results since possible causative genes have been identified in six 
schizophrenia susceptibility loci (Hennah et al. 2004). The progress has, however, been very 
slow and many investigators feel that the results of complex disease genetics have thus far 
been rather disappointing. In the following sections some strategies that can improve the 
chances of identifying genetic factors for complex diseases are discussed. 
2.2.4.1 Monogenic disease models 
Much of the progress in understanding complex diseases has come from studying closely 
related rare monogenic forms of these diseases. These monogenic forms are usually more 
severe and/or have earlier onset than their complex counterparts. Examples of this kind of 
disease genes are genes coding for presenilin and amyloid precursor proteins in Alzheimer’s 
disease (Nussbaum and Ellis 2003), MODY (maturity-onset diabetes of youth) genes in 
diabetes (Fajans
 et al. 2001), and BRCA1&2 genes in breast and ovarian cancer (de la 
Chapelle and Peltomäki 1998). A popular hypothesis is that less severe variants in these genes 
might contribute to susceptibility to the more common subtypes of these diseases. Indeed, in 
two recent studies the resequencing approach has been successfully applied to candidate 
genes selected using this criterion: rare missense variants were identified in genes causing the 
Mendelian forms of colorectal cancer (Fearnhead
 et al. 2004) and low high-density 
lipoprotein cholesterol levels (Cohen
 et al. 2004) in individuals with multifactorial 
counterparts of these diseases. 
Table 3.  Examples of genetic variants associated with common forms of complex diseases. These 
variants are thought to be directly causal and not merely part of an associated haplotype. 
Gene Allele Allele 
frequency 
OR- 
Het 
OR- 
Hom 
Disease Reference(s) 
INS small VNTR 
promoter alleles 
0.85 NA 2.7 Type I diabetes Bell et al. 1984 
APOE ε4 (C112R) 0.15 3 12 Alzheimer’s disease Corder et al. 1993 
PPARγ P12A 0.85 (P) 1.25* Type II diabetes Altshuler et al. 2000 
NOD2 several coding 
variants 
0.06 
(combined) 
2-4 ~40 Crohn’s disease Hugot et al. 2001;  
Ogura et al. 2001 
PTPN22 R620W 0.17 1.7# 3.4# Type I diabetes + other 
autoimmune diseases 
Bottini et al. 2004; 
Siminovitch 2004 
CFH Y402H 0.39 2.4 5.9 Age-related macular 
degeneration 
Edwards et al. 2005; 
Haines et al. 2005; 
Klein et al. 2005 
 
OR-Het  = odds ratio for heterozygotes versus normal homozygotes; OR-Hom = odds ratio for variant 
homozygotes versus normal homozygotes; NA = not available; * allelic OR; # for type I diabetes 
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2.2.4.2 Endophenotypes and animal models  
One approach to decrease genetic complexity is to make use of intermediate or 
endophenotypes that are probably controlled by fewer susceptibility factors than the disease 
state itself (Bearden et al. 2004). Many of these intermediate phenotypes are quantitative 
traits, such as serum IgE and bronchial hyper-reactivity in asthma, plasma lipid concentrations 
and blood pressure in ischemic stroke, and cognitive traits in psychiatric disorders (Wright et 
al. 1999; Laitinen et al. 2004; Paunio et al. 2004). However, a typical problem in these kind 
of studies is the fact that the heritability of the studied traits has often not been established 
(Bearden et al. 2004). Alternatively, in association analysis the contribution of genetic factors 
among cases can possibly be increased by selecting patients with a strong family history 
and/or earlier onset of a disease. In some situations it may also be possible to decrease genetic 
complexity by using inbred animal strains for quantitative trait locus mapping (Cox and 
Brown 2003). After susceptibility loci or variants have been identified in an animal model, 
their role in the human disease phenotype can be examined. Naturally, animal models are of 
very limited use in diseases such as migraine where diagnoses are based on a clinical 
interview.  
2.2.4.3 Isolated populations 
The population history of Finland is quite unique. Based on Y chromosome haplotype 
variation data, the Finns are thought to descend from two different groups of settlers, Uralic 
speakers arriving from the east about 4,000 years ago and Indo-European speakers arriving 
from the south about 2,000 years ago (Kittles et al. 1998; Peltonen et al. 2000). During the 
1500s and the 1600s, the population spread from the coasts (so-called early settlement 
regions) to the eastern and northern parts of the country thus creating regional subisolates 
(late settlement) (Peltonen et al. 2000; Varilo and Peltonen 2004). Until the beginning of the 
1700s the Finnish population grew very slowly and several bottlenecks, such as the great 
famine of 1690s, further strengthened the effect of genetic drift. Population expansion from 
250,000 to the present 5,200,000 inhabitants occurred during the past 250 years (Kere 2001). 
The Finnish disease heritage, a group of 35 mainly recessive diseases more prevalent in 
Finland than in other populations, has its origins in this population history (Norio et al. 1973; 
de la Chapelle 1993; Peltonen et al. 1999). 
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Isolated populations, such as Finns, Bedouin-Arabs, and the Amish, have proven to be ideal 
for the identification of genes causing rare monogenic diseases (Sheffield et al. 1998; 
Peltonen et al. 2000). An extreme example is the mapping of the infantile-onset 
spinocerebellar ataxia locus using only four affected Finnish individuals (Nikali et al. 1995). 
Founder populations have also been suggested to possess some advantages for mapping the 
genes underlying complex diseases (Wright et al. 1999). Reduced heterogeneity caused by a 
small number of founder individuals, subsequent bottlenecks, and genetic drift could have 
restricted the number of susceptibility alleles present in affected individuals. In addition, good 
genealogical records, a more uniform environment and lifestyle, as well as more easily 
standardized diagnostic criteria are obvious advantages of certain isolates (Peltonen et al. 
2000). It has also been proven that LD often extends over wider intervals in founder 
populations than in general populations although this seems to apply only for young isolates 
(Eaves et al. 2000; Service et al. 2001; Varilo et al. 2003). Thus 10-20 generations old 
isolates such as Costa-Rica, Newfoundland, and internal isolates of Finland have been 
suggested to be especially powerful for the initial mapping phase (Wright et al. 1999). Indeed, 
several complex disease genes have been identified using positional cloning in the Finnish 
population (Table 4). Some of these studies have taken advantage of increased disease 
prevalence in certain areas of Finland due to a founder effect, examples being schizophrenia 
in the Kuusamo region and multiple sclerosis in western Finland (Hovatta
 et al. 1997; Tienari 
et al. 2004). On the other hand, it has been argued that disease alleles present in population 
isolates do not necessarily contribute to susceptibility in other populations. In a recent study, 
however, the genetic effects of risk variants were shown to usually be consistent although the 
allele frequencies can differ considerably across populations (Ioannidis et al. 2004).  
   Table 4. Complex disease genes identified using positional cloning in the Finnish population. 
Phenotype Locus Subisolate Gene Reference(s) 
Multiple sclerosis 17q22-q24 Botnia PRKCA Kuokkanen et al. 1997; Saarela et al. 2002 
Familial 
combined 
hyperlipidemia 
1q21-23 - USF1 Pajukanta et al. 1998; Pajukanta et al. 2004 
Schizophrenia* 1q42 Kuusamo ¤  DISC1 Ekelund et al. 2001; Hennah et al. 2003 
Asthma 7p14-p15 Kainuu GPRA Laitinen et al. 2001; Laitinen et al. 2004 
Dyslexia* 15q21 - DYX1C1 Taipale et al. 2003 
Psoriasis # 6p21.3 -  HCR Asumalahti et al. 2002 
Type II diabetes 20q12-q13 - HNF4A Ghosh et al. 1999; Silander et al. 2004 
Obesity Xq24 - SLC6A14 Suviolahti et al. 2003 
 
* locus was first identified using a translocation breakpoint;  # samples from other populations were 
also included; ¤ (also whole Finland) 
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The deCODE project in Iceland is a unique example of identifying complex disease genes 
using genealogical tools. The parliament of Iceland gave permission for the deCODE 
company to anonymously link the genealogical records to health care records of all the 
275,000 inhabitants of Iceland except for those who have asked to be excluded (Gulcher and 
Stefansson 2000). Thus deCODE has an exceptional opportunity to build large 
multigenerational families with several affected individuals. This strategy has proven to be 
very effective since, according to their website (http://www.decode.com), by August 2005 
deCODE has identified 28 susceptibility loci and provided evidence of a causative gene in 12 
of these. Some examples of identified genes are neuregulin 1 in schizophrenia, genes coding 
for 5-lipoxygenase activating protein and phophodiesterase 4D in myocardial infarction and 
stroke, and bone morphogenetic protein 2 gene in osteoporosis (Stefansson et al. 2002; 
Gretarsdottir et al. 2003; Styrkarsdottir et al. 2003; Helgadottir et al. 2004). 
3 CLASSIFICATION OF HEADACHE DISORDERS 
Since 1988, a generally accepted International Classification of Headache Disorders (ICHD), 
published by the International Headache Society (IHS), has been available (Headache 
Classification Committee of the International Headache Society 1988). During 2004 the 
second edition of this classification, ICHD-2, was published (Headache Classification 
Committee of the International Headache Society 2004). These criteria have been the 
scientific basis for diagnosing the heterogeneous group of headache disorders in most 
subsequent studies. According to the ICHD-2 criteria, headaches are divided into primary and 
secondary headaches. Headache is classified as secondary if it is attributed to some other 
disorder such as neck and/or head trauma, cranial or cervical vascular disorder (for example 
subarachnoid hemorrhage), and infections (for example bacterial meningitis) (Headache 
Classification Committee of the International Headache Society 2004). Primary headaches are 
classified into four subgroups: 1) migraine, 2) tension-type headache, 3) cluster headache, and 
4) other trigeminal autonomic cephalalgias and other primary headaches (Headache 
Classification Committee of the International Headache Society 2004). 
Tension-type headache is the most common headache disorder with a 1-year prevalence of 
approximately 60% (Ulrich et al. 2004). Environmental factors were recently shown to be of 
major importance in this disease and thus genetic factors seem to have only a minor role 
(Ulrich et al. 2004). The chronic form of tension-type headache has, however, a prevalence of 
only 2-3% and first-degree relatives have a 2.1 to 3.9-fold increased risk, but no genetic 
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factors predisposing to this disease have yet been identified (Russell et al. 1999; Ulrich et al. 
2004). Cluster headache is regarded as the most severe primary headache. It is characterized 
by unilateral headache attacks lasting 15-180 minutes, occurring as frequent clusters and 
accompanied by ipsilateral autonomic features (Headache Classification Committee of the 
International Headache Society 2004). Prevalence of this disorder is between 1/500–1/1500 in 
the Caucasian population (Russell 2004). A 5-8 times increased risk for first-degree relatives 
has been estimated, suggesting the importance of genetic factors (Russell 2004). Thus far the 
only gene associated with this disease is HCRTR2 that codes for a receptor for a newly 
discovered neuropeptid, hypocretin-2 (Rainero
 et al. 2004a). 
4 MIGRAINE 
4.1 Diagnosis 
Since no diagnostic test for migraine or any other primary headache disorder exists, diagnosis 
is based on the patient’s description of the attacks and exclusion of the other possible 
secondary causes of headache. To standardize migraine diagnosis, criteria published by the 
IHS is now widely accepted at least for scientific purposes (Headache Classification 
Committee of the International Headache Society 2004). Table 5 presents the classification of 
Table 5. Migraine sub-types according to the ICHD-2 (Headache Classification Committee of the 
International Headache Society 2004). 
1.1 Migraine without aura 
1.2 Migraine with aura 
  1.2.1 Typical aura with migraine headache 
  1.2.2 Typical aura with non-migraine headache 
  1.2.3 Typical aura without headache 
  1.2.4 Familial hemiplegic migraine 
  1.2.5 Sporadic hemiplegic migraine 
  1.2.6 Basilar-type migraine 
1.3 Childhood periodic syndromes that are commonly precursors of migraine 
  1.3.1 Cyclical vomiting 
  1.3.2 Abdominal migraine 
  1.3.3 Benign paroxysmal vertigo of childhood 
1.4 Retinal migraine 
1.5 Complications of migraine 
  1.5.1 Chronic migraine 
  1.5.2 Status migrainosus 
  1.5.3 Persistent aura without infarction 
  1.5.4 Migrainous infarction 
  1.5.5 Migraine-triggered seizure 
1.6 Probable migraine 
  1.6.1 Probable migraine without aura 
  1.6.2 Probable migraine with aura 
  1.6.5 Probable chronic migraine 
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migraine subtypes according to ICHD-2. Based on the presence or absence of the aura phase, 
migraine can be divided into two major subtypes, migraine without aura (MO) being more 
common and usually more disabling (Headache Classification Committee of the International 
Headache Society 2004). Migraine with aura (MA) can be further classified into several 
subtypes (Table 5). In Table 6, diagnostic criteria for migraine without aura (ICHD-1.1) and 
for typical aura with migraine headache (ICHD-1.2.1) are listed (Headache Classification 
Committee of the International Headache Society 2004). 
Of the MA subtypes, familial hemiplegic migraine (FHM) (ICHD-1.2.4) is known to be 
autosomal dominantly inherited and can be regarded as the monogenic disease model for the 
more common types of migraine. To be diagnosed as having FHM, a patient must have MA 
attacks including motor weakness and at least one first- or second-degree relative with similar 
attacks. Sporadic hemiplegic migraine (ICHD-1.2.5) patients have comparable attacks but no 
affected family members. Other important MA subtypes are the typical aura without headache 
(ICHD-1.2.3), in which patients simply have attacks with aura without the following 
Table 6. ICHD-2 diagnostic criteria for migraine with and without aura (Headache Classification 
Committee of the International Headache Society 2004). 
 
1.1 Migraine without aura 
  A) At least 5 attacks fulfilling criteria B-D 
  B) Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated) 
  C) Headache has at least two of the following characteristics: 
  1. Unilateral location 
  2. Pulsating quality 
  3. Moderate or severe pain intensity 
  4. Aggravation by or causing avoidance of routine physical activity (eg, walking or 
climbing stairs) 
  D) During headache at least one of the following: 
  1. Nausea and/or vomiting 
  2. Photophobia and phonophobia 
  E) Not attributed to another disorder 
   
1.2.1 Typical aura with migraine headache 
  A) At least 2 attacks fulfilling criteria B-D 
  B) Aura consisting of fully reversible visual symptoms, sensory symptoms, and/or dysphasic 
speech disturbance, but no motor weakness 
  C) At least two of the following: 
  1. Homonymous visual symptoms and/or unilateral sensory symptoms 
  2. At least one symptom develops gradually over ≥5 minutes and/or different aura 
symptoms occur in succession over ≥5 minutes 
  3. Each symptom lasts 5-60 minutes 
  D) Headache fulfilling criteria B-D for 1.1 begins during the aura or follows aura within 60 
minutes 
 
  E) Not attributed to another disorder 
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headache, and basilar-type migraine (ICHD-1.2.6), in which patients have MA symptoms 
originating from the brainstem such as dysarthria, vertigo, tinnitus, and simultaneous bilateral 
visual, sensory, or motor symptoms (Headache Classification Committee of the International 
Headache Society 2004).  
4.2 Clinical features 
4.2.1 Clinical features of MA and MO 
The age of migraine onset is typically 10-40 years of age (Silberstein et al. 1998). Patients 
experience a median of 1 attack per month and 25% have at least two attacks per month 
(Launer et al. 1999). Migraine attack can be divided into four phases: premonitory symptoms, 
aura phase, headache phase, and resolution phase. Premonitory symptoms (prodrome) occur 
in one third of patients, hours to 1-2 days before the headache and include symptoms such as 
tiredness, yawning, neck stiffness, mood change, and gastrointestinal symptoms (Kelman 
2004). One third of migraine patients have, at least occasionally, aura, a focal, gradually 
developing neurological symptom that typically precedes the headache and lasts for less than 
60 minutes (Russell
 et al. 1995a; Launer et al. 1999). Patients often have multiple types of 
aura, the most common symptoms being visual disturbances (99% of patients) such as zig-zag 
lines and scotomas, followed by sensory (31%), aphasic (speech abnormalities; 18%) and 
motor (6%) symptoms (Russell and Olesen 1996).  
The headache phase is the most debilitating part of the migraine attack. As the ICHD-2 
criteria describe, typical migraine headache is unilateral, throbbing, moderate to marked in 
severity, and aggravated by physical activity. In adults, untreated headache attacks usually last 
4-72 hours (Headache Classification Committee of the International Headache Society 2004). 
Headache is always accompanied by other symptoms, most typically nausea (90% of patients) 
(Silberstein 1995). Vomiting occurs in almost 70% of patients and sensitivity to noise 
(phonophobia) and light (photophobia) are also common (Silberstein 1995). Following the 
headache, in the so-called resolution phase, patients can feel exhausted, unusually refreshed or 
even euphoric (Silberstein et al. 1998). 
4.2.2  Clinical features of hemiplegic migraine 
FHM was first described in 1910 (Clarke 1910). FHM attacks are characterized by the 
presence of motor aura symptoms. This motor aura consists of gradually progressing 
unilateral motor weakness or paralysis and is almost invariably preceded by other aura 
symptoms (Thomsen
 et al. 2002a). The age of onset of this disease is typically 10-15 years 
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(Ducros
 et al. 2001). Some patients occasionally have severe attacks with impaired 
consciousness ranging from confusion to coma, fever, prolonged hemiplegia and/or seizures 
(Ducros et al. 2001). A mild head trauma is a typical trigger of such attacks (Ducros et al. 
2001). In about 20% of FHM families the disease is associated with permanent neurological 
symptoms, mainly cerebellar ataxia and nystagmus (Ducros et al. 2001). 
4.3 Epidemiology 
As with other complex disorders, it is very important to make a distinction between 
population-based and clinic-based epidemiological studies of migraine. Those patients that 
seek medical help for their headaches naturally represent the most severely affected 
migraineurs and may differ significantly from unselected subjects. Thus this kind of study 
setting should not be used for epidemiological research. From the other point of view, medical 
diagnosis records should not be used for migraine prevalence estimations, since a significant 
proportion of migraine patients never consult a clinician because of headaches.  
4.3.1 Prevalence 
Prevalence is the proportion of the population with a disease during a particular period of 
time, typically either one year (active) or lifetime. The first prevalence study using ICHD 
criteria was performed in Denmark and reported a one-year migraine prevalence of 10% (6% 
in men, 15% in women) and a lifetime prevalence of 16% (8% in men, 25% in women) 
(Rasmussen
 et al. 1991). Since then, several other studies performed in western countries 
have confirmed the overall one-year prevalence of migraine to be 10-12% (Stewart
 et al. 
1992; Russell
 et al. 1995a; Launer et al. 1999; Hagen et al. 2000; Lipton et al. 2001). These 
studies have also consistently shown that migraine has a male to female ratio of 1:2-3 (one-
year prevalence of 6-8% among men and 15-18% among women). Although migraine is 
common in all races, it seems to be more prevalent in Caucasians than in Africans or Asians. 
This trend can be seen both in the admixed population of the United States (Stewart
 et al. 
1996) and, even more clearly, in the recent population studies performed, for example, in 
Tanzania and Japan where the reported overall one-year migraine prevalence is 5-6% (Dent
 et 
al. 2004; Takeshima et al. 2004). 
The only Finnish population-based epidemiological study of headache is based on a 
questionnaire mailed to twins in 1981 (Honkasalo et al. 1993). In this study, the overall 
prevalence of migraine was 10.1% among women and only 2.5% among men. Unfortunately, 
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this study has some limitations since the ICHD criteria were not available at the time of the 
study and the questionnaire was not designed for distinguishing between MA and MO. 
Although the epidemiology of migraine in general has been thoroughly studied, population-
based data on the prevalence of migraine subtypes are sparse. One-year prevalence of MA is 
estimated to be 4% and of MO 6% (Rasmussen 2001). Lifetime prevalences of MA and MO 
in Denmark are shown in Figure 1 (Russell
 et al. 1995a). Since the various subtypes of MA 
are so rare, their epidemiology has not been thoroughly studied. As a rough estimate, 
approximately 100 FHM families and a similar number of patients with sporadic hemiplegic 
migraine have been described (Thomsen
 et al. 2002b). Recently, however, population-based 
prevalences of FHM and sporadic hemiplegic migraine have been studied in Denmark. 
Interestingly, from the entire Danish population of 5.2 million inhabitants, a population size 
very similar to Finland, 147 FHM patients from 44 different families were identified. The 
total prevalence of hemiplegic migraine was estimated to be 0.008-0.009 % and the familial 
and sporadic forms were found to be equally frequent (Thomsen
 et al. 2002b). 
 
Figure 1. Lifetime 
prevalences of 
migraine with and 
without aura 
(Russell et al. 
1995a). 
 
 
 
 
 
 
4.3.2 Environmental and internal factors 
Given the fact that only around 40-60% of the predisposition to migraine is believed to be due 
to genetic factors (Honkasalo et al. 1995; Larsson et al. 1995), environmental factors are 
clearly important. Twin studies have shown that individual environment is more important 
than the shared family environment (Ziegler et al. 1998; Svensson et al. 2003). However, no 
associations between MA and several socioeconomic and environmental factors including 
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sociodemographic variables or factors related to lifestyle studied showed association with 
migraine in a population-based Danish epidemiological study, the only exception being sleep 
pattern (Rasmussen 1992, 1993). Because migraine is an episodic disorder, environmental 
triggering factors probably have an important role in precipitating attacks. Typically reported 
triggers include stress or the relief of stress, too much or too little sleep, weather changes, 
flickering lights or strong smells, missing a meal, and certain food triggers such as red wine 
and chocolate (Silberstein et al. 1998). 
Before puberty, migraine is slightly more common in boys than in girls but in children aged 
over 12, a female preponderance is evident (Sillanpää 1983; Abu-Arefeh and Russell 1994). 
The increased prevalence of migraine in women is generally thought to reflect the additional 
trigger of fluctuating female hormones during the menstrual cycle. Although pure menstrual 
migraine (defined as attacks occurring exclusively between days -2 to +3 of menstruation) is 
rare, menstrually related attacks are very common and are believed to be due to falling 
concentrations of estrogen (Bousser 2004; MacGregor 2004). In a Swedish population-based 
study, 21% of women with MO and 4% of women with MA reported ≥ 75% of their attacks 
being menstrually related (Mattsson 2003). In a recent clinic-based study, migraine attacks 
were 1.7-2.5 times more likely to occur on days -2 to +3 of menstruation than at all other 
times and, furthermore, these menstrual attacks tended to be more severe and almost 
exclusively without aura (MacGregor and Hackshaw 2004). In addition, the effects of 
pregnancy, oral contraceptives, menopause and hormone replacement therapy on the course of 
migraine speak for the importance of hormonal factors in this disease (Bousser 2004). 
4.4 Pathophysiology 
The pathophysiology of migraine is still relatively poorly understood, although recent 
discoveries have increased our knowledge concerning the sequence of events leading to a 
migraine attack. Some phenomena are almost certainly essential, but the order and the cause-
consequence relationship of these events are still debated. Both neuronal and vascular 
components seem to have a role in the pathophysiology of this disease and, in addition to the 
cerebral cortex, the brainstem and the trigeminovascular system are involved. 
Wolff’s classical view was that migraine aura is due to vasoconstriction and the throbbing 
headache is caused by dilated and pulsating blood vessels (Wolff 1963). Olesen and 
coworkers (1990) were able to prove this theory wrong by showing that a focally reduced 
regional cerebral blood flow (rCBF) is the first observable event during migraine attack, after 
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which the aura symptoms develop. Furthermore, they showed that headache begins before 
rCBF starts to gradually increase to an abnormally high level. 
The causal connection of migraine aura and headache is still a matter of debate. An alternative 
view is that aura and headache are parallel rather than sequential events and that some as yet 
unidentified process could be responsible for both of these symptoms (Spierings 1988; 
Goadsby 2001). Evidence of the brainstem as the migraine generator exists given that during 
migraine attacks activated brain stem nuclei have been detected (Weiller et al. 1995; Bahra et 
al. 2001; Cao et al. 2002). 
4.4.1 The interictal brain status – impaired cortical information processing 
Recent electrophysiological studies performed during the interictal phase of migraine have 
demonstrated that migraine patients are characterized by a dysfunction in cortical information 
processing. In normal subjects, repetition of a stimulus produces amplitude reduction of the 
evoked cortical response, i.e. habituation. However, decreased habituation or even 
potentiation has been consistently observed in migraineurs (Ambrosini and Schoenen 2003). 
The lack of habituation could contribute to the enhanced susceptibility of migraine patients to 
many sensory stimuli, such as flashing lights and strong odors, which are well-known 
migraine attack precipitating factors. Interestingly, one study has also provided evidence of a 
genetic component in cortical-evoked potentials in 20 parent-child pairs affected by migraine 
(Sandor et al. 1999).  
Although the lack of habituation in migraineurs has been proven, it is still debated whether it 
is due to an increased or decreased cortical preactivation level. A more widely accepted 
hypothesis states that the habituation deficit is due to a transient or persistent hyperexcitability 
of the cortex caused by either increased cortical excitability or decreased inhibition (Welch et 
al. 1990). According to the alternative hypothesis, decreased excitability of the cortex could 
be the underlying cause. In this “ceiling effect” model, habituation occurs only when cortical 
activation reaches the ceiling, i.e. slower if the cortical pre-activation level is low (Schoenen 
1996). 
4.4.2 Pathophysiology of the aura 
More than 60 years ago, Lashley (1941) described the features of a typical visual aura – 
scintillation-scotoma that starts at the visual field center, then propagates to the peripheral 
parts within 10-15 minutes and finally returns to normal within another 15 minutes. These 
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characteristics were soon realized to strikingly resemble another phenomenon, cortical 
spreading depression (CSD) first described in animals by Leao (Leao 1944; Milner 1958). 
CSD is a slowly (3-5 mm/min) propagating neuronal and glial depolarization wave that 
spreads across the cortex and leads to a long-lasting suppression of neural activity along with 
dramatic changes in ion homeostasis (Lauritzen 1994). Modern neuroimaging techniques have 
enabled continuous recording during aura in humans. Several recent studies indicated a slowly 
spreading area of abnormal neuronal suppression during aura and provided clear evidence for 
support of the hypothesis that aura is evoked by an electrophysiological event similar to CSD 
and that vascular events develop due to these fluctuations in neuronal activity (Cutrer et al. 
1998; Cao et al. 1999; Bowyer et al. 2001; Hadjikhani et al. 2001). 
4.4.3 Pathophysiology of the headache 
The meninges, layers that protect the central nervous system, are the only pain-sensitive part 
of the brain. Meningeal blood vessels are heavily innervated by trigeminal nerve fibers that 
serve to alert as well as defend brain tissue and headache can be regarded as a consequence of 
the activation of this alert system (Moskowitz and Macfarlane 1993). Trigeminal neurons are 
bipolar neurons whose cell bodies are located in the trigeminal ganglion and whose central 
projections make synaptic connections with the trigeminal nucleus caudalis in the brainstem. 
These fibers can be activated both by primary disturbances in the brain and other events 
occurring in the circulation or inside the vessel walls. Trigeminal axons contain vasoactive 
neuropeptides such as substance P, calcitonin gene-related peptide, and neurokinin A. In 
experimental animal models, release of these inflammatory mediators from activated 
trigeminal nerve endings initiates an inflammatory reaction (“neurogenic inflammation”) 
characterized by vasodilation and plasma protein leakage within dura mater (Markowitz et al. 
1987; Moskowitz and Macfarlane 1993). The headache in migraine is believed to result from 
similar activation of trigeminal neurons and the subsequent inflammatory reaction in the 
meninges (Moskowitz et al. 1979). Chemically-activated trigeminal afferents become 
sensitized and start to respond to normally innocuous mechanical stimuli. This explains how 
pulsating blood vessels can produce the throbbing pain of migraine and why coughing, 
bending over and other physical activities that increase intracranial pressure can worsen the 
pain (Strassman et al. 1996). Activated trigeminal neurons also transmit signals centrally to 
the trigeminal nucleus caudalis in the brainstem and to other brain structures involved in 
processing pain. On the other hand, defected descending antinociceptive activity of the 
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brainstem and subsequent decreased inhibition could make the trigeminovascular system 
hyperexcitable (Knight and Goadsby 2001). 
4.4.4 Central sensitization and triptans 
Using a rat model of intracranial pain Burstein and coworkers (2000) were able to show that 
after chemical simulation of the peripheral trigeminal neurons the central brainstem trigeminal 
neurons also become sensitized and start to respond to previously innocuous stimuli. These 
results could explain the fact that migraine is often associated with cutaneous allodynia, pain 
resulting from a non-noxious stimulus (for example heat, cold, or pressure) to normal skin. 
Cutaneous allodynia develops in 53-79% of patients and, interestingly, allodynamic patients 
have a longer history of migraine and experience attacks more frequently than non-allodynic 
patients (Burstein et al. 2000; Mathew et al. 2004). 
Triptans, specific acute anti-migraine drugs, are serotonin (5-hydroxytryptamine; 5-HT) 
receptor agonists specific to receptor subtypes 5-HT1B/1D. There are several explanations for 
their antimigraine effect including cranial vasoconstriction, inhibition of neurogenic 
inflammation, and inhibition of the excitability of trigeminovascular neurons by stimulating 
receptors in the brain stem (Ferrari 1998). Burstein’s team has shown that migraine should be 
treated with triptans before the development of central sensitization (Burstein et al. 2004). If 
triptans are administrated late in the attack, patients are much less likely to be rendered pain-
free although the throbbing of migraine pain is effectively terminated. Based on this finding 
and subsequent animal experiments, the authors suggested that the mechanism of action of 
triptans is to block synaptic transmission between peripheral and central trigeminovascular 
neurons (Levy et al. 2004). However, triptans have also been shown to activate 
antinociceptive descending pathways in the brainstem (Bartsch et al. 2004).  
4.4.5 How aura can lead to headache 
A recent study by Bolay and coworkers (2002) was the first to establish a pathophysiological 
connection between migraine aura and headache. They were able to demonstrate that CSD 
initiation in rats activates trigeminal afferents and evokes a series of meningeal and brainstem 
events that generate the headache. These events include meningeal vasodilation and plasma 
protein leakage within the dura mater. Furthermore, expression of c-fos, a marker for neuronal 
activity, was shown to be enhanced within the trigeminal nucleus caudalis, a brainstem region 
involved in the processing of nociceptive information. Trigeminal activation could be caused 
by CSD-induced changes in the composition of the extracellular fluid, such as increases in K+, 
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H+, neurotransmitter, and metabolite concentrations (Bolay et al. 2002). CSD has also been 
shown to induce changes in gene expression, especially expression of vasoactive peptides and 
L-type calcium channels (Choudhuri et al. 2002). On the other hand, the fact that the majority 
of migraine patients do not have aura is strong evidence against the causal relationship of 
migraine aura and headache. However, it has been suggested that in MO patients CSD could 
occur in a clinically silent area of the cerebral cortex (Woods et al. 1994; Cao et al. 1999).  
4.5 The burden of migraine 
4.5.1 Socio-economic impacts 
Migraine and other headache disorders constitute an enormous public-health problem with an 
impact on both individual patients and society. Although migraine certainly affects the quality 
of life, the personal impact is difficult to measure. The health-related quality of life in 
migraineurs has been assessed using validated questionnaires in a general population (Lipton 
et al. 2000; Terwindt et al. 2000). In both of these studies migraineurs reported diminished 
mental and physical functioning and well-being. In addition to the suffering caused by the 
attacks, fear of the next attack restricts the lifestyle of many migraine patients. Migraine can 
have a major disturbing effect on normal family functioning, especially childcare and social 
activities. In a study performed in the United States, 61% of patients reported that their attacks 
had a significant effect on their families and in 5% were even the cause of divorce (Smith 
1998). According to the Burden of Disease Statistics published yearly by the World Health 
Organization (WHO), 7666 (0.5% of total) disability-adjusted life-years (defined as one lost 
year of healthy life) were due to migraine in 2002 (www.who.int/whr/2004). 
Socio-economic impacts of migraine are substantial and include both direct costs associated 
with utilization of health care services and indirect costs associated with lost workplace 
productivity. The indirect costs of migraine predominate (Lipton et al. 1997). The absence 
from work because of migraine was estimated at 270 days per year per 1000 employed in 
Denmark (Rasmussen et al. 1992). This is, however, an underestimation, since most of the 
work-loss because of migraine is due to reduced effectiveness (Schwartz et al. 1997). Severe 
migraine can also lead to unemployment (Lipton et al. 1997).  
4.5.2 Comorbidity 
Comorbidity, defined as the co-existence of two disorders with a frequency greater than 
chance, of migraine has been thoroughly studied. Diseases repeatedly associated with 
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migraine include neurological disorders such as epilepsy and stroke, psychiatric disorders 
such as depression, bipolar disorder and anxiety disorders as well as immunologic conditions 
such as asthma and allergy (Merikangas et al. 1990; Tzourio et al. 1993; Ottman and Lipton 
1994; Lipton et al. 2000; Terwindt et al. 2000; Breslau and Rasmussen 2001; Radat and 
Swendsen 2005). Of these, the association between migraine and epilepsy is especially 
interesting since it has been speculated to be based on an underlying state of neuronal 
hyperexcitability that increases the risk of both of these disorders (Lipton et al. 1994). 
Migraine has also been shown to be a risk factor for ischemic stroke, this association being 
especially evident in young female MA patients (Tzourio
 et al. 1993; Tzourio et al. 1995; 
Chang
 et al. 1999; Etminan et al. 2005). 
4.5.3 Migraine – a progressive disorder? 
Two recent large studies, a population-based Dutch magnetic resonance imaging (MRI) study 
and a meta-analysis, have demonstrated an increased prevalence of subclinical white matter 
lesions in migraine patients (Kruit et al. 2004; Swartz and Kern 2004). Lesions in the 
cerebellum, the part of the brain vulnerable in FHM, were shown to be more common 
particularly in patients with MA and a high attack frequency (Kruit et al. 2004). However, 
more studies are needed to clarify whether these clinically silent brain lesions are a 
consequence of tissue damage caused by migraine attacks and whether migraine should 
actually be regarded as a progressive disorder (Lipton and Bigal 2005). Encouragingly, when 
comparing twins affected with migraine and their unaffected co-twins, migraine was not 
associated with deficits in cognitive functioning (Gaist et al. 2005). 
 
5 GENETICS OF MIGRAINE 
 
5.1 Genetic epidemiology 
Familial occurrence of a disease is assumed to be either due to shared genes or shared 
environmental factors. The relative importance of genetic and environmental factors on the 
phenotype can be estimated using different family- and twin-study designs and statistical 
methods (Kaprio 2000).  
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5.1.1 Twin studies –  the role of genetic and environmental factors 
The most common and also the simplest twin study design is to compare the similarity 
(concordance) of monozygotic (MZ) and dizygotic (DZ) twins and thus assess the inherited 
component of a disease. If the concordance for the disease in MZ twins is greater than in DZ 
twins, genetic factors are believed to be important (Kaprio 2000). The structural equation 
modeling technique is a more sophisticated method for estimating the contribution of genetic 
factors in disease susceptibility. The aim of this method is to determine the combination of 
genetic and environmental liability factors that best fit the data. Heritability (h2) is defined as 
the proportion of the overall phenotypic variance attributable to genetic factors (Kaprio 2000). 
Several large population-based twin studies in migraine have been performed. The Finnish 
study published in 1995 produced a heritability estimate of 40-50% (Honkasalo et al. 1995). 
The recently established GenomEUtwin project (Peltonen 2003) includes almost 30,000 twin 
pairs affected by migraine from six countries (Mulder et al. 2003). In this patient material, the 
estimated genetic variability of migraine was shown to be 34-56% (Table 7). Based on 
structural equation modeling, additive genetic factors and non-shared environmental factors 
seemed to contribute significantly to the susceptibility to migraine while shared 
environmental factors did not seem to have any impact. Furthermore, two migraine studies 
comparing twins raised together and apart have been performed (Ziegler et al. 1998; Svensson 
et al. 2003). Neither of these studies provided any evidence of a role of shared rearing 
environment in migraine susceptibility. 
 
 
Table 7. Heritability estimates for migraine in general according to the GenomEUtwin data (adapted from 
Mulder et al. 2003). 
 
  Twin correlations* h2 Total pairs  
 Population MZ DZ (ADE model) (N)  
 Australia 0.34 0.15 0.34 2718  
 Denmark 0.56 0.21 0.56 1882  
 Finland, younger 0.41 0.12 0.41 1912  
 Finland, older 0.51 0.22 0.51 8187  
 Netherlands, younger 0.53 0.22 0.53 1139  
 Netherlands, older 0.52 0.28 0.52 330  
 Sweden 0.44 0.13 0.44 12121  
 UK 0.42 0.17 0.42 1428  
* tetrachoric correlation of liability; MZ = monozygotic; DZ = dizygotic; h2 = heritability; ADE = model 
including additive genetic (A), non-additive genetic (D) and non-shared environmental (E) influences 
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Although one of the GenomEUtwin project aims is to separate migraine subtypes in the 
future, studies based on the Danish Twin Registry are by far the only ones that have provided 
information on the specific concordance rates for MO and MA (Gervil
 et al. 1999a; Gervil et 
al. 1999b; Ulrich et al. 1999b; Ulrich et al. 1999a). Based on these results, the concordance 
rates for MO seem to be only a little lower than for MA. Furthermore, the heritability 
estimates for both migraine subtypes exceed 60% (Table 8). 
5.1.2  Family studies 
Familial aggregation of migraine has been known for centuries but the high prevalence of the 
disease could cause this simply by chance (Merikangas 1996). Two population-based studies 
performed in the 1990's showed that the familial risk of migraine is indeed increased (Russell 
and Olesen 1995; Stewart et al. 1997). The American study found only modest evidence of 
increased migraine risk (~1.5-fold) in first-degree relatives but suggested familial aggregation 
to be associated with the severity of the disease (Stewart et al. 1997). The Danish study 
showed that first-degree relatives of probands with MO had a 1.9-fold increased risk of MO 
and 1.4 of MA while first-degree relatives of probands with MA had a 3.8-fold increased risk 
of MA and no increased risk of MO (Table 8) (Russell and Olesen 1995). In addition, they 
found that the spouses of MO probands had a 1.5-fold risk of MO and concluded that MO 
seems to be caused by a combination of genetic and environmental factors while MA is 
mainly determined by genetic factors (Russell and Olesen 1995). 
5.1.3 Mode of inheritance 
Complex segregation analysis performed in a population-based Danish sample indicated that 
the multifactorial inheritance model is most likely in both MO and MA (Russell
 et al. 1995b). 
A study analyzing a set of 31 high-risk MA families provided further support for this result 
 Table 8. Heritability estimates and familial risks for migraine subtypes according to Danish studies 
(Russell and Olesen 1995; Gervil et al. 1999a; Gervil et al. 1999b; Ulrich et al. 1999b; Ulrich et al. 1999a). 
 
  MO MA  
 Twin studies MZ DZ  MZ DZ  
 Pairwise concordance rate* 0.28 0.18  0.34 0.12  
 Tetrachoric correlation of liability 0.62 0.41  0.68 0.22  
 Heritability # 0.61 0.65  
 Family studies  
 Population relative risk among first-degree relatives 1.9 3.8  
 * the proportion of concordant pairs among all affected pairs (i.e. pairs in which at least one twin is 
affected); # estimated using structural equation model fitting 
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(Ulrich
 et al. 1997). However, the possibility of a subgroup of families having a Mendelian or 
mitochondrial pattern of inheritance still remains (Russell
 et al. 1995b). 
5.2 Linkage studies 
5.2.1 Genome-wide scans  
It is somewhat encouraging that despite the known difficulties of complex disease linkage 
studies, seven successful whole-genome scans have been conducted for migraine (Table 9). 
Five of these have been performed in multiple migraine families, our study being the first that 
was published (Wessman et al. 2002). Both in this and a subsequent study by the Icelandic 
deCODE a susceptibility locus on chromosome 4q was identified. However, in our study 
significant linkage to the MA phenotype was observed, while the deCODE study used MO 
with a slightly relaxed diagnostic criteria as a phenotype (Wessman et al. 2002; Björnsson et 
al. 2003). The Canadian study showed that there is a susceptibility locus for MA also in 
chromosome 11q (Cader et al. 2003). Interestingly, this susceptibility region contains several 
ion channel genes. A recently published Australian genome-scan showed suggestive evidence 
of linkage to 18p11 using a “severe migraine” phenotype, determined with latent class 
analysis (LCA), as the affection criterion (Nyholt
 et al. 2004; Lea et al. 2005). Subsequently, 
this LCA phenotyping has been used in another Australian genome-scan involving twin pairs 
(Nyholt
 et al. 2005). This study produced evidence of a migraine susceptibility locus on 
chromosome 5q21 and associated this locus specifically with pulsating headache (Nyholt
 et 
al. 2005). The two other studies, each carried out with a single large family, identified 
susceptibility loci on 14q in an Italian MO family (Soragna
 et al. 2003) and on 6p in a 
Swedish family with both MA and MO patients (Carlsson
 et al. 2002).  
 
 
Table 9. Genome-wide screens on migraine. 
 
 Identified 
locus 
Migraine 
subtype 
Family material Patients 
(N) 
LOD 
score 
Reference 
  
 
 4q24 MA 50 Finnish 246 4.5 Wessman et al. 2002  
 6p12.2-p21.1 MA, MO* 1 Swedish 30 5.8 Carlsson et al. 2002  
 11q24 MA 43 Canadian 248 5.6 Cader et al. 2003  
 4q21 MO* 117 Icelandic 351 4.1# Björnsson et al. 2003  
 14q21.2-q22.3 MO 1 Italian 22 5.3 Soragna et al. 2003  
 3q-tel 
18p11 
“LCA-severe” 92 Australian 380 2.3# 
2.3# 
Lea et al. 2005  
 5q21 “LCA-migraine” 790 Australian sib-pairs 556 3.7¤ Nyholt et al. 2005  
 MA = migraine with aura; MO = migraine without aura; LCA = latent class analysis;  * slightly relaxed 
diagnostic criteria; # nonparametric LOD score; ¤ MERLIN-regress LOD score 
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5.2.2 Candidate locus studies 
The contribution of several candidate chromosomal regions including 1q23, 1q31, 19p13, 
15q11-q13, and the X-chromosome to migraine susceptibility has been investigated. A 
functional candidate locus on 15q11-q13 that contains several gamma-amino butyric acid 
(GABA) receptor genes has recently been shown to be linked to MA in 10 Italian families 
(Russo et al. 2005). Chromosomal areas 1q23, 1q31, and 19p13 have been studied because of 
their known or suspected involvement with FHM, the autosomal dominant form of migraine 
(Joutel et al. 1993; Ducros et al. 1997; Gardner et al. 1997). Most thoroughly studied is the 
19p13 region that contains the CACNA1A gene, mutations of which cause FHM (Ophoff et al. 
1996a). Results of these studies are summarized in Table 10. It has been thought that the 
same cellular pathways could underlie both common and rare migraine subtypes but the 
overall evidence for CACNA1A involvement in MA or MO is weak even though some studies 
have reported suggestive linkage (May
 et al. 1995; Nyholt et al. 1998a; Terwindt et al. 2001). 
Furthermore, CACNA1A screening was negative even in one Australian family showing 
linkage to 19p13 (Lea
 et al. 2001b). In addition, several other investigators have searched for 
 
Table 10. Studies on the CACNA1A migraine susceptibility locus on chromosome 19p13. 
 
 
Linkage analysis studies 
 
 Families (N) Nationality Methods Results Phenotype Reference  
 4  Finnish Parametric linkage negative MA+MO Hovatta et al. 1994  
 28  German  ASP LOD 1.38 MA+MO May et al. 1995  
 4  Australian Parametric linkage, NPL HLOD 3.59 
NPL 6.64* 
MA+MO Nyholt et al. 1998a   
 82 Australian NPL, 
association  
negative MA+MO Lea et al. 2001a   
 36 Dutch ASP LOD 1.41 MA Terwindt et al. 2001  
 64 Canadian  Linkage, TDT negative MA Noble-Topham et al. 
2002 
 
 72 Finnish Parametric linkage, NPL negative MA Kaunisto et al. 2005  
 
Mutation screening studies 
 
 Patients (N) Nationality Methods Results Phenotype Reference  
 9 USA SSCP  negative migraine + 
vertigo 
Kim et al. 1998  
 1 family linked 
to 19p13 
Australian Sequencing negative MA+MO Lea et al. 2001a   
 32 Italian SSCP negative MA Brugnoni et al. 2002  
 143 German Searching for known 
mutations 
negative MA+MO Wieser et al. 2003  
 50 USA dHPLC negative MA+MO Jen et al. 2004b   
 ASP = affected sib-pair; LOD = logarithm of odds; HLOD = LOD score under heterogeneity; NPL = 
nonparametric linkage; TDT = transmission disequilibrium test; SSCP = single-strand conformation 
polymorphism; dHLPC = denaturing high-performance liquid chromatography; * GENEHUNTER Z score 
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CACNA1A mutations in migraine patients but the results have been consistently negative 
(Kim
 et al. 1998; Brugnoni et al. 2002; Wieser et al. 2003; Jen et al. 2004b). 
Interestingly, another locus on 19p13 that is close to but separate from CACNA1A has been 
connected with migraine. Thirteen out of 16 MA families were shown to be linked to a region 
containing the insulin receptor
 
gene (INSR), thus providing evidence of a major susceptibility 
locus for MA (Jones
 et al. 2001). This or the subsequently published association of MA to 
INSR polymorphisms (McCarthy et al. 2001) has, however, not yet been replicated. 
Due to its more recent discovery, involvement of the FHM2 gene, ATP1A2, in common 
migraine has been studied considerably less than the contribution of CACNA1A. No ATP1A2 
mutations were found in 50 probands with migraine with or without aura (Jen
 et al. 2004b). 
On the other hand, in a very recent publication, rare ATP1A2 variants were identified in two 
out of 45 migraine families and thus the gene was proposed to be involved also in the 
susceptibility to common migraine (Todt
 et al. 2005). The clinical details and functional 
results of this study are, however, somewhat confusing and thus no firm conclusions can be 
drawn at the moment. Nevertheless, it is worth mentioning that some evidence of linkage to 
chromosomal area 1q21-23 containing the ATP1A2 gene has been found in two recent 
Australian migraine whole-genome scans (Lea
 et al. 2005; Nyholt et al. 2005). 
Furthermore, the same Australian group has found some evidence of the presence of migraine 
susceptibility loci on 1q31 and Xq24-28 (Nyholt
 et al. 1998b; Nyholt et al. 2000; Lea et al. 
2002). Two families showing linkage to this X-chromosomal region were identified and a 
candidate gene HTR2C coding for a serotonin receptor 2C was studied but no evidence of 
association or potential mutations were found (Johnson et al. 2003).  
5.3 Association studies 
Numerous association studies using mainly the case-control setting have been performed in 
migraine. Unfortunately, the impact of these studies is relatively modest since only one or two 
polymorphisms per candidate gene have been studied in a small number of patients. 
Furthermore, in most cases confirmatory replication studies have not been published. An 
exception is the C677T polymorphism of the methylenetetrahydrofolate reductase gene 
(MTHFR) that decreases the enzyme activity to less than half of that of the wild type and thus 
leads to a mild hyperhomocysteinemia. This functional SNP has been suggested to be 
associated with MA in Turkish, Spanish, Japanese, and Australian populations (Kowa et al. 
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2000; Kara et al. 2003; Lea et al. 2004; Oterino et al. 2004). Other frequently studied 
candidate genes code for hormone receptors, serotonergic and dopaminergic signaling 
components, nitric oxide synthases, and components of the endothelin system (Lea
 et al. 
2001a; Tzourio
 et al. 2001; Palotie et al. 2002; Colson et al. 2005). To mention a few, 
migraine has been significantly associated with variants in both estrogen and progesterone 
receptors as well as promoter variants of the endothelin type A receptor, tumor necrosis factor 
α, and serotonin transporter genes (Tzourio
 et al. 2001; Colson et al. 2004; Rainero et al. 
2004b; Colson
 et al. 2005; Marziniak et al. 2005). 
6 CHANNELS AND CHANNELOPATHIES 
6.1 Ion channels and pumps and their role in neuronal signaling 
Ion channels are pore-forming membrane proteins through which specific ions can passively 
diffuse down an electrochemical gradient at a very high rate (~107 ions per second) 
(Ackerman and Clapham 1997). They are thus responsible for the selective ion permeability 
of the cell membrane and central to the function of excitable cells, but are also found in non-
excitable cells and in a wide range of organisms from bacteria and fungi to mammals and 
plants (Anderson and Greenberg 2001). There are more than 400 channel genes in the human 
genome (Gargus 2003). Typically ion channels are highly selective for the type of ion that can 
pass through, and based on this selectivity channels are classified into potassium (K+), sodium 
(Na+), calcium (Ca2+), chloride (Cl-), and unspecific cation channels (Hübner and Jentsch 
2002). Ion channels open and close in a tightly regulated way via a process called gating. 
Based on the gating-mechanism, channels can be grouped into channels gated by changes in 
the membrane potential (voltage-gated), by the binding of extracellular or intracellular ligands 
(ligand-gated), and by physical stimuli (swelling- or stretch-activated and heat sensitive 
channels) (Hübner and Jentsch 2002). 
Most members of the superfamily of voltage-gated channels share a common molecular 
structure. The pore forming (α1) subunits of the Na+ and Ca2+ channels contain four sets of six 
hydrophobic transmembrane segments (S1-S6) and intracellular N- and C-terminal domains 
(see Figure 2, page 46). K+ channels are the largest and most diverse class of voltage-gated 
channels. Most K+ channels span the membrane only six times, thus four such subunits must 
aggregate to form a functional channel. However, some K+ channels such as the inwardly 
rectifying K+ channels, consist of only two transmembrane segments (2TM) resembling the 
S5 and S6 regions of the other channels (Armstrong and Hille 1998). It is likely that 
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analogous 2TM channels are the evolutionary starting point of the whole superfamily of 
voltage-gated ion channels since they are also found in prokaryotes (Armstrong and Hille 
1998). 
Ion pumps carry out the essential task of generating and maintaining concentration gradients 
by actively transporting specific ions against their gradients. Pumps can either use the 
electrochemical gradients of other ions (ion exchangers/antiporters) or directly acquire energy 
by hydrolyzing adenosine triphosphate (ATP) (ATPase pumps) (Purves et al. 1997). Na+,K+-
ATPases found in the plasma membranes of virtually all animal cells are a classic example of 
such ion pumps. They are electrogenic E1-E2 type ion pumps and members of the P-type 
(phospho-intermediate type) ATPase family (Kaplan 2002). They transport three Na+ ions out 
and two K+ ions into the cell per every ATP-molecule hydrolyzed. 
In neurons, as well as in all other animal cells, electrical transmembrane potential is based on 
the two factors described above: 1) selective ion permeability of the cell membrane that is 
largely achieved by ion channels and 2) ion concentration differences across the cell 
membranes created by energy-consuming ion pumps. Most importantly, the intracellular 
concentrations of K+ and Na+ ions in, for example, mammalian neurons are 140 and 5-15 mM 
while the extracellular concentrations are 5 and 145 mM (Purves et al. 1997). Certain K+ 
channels that are open also in the resting cell and thus allow K+ ions to leak out are mainly 
responsible for maintaining the negative resting membrane potential of -40 to -90 mV in 
neurons (Purves et al. 1997). 
Neurons send information over long distances via action potential. Using squid giant axons, 
Alan Hodgkin and Andrew Huxley were able to describe the principles of the propagation of 
action potential more than 50 years ago (Hodgkin and Huxley 1952). When the membrane 
potential of a neuron depolarizes and reaches a threshold potential, an action potential occurs. 
Depolarization opens the voltage-gated Na+ channels, which leads to a brief influx of Na+ 
ions, further depolarization and the propagation of an action potential. A slower activation of 
voltage-gated K+ channels leads to an efflux of K+ ions and subsequent restoration of the 
resting-level membrane potential. When an action potential reaches a synapse, a specialized 
area that connects two interacting neurons, voltage-gated Ca2+ channels open. The increased 
internal Ca2+ concentration allows neurotransmitter-filled synaptic vesicles to fuse with the 
presynaptic membrane. Released neurotransmitters then diffuse throughout the synaptic cleft, 
bind to receptors in the plasma membrane of the postsynaptic neuron, and activate ligand-
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gated ion channels (fast synaptic transmission) or other regulatory proteins (slow synaptic 
transmission).  
6.2 Voltage-gated Ca2+ channels 
Calcium regulates various neuronal processes. Basically, in all cells intracellular Ca2+ levels 
are held 10,000 fold lower than the extracellular levels and cells are activated when the 
intracellular Ca2+ concentration rises from the resting level of 100 nM to 1000 nM (Berridge 
et al. 2000). In neurons, the Ca2+ signal is generated mainly by allowing the entry of 
extracellular Ca2+ into the cell through activated voltage-gated or ligand-gated Ca2+ channels. 
This signal is then amplified using intracellular sources of Ca2+, namely Ca2+ stored within the 
endoplasmic reticulum and released through Ca2+-inducible inositol 1,4,5-triphosphate and 
ryanodine receptors (Berridge 1998).  
Voltage-gated Ca2+ channels are composed of various subunits (Figure 2). α1 subunits consist 
of  intracellular  C-  and N-termini  and four  repeated domains  (I  to  IV)  each containing six 
Figure 2. Voltage-gated calcium channel subunits (modified from Catterall 2000). α1 subunit of 190-250 
kDa is the main pore-forming channel subunit while three auxiliary subunits, α2δ, β, and γ fine-tune 
channel function (Ertel et al. 2000). Intracellular β subunits have a large, isoform-specific effect on 
channel kinetics (Moreno et al. 1997). In addition, they are responsible for trafficking of the channel to 
the plasma membrane by masking the endoplasmic reticulum retention signal located in loop I-II (Bichet 
et al. 2000). The heavily glycosylated, mainly extracellular α2δ subunit and the γ subunit that contains 
four transmembrane regions also modify the electrophysiological properties of α1 subunits (Catterall 
2000). 
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membrane spanning segments (S1 to S6) and a membrane-associated loop between segments 
S5 and S6 (Tanabe et al. 1987). S4-S6 segments are the functionally most important channel 
parts. The S5 and S6 segments and the pore loops located between them form the pore lining 
responsible for the ion selectivity of voltage-gated ion channels. The 20 amino acids long pore 
loops narrow the pore of the channel and contain ion specificity-determining signature 
sequences (Armstrong and Hille 1998). Typically voltage-gated channels respond to 
membrane polarization by opening. The voltage sensor of the channel is formed by the S4 
segments containing positively charged amino acids that move in response to voltage. This 
leads to a conformational change that opens the channel (Catterall 1995). 
Ten genes coding for α1 subunits have been identified while the auxiliary subunits are 
encoded by 3-8 genes each. Furthermore, at least α1 and β subunits are subject to alternative 
splicing thereby adding to the complexity of possible channel subunit compositions 
(Pietrobon 2002). The ten α1 subunits are grouped into three subfamilies (Cav1, Cav2 and 
Cav3) based on amino acid sequence similarities (Table 11) (Ertel et al. 2000). The amino 
acid sequences of α1 subunits are more than 70% identical within a subfamily but less than 
40% identical among subfamilies (Ertel et al. 2000). Furthermore, several types of 
electrophysiologically and pharmacologically distinct Ca2+ currents, named as L-, N-, P-, Q-, 
 
Table 11. Voltage-gated calcium channel (Cav) α1 subunits. 
 
 
α1 
subunit Gene Location 
Current 
type Primary tissues 
Related 
human 
diseases Reference(s) 
 
 Cav1.1 CACNA1S 1q31-q32 L skeletal muscle hypoKPP, 
MHS 
Ptacek et al. 1994; 
Monnier et al. 1997 
 
 Cav1.2 CACNA1C 12p13.3 L heart, endocrine, 
neurons 
Timothy 
syndrome 
Splawski et al. 2004  
 Cav1.3 CACNA1D 3p14.3 L endocrine, 
neurons 
-   
 Cav1.4 CACNA1F Xp11.23 L retina CSNB2 Bech-Hansen et al. 1998  
 Cav2.1 CACNA1A 19p13.1-2 P/Q neurons FHM1, EA-2, 
SCA-6, IGE 
Ophoff et al. 1996b; 
Zhuchenko et al. 1997; 
Chioza et al. 2001 
 
 Cav2.2 CACNA1B 9q34 N neurons -   
 Cav2.3 CACNA1E 1q25-q31 R neurons -   
 Cav3.1 CACNA1G 17q22 T heart, skeletal 
muscle, neurons 
-   
 Cav3.2 CACNA1H 16p13.4 T heart, neurons absence 
epilepsy 
Chen et al. 2003  
 Cav3.3 CACNA1I 22q2.3-
q13.2 
T neurons -   
 hypoKPP = hypokalemic periodic paralysis; MHS = malignant hyperthermia susceptibility; CSNB2 = X-
linked congenital stationary night blindness; FHM = familial hemiplegic migraine; EA = episodic ataxia; 
SCA = spinocerebellar ataxia; IGE = idiopathic generalized epilepsy 
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R-, and T-type currents, exist but the correlation with the different α1 subunits is somewhat 
loose (Table 11) (Catterall 2000). 
 
The Cav1 subfamily includes channels mediating L-type (long-lasting) currents while 
channels belonging to the Cav2 subfamily mediate primarily neuronal P/Q-, N-, and R-type 
currents (Ertel et al. 2000). T-type (transient) currents are mediated by channels belonging to 
the Cav3 subfamily. L-type currents are the main type of current in muscle and endocrine 
cells. This type of current, as well as N-, P/Q-, and R-type currents expressed mainly in 
neurons, requires a strong depolarization (~50 mV) for activation unlike T-type current which 
is activated at much more negative potentials and expressed in many cell types (Catterall 
2000). 
Different parts of the neurons contain specific Ca2+ channels that perform separate functions. 
Presynaptic membranes have N- and P/Q-type voltage-gated channels that trigger the release 
of neurotransmitters into the presynaptic cleft. The cell body and dendrites contain mainly L-
type voltage-gated and ligand-gated Ca2+ channels that act in the generation of Ca2+ signals 
important in the modification of the strength of synaptic transmission. Furthermore, Ca2+ has 
been shown to regulate both long term potentiation and long term depression, processes 
known to be the basis of learning and memory (Augustine et al. 2003). These various effects 
of Ca2+ can only be achieved using an extensive network of signaling components and, 
indeed, numerous proteins such as calmodulin, troponin C, and synaptotagmin activate in 
response to increased Ca2+ concentration (Berridge et al. 2000). 
6.3 Channelopathies 
Channelopathies are a recently identified and rapidly expanding group of disorders defined as 
diseases caused by defective ion channels. The first channelopathies, characterized 
approximately 15 years ago, were a group of muscle disorders called periodic paralysis and 
nondystrophic myotonias (Ptacek et al. 1991; McClatchey et al. 1992). Since then, many 
different ion channel genes have been implicated in the pathophysiology of various disorders 
affecting the skeletal muscle, heart, peripheral nerves, and brain. In addition to the traditional 
genetic channelopathies, two other channelopathy forms have been identified. Autoimmune 
channelopathies include diseases such as Lambert-Eaton myasthenic syndrome in which 
channel function is disturbed due to antibodies raised against Cav2.1 channels (Lennon et al. 
1995). Transcriptional channelopathies, on the other hand, are caused by dysregulated 
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transcription of non-mutated channel genes as a result of injury to neurons (Waxman 2001). 
An example of this kind of disease process is peripheral nerve injury, which can lead to 
altered Na+ channel expression resulting in hyperexcitability, neuropathic pain and 
paresthesiae (Waxman 2001). 
Practically all channelopathies are rare and episodic in nature and most have their onset in 
childhood. Furthermore, the attacks are precipitated by largely overlapping factors such as 
stress and fatigue and are treated with similar drugs, for instance carbonic anhydrase 
inhibitors (Ptacek and Fu 2004). The phenotype both within and between families is often 
highly variable. Locus heterogeneity is common since mutations in different ion channel 
genes can cause extremely similar phenotypes (Kullmann and Hanna 2002). A good example 
of this is the long QT syndrome caused by mutations in several different Na+ and K+ channel 
genes (Bulman 1997). On the other hand, different mutations in the same gene can lead to 
diverse phenotypes; for instance CACNA1A gene mutations cause both episodic ataxia and 
familial hemiplegic migraine (Ophoff
 et al. 1996a). Interestingly, channelopathies typically 
affect only one specific tissue type although the gene in question can be expressed in many 
other tissues. A recently described exception is a specific CACNA1C mutation that causes 
Timothy syndrome, a multisystem disorder with symptoms as diverse as arrhythmia, 
developmental abnormalities, and autism (Splawski et al. 2004). There are several possible 
mechanisms by which an ion channel gene mutation can cause a disease, including gain or 
loss of function of the channel, and dominant negative effects (Felix 2000). In order to 
understand the functional consequences of potential disease-causing mutations, functional in 
vitro tests, typically performed using patch clamp methods, are needed. 
Although the best understood channelopathies are those affecting either cardiac contractility, 
such as long QT syndrome, or muscle-fiber excitability, for instance periodic paralysis and 
myotonias, many neuronal channelopathies have also been described. In Table 12, these 
central nervous system disorders are listed (Kullmann and Hanna 2002). Most of these 
diseases belong to a group of childhood idiopathic epilepsies. Several subtypes of this 
phenotype have been shown to be caused by mutations in both voltage-gated and ligand-gated 
ion channels and primary neuronal hyperexcitability is believed to be the underlying disease 
mechanism (Steinlein 2004). Other examples of neuronal channelopathies are autosomal 
dominant episodic ataxias, characterized by either brief (EA-1) or prolonged (EA-2) episodes 
of cerebellar incoordination (Table 12). 
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6.4 Diseases caused by CACNA1A mutations 
CACNA1A codes for the α1 subunit of Cav2.1 channels. The complementary DNA (cDNA) 
for this gene was first cloned and sequenced from rabbit and rat brain in the beginning of 
1990s (Mori et al. 1991; Starr et al. 1991). The human ortholog (previously called 
CACNL1A4) is located on chromosome 19p13 (Diriong et al. 1995). The gene was shown to 
cover more than 300 kb and consist of 47 exons that encode a protein of 2261 amino acids 
(Ophoff
 et al. 1996a). Several alternatively spliced exons have since been identified (Soong et 
al. 2002). The Cav2.1 channels are widely expressed in the presynaptic terminals, cell bodies 
and dendrites of cerebellar, hippocampal and most other neurons, expression being most 
prominent in the Purkinje cells (Westenbroek
 et al. 1995). Expression at the neuromuscular 
junction is also abundant (Protti et al. 1996). The Cav2.1 channels have a predominant role in 
the regulation of neurotransmitter release by directly interacting with proteins of the synaptic 
vesicle docking/fusion machinery (Catterall 1998). The postsynaptic Cav2.1 channels have 
 
Table 12. Neurological channelopathies (excluding diseases associated with blindness or deafness).  
 
 Channel type Gene Phenotype(s) Reference(s)  
 Voltage-gated     
 KCNA1 EA-1 Browne et al. 1994  
 KCNQ2 BFNC Singh et al. 1998  
 
K+ channels 
KCNQ3 BFNC Charlier et al. 1998  
 SCN1A GEFS+ , SMEI, FHM Escayg et al. 2000b; Dichgans et al. 2005   
 SCN2A GEFS+ Sugawara et al. 2001  
 
Na+ channels 
SCN1B GEFS+ Wallace et al. 1998  
 CACNA1A FHM1, EA-2, SCA-6, IGE Ophoff et al. 1996b; Zhuchenko et al. 
1997; Chioza et al. 2001 
 
 CACNA1C Timothy syndrome Splawski et al. 2004  
 CACNA1H Childhood absence epilepsy  Chen et al. 2003  
 
Ca2+ channels 
CACNB4 Juvenile myoclonic epilepsy Escayg et al. 2000a   
 Cl- channels CLCN2 Absence epilepsy Haug et al. 2003  
 Cyclic-nucleotide gated  
 K+ channels KCNMA1 GEPD Du et al. 2005  
 Ligand-gated     
 CHRNA4 ADNFLE Steinlein et al. 1995  
 
Nicotinic 
acetylcholine 
receptors 
CHRNB2 ADNFLE De Fusco et al. 2000  
 Glycine 
receptors  
GLRA1 Familial hyperekplexia Shiang et al. 1993  
 GABRA1 Juvenile myoclonic epilepsy Cossette et al. 2002  
 
GABA-
receptors GABRG2 GEFS+ Wallace et al. 2001  
 EA = episodic ataxia; BFNC = benign familial neonatal convulsions; GEFS+ = generalized epilepsy with 
febrile seizures plus; SMEI = severe myoclonic epilepsy of infancy; FHM = familial hemiplegic migraine; 
SCA = spinocerebellar ataxia; IGE = idiopathic generalized epilepsy; GEPD = generalized epilepsy and 
paroxysmal dyskinesia; ADNFLE = autosomal dominant nocturnal frontal lobe epilepsy; GABA = gamma-
amino butyric acid 
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other important functions especially in the cerebellum, including shaping neuronal 
excitability, activity-dependent gene expression, as well as neuronal survival and 
differentiation (Pineda et al. 1998; Sutton et al. 1999; Miyazaki et al. 2004). Cav2.1 channels 
are tightly regulated and fine-tuned by numerous mechanisms as could be expected because of 
their diverse roles (De Waard
 et al. 1997; Lee et al. 1999; Zhong et al. 1999). 
CACNA1A mutations have been shown to cause at least three neurological diseases, i.e. EA-2, 
FHM, and spinocerebellar ataxia type 6 (SCA-6). In addition, there is evidence of association 
to idiopathic generalized epilepsy (Kors
 et al. 2004b). 
6.4.1 Episodic ataxia type 2 
6.4.1.1 Clinical features 
Patients with periodic ataxia were first described in 1946 (Parker 1946). Episodic ataxia type 
2 (EA-2; previously also called hereditary paroxysmal cerebellar ataxia) is characterized by 
recurrent episodes of severe truncal and gait ataxia (unsteadiness and limb incoordination) as 
well as dysarthria lasting typically from 15 minutes to a few hours (Vahedi et al. 1995). 
Attacks are often associated with vertigo, nausea, and migraine headaches (Baloh et al. 1997). 
Interictal findings include mainly gaze-evoked nystagmus and mild permanent cerebellar 
ataxia although in some patients ataxia can also be slowly progressive (Vahedi et al. 1995). In 
rare cases, the clinical phenotype also includes mental retardation and/or epilepsy (Denier
 et 
al. 1999; Jen et al. 2004a). In many ways, this disease can be regarded as a prototype of an 
ion channel disorder. It is of episodic nature, the phenotype both between and within families 
is very variable and the attacks can be precipitated by several factors such as emotional stress, 
physical exercise, alcohol, caffeine, and heat (e.g. sauna). Age of onset is typically in 
childhood, before the age of 20 (Baloh et al. 1997). Acetazolamide, a carbonic anhydrase 
inhibitor, prevents attacks in most patients (Griggs et al. 1978). Although the typical clinical 
course of EA-2 can be regarded as being relatively benign, fear of the next attack can be 
stressful and disturb a patients social life similarly to severe migraine.  
6.4.1.2 Genetics 
EA-2 is inherited as an autosomal dominant trait with incomplete penetrance. Some sporadic 
cases with de novo mutations have also been described (Jen et al. 2004a). Significant 
evidence of linkage to chromosome 19p13 was obtained by several groups during 1995 
(Kramer
 et al. 1995; Teh et al. 1995; Vahedi et al. 1995; von Brederlow et al. 1995). A year 
later, mutations in CACNA1A  were identified and at the same time the disease was shown  to  
REVIEW OF THE LITERATURE 
 
 52
be allelic to FHM (Ophoff
 et al. 1996a). At least 46 EA-2-causing mutations in the CACNA1A 
gene have been described. Twenty-one of these are nonsense mutations that lead to premature 
STOP-codons either directly or by deleting or inserting 1, 2 or 4 nucleotides and thus 
producing a frameshift (Table 13). Furthermore, nine splice site mutations (all but one of 
them affecting the donor splice site) have been identified (Table 13). Interestingly, two of 
these mutations do not involve the invariant GT donor splice site nucleotides, but still cause 
aberrant splicing (Wan
 et al. 2005a). In addition to the mutations described above, small 
 
Table 13. CACNA1A nonsense mutations causing EA-2 (in parenthesis the nomenclature used in the 
original publication). 
 
 Nucleotide and protein change 
(ref. sequence X99897) 
Location Domain Reference(s)  
 IVS6+1G>A→ aberrant splicing intron 6 I S5-S6 Subramony et al. 2003  
 IVS11+1G>A→ aberrant splicing intron 11 II S1-S2 Denier et al. 1999  
 del2145-48 TTCA→ FS + stop at aa 658 exon 14 II S5 van den Maagdenberg et al. 2002  
 del2317-8 AG→ FS + stop at aa 780 exon 16 II S5-S6 Denier et al. 1999;  
van den Maagdenberg et al. 2002;
Jen et al. 2004a  
 
 ”del2259-60 AG→ FS + stop at aa 780” exon 16 II S6  Denier et al. 1999  
 ins 3091G→ FS + stop at aa 1067 exon 19 II-III loop Scoggan et al. 2001; 
Rucker et al. 2005 
 
 ins3689C→ FS + stop at aa 1144 exon 20 II-III loop Matsuyama et al. 2003  
 del3765C (3772) → FS + stop at aa 1186 exon 20 II-III loop Spacey et al. 2005  
 IVS21+1G>A→ aberrant splicing intron 21 II-III loop Eunson et al. 2005  
 “del3797C→ FS + stop at aa 1293” exon 22 III S1 Denier et al. 1999  
 del4073C→ FS + stop at aa 1294 exon 22 III S1 Ophoff et al. 1996b   
 C4110T→ R1279X exon 23 III S1-S2 Yue et al. 1998  
 IVS24+1G>A→ aberrant splicing intron 24 III S3 Ophoff et al. 1996b   
 IVS24+3insT→ aberrant splicing intron 24 III S3 Wan et al. 2005a  
 del4451C→ FS + stop at 1430 exon 26 III S5 van den Maagdenberg et al. 2002  
 IVS26+1G>A→ aberrant splicing intron 26 III S5-S6 Denier et al. 1999  
 C4607G→ Y1444X (1443) exon 27 III S5-S6 Denier et al. 1999  
 G4621A→ W1449X (1451) exon 27 III S5-S6 Jen et al. 2004a   
 IVS27+1G>T→ aberrant splicing intron 27 III S5-S6 Jen et al. 2004a   
 C4914T→ R1547X (1546) exon 29 III-IV loop Denier et al. 1999; 
Jen et al. 1999 
 
 C4959T→ Q1562X (1561) exon 29 III-IV loop Spacey et al. 2005  
 del5123G→ FS + stop at aa 1624 exon 30 IV S2 Scoggan et al. 2001  
 C5616T→ R1781X (1785) exon 35 IV S5-S6 Jen et al. 2004a   
 C5733T→ R1820X* exon 36 C-terminus Jouvenceau et al. 2001  
 IVS36-2A>G→ aberrant splicing intron 36 C-terminus Kaunisto et al. 2004a   
 del5837-38CA→Y1854X  exon 37A C-terminus Kors 2004  
 C5837G→Y1854X exon 37A C-terminus Kors 2004  
 del IVS41+3-6→ aberrant splicing intron 41 C-terminus Wan et al. 2005a; 
Eunson et al. 2005 
 
 C6378T→ Q2035X (2039) exon 42 C-terminus Jen et al. 2004a   
 del6431C→ FS + stop at aa 2123 (2126) exon 42 C-terminus Jen et al. 2004a   
 FS = frameshift; del = deletion; ins = insertion; aa = amino acid; * epilepsy phenotype. If the mutation is 
inside quotation marks, the reference sequence used in the original publication is not known.  
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expansions of the CAG-repeat normally causing the SCA-6 phenotype have been identified in 
two EA-2 families (Jodice et al. 1997). 
In the thus far largest EA-2 study, 18 families and nine sporadic patients were studied (Jen
 et 
al. 2004a). Approximately 60% of the EA-2 families were shown to be linked to 19p13, thus 
it seems that there has to be other EA-2 susceptibility loci but these have not yet been 
identified. Mutations in CACNA1A were found in nine of 11 linked families and in four of 
nine sporadic patients. Four of these 13 mutations were missense mutations. Other studies 
have also shown that non-truncating EA-2 mutations are not as rare as previously thought. 
Thus far 16 different missense mutations have been identified in EA-2 patients (Figure 3, 
Table 14). Interestingly, they seem to be clustered in the highly conserved S5-S6 linkers of 
the channel (Jen
 et al. 2004a; Mantuano et al. 2004). It is possible that these parts of the 
channel are particularly vulnerable and that missense mutations in these areas are more likely 
to produce the EA-2 phenotype (Mantuano et al. 2004). Furthermore, is has been suggested 
that the clinical phenotype of the patients carrying missense EA-2 mutations is possibly 
somewhat milder (later age of onset, no mental retardation) than that of patients with 
truncating mutations (Mantuano et al. 2004). 
 Table 14. Missense mutations and small in-frame deletions that cause EA-2 (in parenthesis the nomenclature 
used in the original publication).  
 
 Nucleotide and protein change 
(ref. sequence X99897) 
Location Domain Reference  
 714G>A → E147K* exon 3 I S2 Imbrici et al. 2004  
 1032C>T→ H253Y exon 5 I S5-S6 van den Maagdenberg et al. 2002  
 1041T>C→ C256R exon 5 I S5-S6 Mantuano et al. 2004  
 1135G>A→ C287Y exon 6 I S5-S6 Jen et al. 2004a   
 1152G>A→ G293R# exon 6 I S5-S6 Yue et al. 1997  
 2272C>T→ T666M¤ exon 16 II S5-S6 Jen et al. 2004a  
 4486T>G→F1404C (F1406C) exon 26 III S5-S6 Jen et al. 2001  
 4722G>A→ G1483R exon 28 III S6 Mantuano et al. 2004  
 del4739-44GTCCAT→ del MS 1488-9 exon 28 III S6 Mantuano et al. 2004  
 4747T>C→ F1491S exon 28 III S6 Guida et al. 2001  
 4755G>A→ V1494I exon 28 III S6 Mantuano et al. 2004  
 del5056-58CTT→ delY1595, A1594D 
(delY1594, A1593D) 
exon 30 IV S2 Denier et al. 1999  
 5260G>A→ R1662H (R1666H) exon 32 IV S4 Friend et al. 1999  
 5485A>T→H1737L (H1736L) exon 34 IV S5-S6 Spacey et al. 2004  
 5544G>A→ E1757K exon 35 IV S5-S6 Denier et al. 2001  
 6681C>T→R2136C exon 45 C-terminus Mantuano et al. 2004  
 Additional phenotypic features: * epilepsy,  # severe progressive ataxia, ¤ hemiplegic migraine  
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Figure 3. Identified missense EA-2 mutations shown on the Cav2.1 channel topology. 
In summary, a wide range of CACNA1A mutations have been shown to cause EA-2. These 
mutations are located all over the gene and nearly all have been found in only one family or 
patient. Thus no common mutations that would make genetic testing easier have been 
identified (Jen
 et al. 2004a). 
6.4.1.3 Functional consequences of EA-2 mutations 
The pathogenetic mechanisms of EA-2 are still incompletely understood. In principle, the 
CACNA1A mutations resulting in truncated channel proteins could completely or partially 
prevent the translation process due to nonsense-mediated mRNA decay (Baker and Parker 
2004). If truncated gene products are present, they might be unstable and degrade quickly or 
might not be targeted to the cell membrane. Alternatively, these truncated gene products could 
be targeted normally, but severely disrupt the channel function. 
Electrophysiological studies have consistently shown that EA-2 mutations cause a complete 
or pronounced loss of function of the Cav2.1 channel (Guida et al. 2001; Jen et al. 2001; 
Wappl
 et al. 2002; Imbrici et al. 2004; Spacey et al. 2004; Wan et al. 2005b). This loss of 
function is seen in both missense and nonsense mutations and is either due to decreased single 
channel conductance or to reduced current density or both, depending on the mutation. 
Furthermore, in contrast to most published results, two missense EA-2 mutations were 
recently shown to cause abnormal channel trafficking in addition to altered channel kinetics 
(Wan
 et al. 2005b). It is still under debate whether simple haploinsufficiency could explain 
the EA-2 symptoms or if a dominant negative effect, e.g. competition for auxiliary subunits, is 
the underlying mechanism. Recently, a dominant negative effect was reported in a study of a 
construct mimicking one of the EA-2 truncating mutations (Page et al. 2004). In co-
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expression experiments this two-domain mutant construct strongly inhibited Cav2.1 currents. 
Misfolding of the full-length channels due to interaction with the truncated channels and 
subsequent activation of an endoplasmic reticulum resident ribonucleic acid (RNA)-
dependent kinase, a component of the unfolded protein response, was suggested to be the 
mechanism of this dominant-negative suppression (Page et al. 2004). 
Since EA-2 patients are typically very responsive to acetazolamide, the effects of this drug on 
Cav2.1 channels have also been investigated. However, no effect on the electrophysiological 
properties of either wild type or mutated channels was seen and thus the mechanism of action 
of this drug is currently unknown (Spacey et al. 2004)  
6.4.1.4 Relevant mouse models 
Several spontaneous mutations in the mouse orthologue of CACNA1A have been identified. 
Tottering (Cacna1atg), rocker (Cacna1arkr) and rolling Nagoya (Cacna1arol) phenotypes are 
caused by missense mutations and characterized by relatively mild ataxia and, except for 
rolling Nagoya, intermittent seizures that resemble human absence epilepsy (Fletcher et al. 
1996; Mori et al. 2000; Zwingman et al. 2001). A splice site mutation in the 3’ end of 
Cacna1a is the cause of the leaner phenotype (Cacna1atg-la) characterized by more severe 
ataxia, degeneration of cerebellar neurons and a shortened lifespan (Fletcher et al. 1996). 
Electrophysiological studies have shown that the main effect of the tottering, leaner and 
rolling Nagoya mutations is, similar to EA-2 mutations, marked reduction in Ca2+ current 
density (Wakamori et al. 1998; Mori et al. 2000). In addition, tottering and leaner mice show 
defective neurotransmitter release and, interestingly, elevated thresholds for cortical spreading 
depression (Caddick et al. 1999; Ayata et al. 2000; Plomp et al. 2000).  
Two different Cacna1a knock-out strains have been developed (Jun et al. 1999; Fletcher et al. 
2001). Since N-and L-type channel currents are elevated in these knock-out mice and thus 
compensate for the lack of P/Q-type currents, they are initially viable but develop a rapidly 
progressive neurological deficit with ataxia and dystonia and die at the age of 3-4 weeks. 
Similar to the spontaneous mutant mice, heterozygous knock-out animals are healthy even 
though the P/Q-type current density is 50% reduced (Fletcher et al. 2001). 
6.4.2 Spinocerebellar ataxia type 6 
Spinocerebellar ataxias (SCAs) comprise a large and heterogeneous group of dominantly 
inherited, slowly progressive neurodegenerative disorders. Spinocerebellar ataxia type 6 
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(SCA-6) is characterized by atrophy of cerebellar Purkinje cells, which leads to a late-onset 
cerebellar ataxia. The overall prevalence of SCAs is estimated to be 0.003% and SCA-6 
patients comprise around 15% of all SCA cases (Schöls et al. 2004). Like several other SCAs, 
SCA-6 is a polyglutamine disorder since small expansions of the CAG repeat located in the 
3’-end of CACNA1A are the cause of this disease (Zhuchenko et al. 1997; Frontali 2001). The 
pathogenic mechanism of polyglutamine disorders is thought to involve cytotoxic aggregation 
of the polyglutamine tract-containing proteins within neurons (Schöls et al. 2004). However, 
SCA-6 differs in many ways from the other trinucleotide repeat diseases. In SCA-6 the CAG 
repeat expansion is exceptionally small (21-33 copies) and relatively stable (Zhuchenko et al. 
1997; Frontali 2001). Furthermore, anticipation is quite rare (Frontali 2001). Based on these 
features and recent electrophysiological evidence it has been suggested that dysfunctioning 
Cav2.1 channels cause the SCA-6 phenotype (Toru et al. 2000; Matsuyama et al. 2004). Thus 
this disease could also be regarded as a channelopathy rather than a polyglutamine disorder 
(Frontali 2001). 
6.4.3 Idiopathic generalized epilepsy 
In one sporadic patient and one family, the CACNA1A mutations have been shown to cause a 
complex phenotype with both ataxia and epilepsy (Jouvenceau et al. 2001; Imbrici et al. 
2004). In addition, CACNA1A SNPs located within and around exon 8 have been shown to be 
associated with idiopathic generalized epilepsy (Chioza et al. 2001; Chioza et al. 2002). This 
is, however, still controversial since a replication study found no evidence of association 
(Sander et al. 2002). 
6.4.4 Familial hemiplegic migraine type 1 
6.4.4.1 Genetics 
Like EA-2, familial hemiplegic migraine is inherited as an autosomal dominant trait with 
incomplete penetrance (Joutel et al. 1993). The penetrance has been estimated to be about 0.9 
and, interestingly, environmental factors also seem to have a role since MZ twins discordant 
for FHM have been reported (Ducros et al. 1995). The first locus linked to FHM was mapped 
to chromosome 19p13 using two large pedigrees and a candidate locus strategy in 1993 
(Joutel et al. 1993). After demonstrating genetic heterogeneity of this disease, narrowing the 
critical chromosomal region and excluding the protein-kinase C substrate heavy-chain 
(PRKCSH) gene, a Dutch group identified causative mutations in CACNA1A (Ophoff et al. 
1994; Ophoff
 et al. 1996b; Ophoff et al. 1996a). Mutations in this gene are the cause of FHM 
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in at least 50% of families including practically all of the families with progressive cerebellar 
symptoms (Ducros et al. 2001). By August 2005, 17 different CACNA1A mutations resulting 
in FHM1 have been described in 40 families and 6 sporadic cases (Figure 4) (Ophoff
 et al. 
1996a; Battistini
 et al. 1999; Carrera et al. 1999; Ducros et al. 1999; Friend et al. 1999; 
Gardner
 et al. 1999; Vahedi et al. 2000; Ducros et al. 2001; Kors et al. 2001; Takahashi et al. 
2002; Terwindt
 et al. 2002; Wada et al. 2002; Alonso et al. 2003; Kors et al. 2003; Alonso et 
al. 2004; Beauvais et al. 2004; Kors et al. 2004a). However, only a small percentage of 
patients with sporadic hemiplegic migraine seem to carry CACNA1A mutations (Carrera et al. 
1999; Vahedi et al. 2000; Ducros et al. 2001; Terwindt et al. 2002; Beauvais et al. 2004). 
 
 
Figure 4. Identified FHM1 mutations. HM =hemiplegic migraine; PCA = progressive cerebellar ataxia. 
The FHM1-associated mutations in CACNA1A are exclusively missense mutations and are 
clearly aggregated in the functionally most significant parts (transmembrane domains S4-S6 
and the P-loop) of the channel. The unquestionably most common mutation is T666M, 
identified in 18 families and 3 sporadic cases (Ophoff
 et al. 1996a; Ducros et al. 1999; Friend 
et al. 1999; Takahashi et al. 2002; Terwindt et al. 2002; Wada et al. 2002; Kors et al. 2003; 
Jen
 et al. 2004b). Typically, this mutation causes a phenotype of hemiplegic migraine 
associated with cerebellar signs, although a strict genotype-phenotype relationship does not 
seem to exist (Wada et al. 2002; Kors et al. 2003). The R583Q mutation is also recurrent 
(described in 5 families and 1 sporadic patient) and, similar to T666M, is associated with the 
phenotype of permanent neurological signs (Battistini et al. 1999; Ducros et al. 2001; 
Terwindt et al. 2002; Alonso et al. 2003). All other FHM1 mutations have only been 
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identified once or twice. Of these, mutations S218L and I1710T are associated with 
distinctive FHM phenotypes. In addition to FHM and progressive ataxia, I1710T causes 
epilepsy while S218L can lead to a delayed severe cerebral edema (swelling caused by an 
abnormal accumulation of fluid) and coma after a minor head trauma (Kors
 et al. 2001; 
Beauvais
 et al. 2004; Kors et al. 2004a). 
In the thus far largest FHM1 genotype-phenotype correlation study, 89% of the CACNA1A 
mutation carriers were shown to be affected and one third of these at least occasionally had 
severe attacks with either coma or prolonged hemiplegia (Ducros et al. 2001). Of the patients 
that carry mutations associated with progressive neurological symptoms, only approximately 
80% actually demonstrate these signs (Ducros et al. 2001). Reasons for the incomplete 
penetrance and phenotype variability are unknown, although modifier genes are one possible 
explanation (Buchner et al. 2003). 
 
6.4.4.2 Electrophysiological studies and the knock-in mice model 
Electrophysiological techniques have been used to investigate the pathophysiological 
consequences of most known FHM1 mutations (Kraus et al. 1998; Hans et al. 1999; Kraus et 
al. 2000; Tottene et al. 2002; Melliti et al. 2003; Müllner et al. 2004; Tottene et al. 2005). 
These mutations have been shown to affect the biophysical properties of individual channels, 
especially channel gating and the density of functional channels on the cell surface, but 
uncovering an overall mechanism common to all FHM1 mutations has not been 
straightforward. Using cerebellar neurons from Cacna1a knock-out mice, Tottene and 
coworkers (2002) were able to show that the functional deficiency relevant for FHM 
pathogenesis is most likely a defect in gating that allows the mutant channel to open in 
response to smaller depolarizations than in the wild type channel. This enhanced channel 
activity at negative potentials leads to an increased local Ca2+ influx (gain of function at the 
single-channel level), which could contribute to the neuronal hyperexcitability, a possible 
underlying factor in migraine susceptibility. Consistent with this hypothesis, the gain of 
function effect of the S218L mutation, producing the most severe FHM phenotype, was 
recently shown to be exceptionally large (Tottene et al. 2005). The effect of the mutations has 
also been shown to vary depending on the type of β-subunit present and thus to be cell-type 
specific (Müllner et al. 2004).  
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A recently developed Cacna1a knock-in mouse homozygous for the human FHM R192Q 
mutation shows enhanced neurotransmission at the neuromuscular junction and also, most 
interestingly, increased susceptibility to cortical spreading depression (van den Maagdenberg 
et al. 2004). Electrophysiological studies performed using cerebellar granule cells of this 
mouse model have also provided further evidence of the gain of function mechanism in FHM. 
However, contradictory studies suggesting a loss of function/dominant negative effect for 
FHM mutations also exist (Cao
 et al. 2004; Barrett et al. 2005a; Cao and Tsien 2005). 
6.5 ATP1A2 – the second FHM gene 
Soon after identifying the FHM1 locus on chromosome 19p13 it was realized that all FHM 
families are not linked to this chromosomal region (Joutel et al. 1994; Ophoff et al. 1994). 
The second FHM-locus on chromosome 1q was discovered in 1997 by the research group of 
Elisabeth Tournier-Lasserve (Ducros
 et al. 1997). They conducted a genome-wide linkage 
scan in one large French family and, after identifying the 1q21-q23 locus, showed that two 
more families were also linked to this region (Ducros et al. 1997). Evidence of linkage to 1q 
was also seen in a large German-Native American family (Gardner et al. 1997). A large 
Italian FHM family made refining the 1q21-23 locus possible (Marconi et al. 2003). By 
identifying mutations in this and another FHM family, the same group showed that ATP1A2 
encoding the Na+,K+-ATPase α2 subunit is the underlying gene (De Fusco et al. 2003). In 
addition to being a particularly interesting finding for migraine researchers, this was also the 
first report of a disease caused by mutations in a Na+, K+-ATPase. After that, mutations in the 
ATP1A3 gene encoding the Na+,K+-ATPase α3 subunit have been shown to cause rapid-onset 
dystonia-parkinsonism, an autosomal dominant movement disorder (de Carvalho Aguiar et al. 
2004).  
Na+,K+-ATPases consist of at least two subunits, a catalytic α subunit and a modulatory β 
subunit, while a γ subunit with unknown function has also been discovered (Mercer et al. 
1993). Four different tissue-specific and developmentally regulated Na+,K+-ATPase α 
subunits have been identified and all but the testis-specific α4 are expressed in the brain 
(Moseley et al. 2003). α1 is ubiquitously expressed and functions as a housekeeping enzyme. 
Expression of the α3 isoform is restricted to neurons and heart while expression of α2 is most 
abundant in skeletal muscle, heart and brain, especially in glia (astrocytes) (Orlowski and 
Lingrel 1988; Watts et al. 1991; He et al. 2001). However, at least in mice the α2 isoform is 
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highly expressed in neurons during development and at the time of birth (Moseley et al. 
2003).  
ATP1A2 consists of 23 exons that span approximately 25 kb (Shull et al. 1989). In Figure 5, 
the secondary structure of the Na+,K+-ATPase α2 subunit is depicted. The N-terminal region 
of the protein contains four membrane-spanning domains (M1-4) followed by a large 
intracellular loop and six more transmembrane domains (M5-10) (Kaplan 2002). Altogether 
23 FHM2 mutations have been identified thus far (Figure 5) (De Fusco
 et al. 2003; 
Vanmolkot
 et al. 2003; Gardner et al. 2004; Jurkat-Rott et al. 2004; Kaunisto et al. 2004b; 
Spadaro
 et al. 2004; Vanmolkot et al. 2004; Riant et al. 2005). Most of them localize within 
the large intracellular M4-5 loop of the protein. This loop is critical for the correct function of 
the channel since it harbors hydrolase and ATP-binding domains and undergoes major 
conformational changes during the enzymatic cycle (Kaplan 2002). All but two of the 
published FHM2 mutations are missense mutations. Of these, the X1021R mutation changes 
the STOP-codon to an amino acid coding one and thus extends the protein by 27 residues 
(Jurkat-Rott  et al.  2004)  and the  other, a  2 nucleotide  deletion,  leads to  a frameshift and a 
Figure 5. Schematic structure of the Na+, K+-ATPase and the identified ATP1A2 mutations. MO = 
migraine without aura; HM =hemiplegic migraine; PCA = progressive cerebellar ataxia; BFIC = benign 
familial infantile convulsions; AHC = alternating hemiplegia of childhood; FS = frameshift 
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premature STOP-codon within the second last exon of ATP1A2 (Riant et al. 2005). Some 
FHM2 mutations have been investigated by transfecting cells with mutant ATP1A2 constructs. 
Both complete abolishment of Na+,K+-ATPase activity and subtle kinetic alterations leading 
to reduced activity, depending on the mutation, have been observed (De Fusco
 et al. 2003; 
Segall
 et al. 2004; Segall et al. 2005). 
In addition to the FHM2 mutations listed above, four other ATP1A2 missense mutations have 
been described in families with common forms of migraine (Figure 5) (Castro
 et al. 2004; 
D'Onofrio
 et al. 2004; Todt et al. 2005). More functional studies are, however, needed to 
prove their causality. Furthermore, the T378N mutation in ATP1A2 has been identified in a 
family with alternating hemiplegia of childhood (AHC), a phenotype that is clinically 
different but overlapping to FHM (Bassi et al. 2004). The T378N mutation affects the highly 
conserved ATPase phosphorylation site located in the hydrolase domain. However, no 
mutations have been identified in the other familial or sporadic AHC patients studied (Bassi
 et 
al. 2004; Kors et al. 2004c). 
There are no definitive phenotypic differences between FHM1 and FHM2. The penetrance is 
possibly somewhat lower for FHM2 (Ducros et al. 1997). Cerebellar signs have been almost 
exclusively associated with FHM1 families. However, subtle cerebellar signs have also been 
reported in some of affected family members of two FHM2 families (Cevoli et al. 2002; 
Spadaro et al. 2004). The ATP1A2 R689Q mutation was described in a family segregating 
both FHM and benign familial infantile convulsion (BFIC) (Vanmolkot et al. 2003). In light 
of this finding, it has been noted that a history of seizures is much more common among 
FHM2 patients than FHM1 patients (Ducros et al. 1997; Marconi et al. 2003; Jurkat-Rott et 
al. 2004).  
Mice carrying spontaneous mutations in the Atp1a2 gene have not been identified but Atp1a2 
knock-out mice strains are available. Atp1a2-/- mice die after birth as they are unable to 
breath, possibly due to altered neuronal activity in respiratory center neurons (Moseley et al. 
2003). Enhanced neuronal activity as a result of impaired neurotransmitter uptake causes 
extensive neuronal cell loss in the amyglada and piriform cortex of these mice (Ikeda et al. 
2003). Atp1a2+/- mice appear healthy, and show an increase in the force of contraction of both 
cardiac and skeletal muscle (Lingrel et al. 2003). However, the heterozygous mice have 
enhanced fear-anxiety behaviors and enhanced neuronal activity in the amyglada and piriform 
cortex after conditioned fear stimuli (Ikeda et al. 2003). Knock-in mice with FHM2 mutations 
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would certainly increase our knowledge of the pathophysiology of FHM but these mice have 
not yet been developed. 
6.6  Latest advances in FHM genetics 
Very recently, a third locus and gene for FHM, SCN1A on chromosome 2q24, was identified 
(Dichgans
 et al. 2005). This gene codes for a neuronal voltage-gated sodium channel and 
mutations in it have previously been associated with different epilepsy phenotypes. Only one 
FHM mutation, Q1489K, has been published thus far. The finding seems, however, to be 
reliable since the same mutation was found in three German families and was shown to 
accelerate the recovery of a homologous channel from fast inactivation and thus probably 
leads to excessive firing of neurons expressing the mutant channel (Dichgans
 et al. 2005). 
Furthermore, identification of a de novo mutation in the SLC1A3 gene coding for a glutamate 
transporter (excitatory amino acid transporter; EAAT1) of a single patient with episodic 
ataxia, seizures, migraine, and alternating hemiplegia has raised a possibility of a fourth FHM 
gene (Jen
 et al. 2005). This gene was studied based on a hypothesis that defected transmission 
of glutamate, the most abundant excitatory neurotransmitter, might be the underlying 
pathological mechanism of FHM (Moskowitz
 et al. 2004). The activity of the mutant EAAT1 
transporter was markedly reduced thus supporting the role of this gene in the disease 
phenotype described (Jen
 et al. 2005) but more studies are clearly needed to clarify whether 
glutamate transporters contribute to the FHM phenotype more generally. 
6.7  Migraine as a channelopathy 
The main symptoms of FHM are undoubtedly very similar to those of MA. Cortical 
hyperexcitability and the following increased susceptibility to cortical spreading depression 
have been suggested as the underlying shared pathophysiological mechanism (Moskowitz et 
al. 2004). Since Cav2.1 channels play a major role in the release of the excitatory 
neurotransmitter glutamate from cortical neurons, increased Ca2+ influx through mutant 
channels could lead to hyperexcitability (Turner et al. 1992; Moskowitz et al. 2004). In 
accordance with this hypothesis, the Cacna1a R192Q knock-in mice show a decreased 
threshold for CSD (van den Maagdenberg et al. 2004). Cav2.1 channels have also been 
demonstrated to have a role in modulating trigeminal nociception (Knight et al. 2002; 
Akerman et al. 2003).  
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Although no convincing evidence of association of CACNA1A or ATP1A2 with MA or MO 
exists, certain clinical features (especially the episodic occurrence of symptoms and the 
existence of triggering factors) definitely support the hypothesis of the common forms of 
migraine also being channelopathies (Ptacek 1998). Theoretically, several polymorphisms in 
different ion channel and receptor genes that contribute to maintaining the delicate balance of 
excitatory and inhibitory influences could together lead to increased neuronal excitability 
(Ptacek 1998). 
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AIMS OF THE PRESENT STUDY 
The main aim of this work was to search for genetic loci and variants predisposing to 
migraine with aura – a common complex trait – and its rare Mendelian subtype, familial 
hemiplegic migraine. Two research strategies, a genome-wide linkage approach and a 
candidate locus/gene strategy, were applied. 
 
The specific aims were to: 
1. Search for genetic loci predisposing to MA using a genome-wide linkage strategy. 
2. Study the role of a migraine susceptibility locus on chromosome 19p13 and the role of 
MTHFR and ESR1 candidate genes in a large family/case-control sample. 
3. Establish linkage and identify the causative mutation in a Finnish FHM family. 
4. Identify the mutation underlying EA-2, a phenotype allelic to FHM, in a Finnish 
family. 
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PATIENTS AND METHODS 
1 STUDY SUBJECTS 
Informed consent was obtained from all study subjects. The ethics committee of the 
Department of Neurology, Helsinki University Central Hospital has approved these studies. 
1.1 MA families and patients  
Since 1996, we have recruited migraine families mainly from headache clinics in Helsinki, 
Turku, Jyväskylä, and Kemi. Furthermore, we have advertised in the newsletter of the Finnish 
Migraine Society. More than 700 families with at least four affected family members (most of 
them having MA) are taking part in this migraine project. Participants have been asked to 
provide a blood sample and to complete the validated Finnish Migraine Specific 
Questionnaire for Family Studies (Kallela
 et al. 2001a). The index cases and other family 
members have been diagnosed according to the IHS criteria on the basis of this questionnaire, 
which contains 37 detailed questions about headache and other aspects of migraine, especially 
the characteristics of aura. The diagnoses of individuals with incomplete or contradictory 
answers in questionnaires have been confirmed by telephone interviews. 
In study I, 50 multigenerational families with a seemingly autosomal dominant mode of 
inheritance were selected for the genome-wide analysis. An additional 22 families were 
included when the contribution of the chromosome 19p locus in MA was studied (study II). 
Tables 15 and 16 describe the diagnosis distribution and the pedigree structure of these 
families.  
In study III, 898 unrelated migraine patients were compared to 900 healthy control 
individuals. The patient group consisted mainly of the index cases of our migraine family 
cohort. However, several genetically unrelated individuals from each pedigree were selected 
 Table 15. Diagnosis distribution of the genotyped subjects.  
 Diagnosis (IHS classification) Subjects (N)  
  Genome-scan (study I) 19p13 locus (study II)  
 Typical aura with migraine headache (1.2.1) 246 417  
 Typical aura without headache (1.2.3) 6 8  
 Migraine without aura (1.1) 53 91  
 Headaches other than migraine 10 23  
 No headache 91 170  
 Missing Diagnosis 24 48  
 Total 430 757  
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when applicable. In addition, 285 patients originated from a Finnish cohort of like-sexed twin 
pairs born before 1958 (Kaprio et al. 1978). All patients had a family-history of migraine. Of 
these, 718 (80.0%) were women and all had headache fulfilling the IHS criteria for migraine 
as well as aura symptoms before the headache. However, the aura symptoms did not fulfil the 
IHS criteria for MA in 114 (12.7%) patients. 
1.2 Control samples 
For association analysis (study III), the age- and sex-matched control sample comprised 900 
unrelated individuals from a Finnish twin-cohort of opposite-sex pairs born 1939-1957. Of the 
control individuals 76% were women and all self-reportedly did not have migraine. 
Furthermore, to minimize the presence of genetic migraine susceptibility factors, only 
individuals reporting that their co-twin and other first-degree family members do not have 
migraine were included.  
In studies IV and V, the presence of the identified mutations in 132 healthy control 
individuals was excluded. This same control sample consisting of anonymous Finnish blood 
donors was also used in study IV when the frequencies of the identified polymorphisms were 
determined in pooled DNA samples. For this purpose, a Coriell Cell Repositories human 
variation DNA pool NA16129 consisting of 24 individuals belonging to different Asian, 
American Indian and Pygmy populations was also analyzed.  
1.3 FHM2 family 
In study IV, a Finnish FHM family ascertained through Helsinki University Children’s 
Hospital with 11 affected family members was studied (Figure 14, page 94). Diagnoses were 
 Table 16. Pedigree structure of the studied MA families.   
 Number of  Genome-scan (study I) 19p13 locus (study II)  
 Pedigrees 50 72  
 Generations/pedigree           
 1 5 3  
 2 19 27  
 3 24 41  
 4 2 1  
 Subjects in pedigrees 646 978  
 Genotyped subjects 430 757  
 Genotyped subjects/pedigree (mean) 8.6 10.5  
 Genotyped MA (MA+ MO) patients/ 
pedigree (mean) 
4.9 (5.9) 5.8 (7.1)  
 MA = migraine with aura; MO = migraine without aura  
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made according to the IHS criteria. Table 17 describes the typical clinical characteristics of 
migraine in these patients. Interictal nystagmus or ataxia was not present in any of the 
affected individuals and none of them had seizures.  
 
Table 17. Characteristics of the FHM-patients. 
 
 Patient  II:2 II:4 II:6 II:10 II:11 III:6 III:7 III:9 III:11 III:14 III:15  
 Sex F F F F M F M F F F F  
 Age at onset of migraine  31 8 9 13 7 11 10 5 12 6 5  
 Migraine frequency 
(times/year) 
24 12 2 6 NA* 12 NA* 24 1 1 24  
 Visual aura - + + + + + - + - + +  
 Hemisensoric/hemiplegic aura +/+ +/+ +/+ +/+ +/+ +/+ -/+ +/+ +/+ +/+ +/+  
 Confusion/coma -/- +/- -/- -/- +/+ -/- +/+ +/+ -/- -/- +/+  
 Dysphasia - + + + + + + + + - +  
 Fever - - - - + - + + - - +  
 Head trauma as a trigger - - + - + - + + - - +  
 F = female, M = male, NA = not applicable; * ceased at the age of 14-15  
 
1.4 EA-2 family 
In study V, clinical information and DNA samples were obtained from 47 family members 
belonging to a four-generation Finnish EA-2 family (Figure 15, page 98). After identification 
of the disease-causing mutation, seven additional more distant relatives (family of the affected 
grandfather’s sister) were studied. For the linkage analysis, 13 individuals were diagnosed as 
affected. The most common attack symptoms included vertigo, nausea, vomiting, ataxia, 
impaired focusing ability, dysarthria, and fatigue. In addition, one individual was regarded as 
possibly affected since her only symptom was an exquisite sensitivity to alcohol. The attacks 
started at the age of 4-35 years (mean age of onset 10 years). The attacks, typical duration of 
which was two hours, were commonly triggered by exercise, emotional stress, coffee, bright 
sunshine, and heat. The interictal neurological status of most patients was either normal or 
only slightly impaired (for example gaze-evoked nystagmus) but three elderly individuals had 
pronounced cerebellar ataxia. Furthermore, eight family members were diagnosed as having 
MO. 
2 METHODS 
2.1 DNA extraction 
Genomic DNA was extracted from peripheral blood either using the standard phenol-
chloroform extraction procedure (Blin and Stafford 1976) or the Autopure LS automated 
DNA purification instrument (Gentra Systems, Minneapolis, USA).  
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2.2 Genotyping 
2.2.1 Microsatellite genotyping 
In studies I, II, IV, and V subjects were genotyped using polymorphic microsatellite markers 
and fluorescence-based detection methods. In the genome-wide scan, 350 microsatellite 
markers spaced approximately 11 cM apart were amplified by polymerase chain reaction 
(PCR) using multiplex PCR assays with fluorescent primers in microtiter 96-well plates. The 
markers were mainly from the Human MapPairs Genome-Wide Screening Set (LI-COR 
Biosciences, Lincoln, NA, USA), a modification of the ninth version of the Weber lab 
screening set (Broman et al. 1998). The genotyping was performed using a LI-COR DNA 
4200 Genetic Analyzer (LI-COR) and the Saga1.0 software package (University of 
Washington and LI-COR). In study II, eight microsatellite markers (D19S247, D19S427, 
D19S592, D19S391, D19S394, D19S221, D19S1150, and D19S226) surrounding the INSR 
and the CACNA1A genes (study II, Figure 1) were analyzed on an ABI3700 DNA analyzer 
(Applied Biosystems, Foster City, CA, USA) using the GeneScan and Genotyper Software 
(Applied Biosystems). In both cases, the genotyping was performed at the University of 
California, Los Angeles (UCLA).  
In studies IV and V, three microsatellite markers (D19S221, D19S1150, and D19S226) 
flanking the previously identified FHM1/EA-2 susceptibility locus on 19p13 (CACNA1A) 
were genotyped. In study IV, 20 additional markers covering the chromosomal area 1q21-32 
(FHM2 locus) were genotyped. Primer sequences for the markers were obtained from the 
GDB Human Genome Database (http://www.gdb.org). In both studies, Cy5-labeled PCR 
fragments were separated using denaturing polyacrylamide gels on an Automated Laser 
Fluorescence (ALF) DNA sequencer (Amersham Biosciences, Buckinghamshire, UK) and the 
genotypes assigned with the AlleleLinks software (Amersham Biosciences).  
The order and distances between markers were determined from The Marshfield Medical 
Research Foundation Genome Database (http://research.marshfieldclinic.org/genetics/) and 
from the USCS Genome Browser (http://genome.ucsc.edu/). Allele sizes were standardized to 
known Centre d’Etudes du Polymorphisme Humain (CEPH) control individuals 
(http://www.cephb.fr/). All genotypes were verified by human inspection and Mendelian 
inheritance confirmed by the PedCheck program (O'Connell and Weeks 1998). In addition, 
the mistyping option of SimWalk2 program (Sobel and Lange 1996) was used to detect 
genotyping errors. 
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2.2.2 SNP genotyping 
In studies III, IV, and V, SNPs were genotyped either to detect variants associated with MA 
(study III) or to study the frequency of potential mutations and other sequence variants 
identified by sequencing (studies IV and V). The SNPs that were genotyped in study III were 
selected from the public dbSNP database (http://www.ncbi.nlm.nih.gov/projects/SNP/). 
2.2.2.1 Minisequencing 
After the potential mutations had been identified in studies IV and V, family members and 
healthy controls were screened for the presence of the variation in question using solid-phase 
minisequencing (study IV) or cycle minisequencing (study V), a modification of the 
minisequencing method (Syvänen et al. 1990; Järveläinen et al. 2001). Cycle minisequencing 
was also used to estimate the population frequencies of the CACNA1A polymorphisms 
identified (study V). The principle of solid-phase minisequencing is shown in Figure 6 with 
the primers used in study IV. Shortly, two aliquots of biotinylated PCR 
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Figure 6. Principle of the solid-phase minisequencing method. The figure is a kind gift from docent Arto 
Orpana. 
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product were immobilized on streptavidin-coated microtiter wells (Wallac/PerkinElmer, 
Wellesley, USA) and denatured with NaOH to remove the unbiotinylated complementary 
DNA strand. Next a detection primer was added and elongated by a single 3H-labeled 
nucleotide (normal or mutant) using a DNA polymerase. The genotypes were then defined by 
calculating the ratio of the radioactivity of the incorporated nucleotides measured with a 
scintillation counter (Microbeta/PerkinElmer). The cycle minisequencing procedure differed 
from standard minisequencing in two main ways: normal PCR-primers were used while the 
extension primer was biotinylated and the primer extension reaction was performed by 
cycling at 96°C and at 59°C for 50 cycles using a PCR-machine. 
2.2.2.2 Sequenom MassARRAY system 
In study III, over 53,000 genotypes were produced using the Homogenous MassExtend 
MassARRAY system (Sequenom, San Diego, CA, USA). Similar to minisequencing, this 
method is based on primer extension but here the extension products are analyzed using 
matrix-assisted laser desorption ionization time-of-flight mass spectrometry. In this method, 
the genotypes are assigned based on the differences in mass between the two primer extension 
products (Figure 7). The assays were designed using the AssayDesign software (Sequenom) 
so that the extension products were 1-3 bases longer than the extension primer and 
multiplexing of the SNPs was possible. The multiplex PCR and primer extension reactions 
were performed according to the manufacturer’s instructions except that more DNA (9 ng) 
was used as a template. SpectroTYPER software (Sequenom) was used for determining the 
genotypes, although verified by human inspection. 
In study IV, the same MassARRAY system together with the Allelotyping (Sequenom) and 
the MassARRAY Typer (Sequenom) software were used for estimating allele frequencies of 
the identified ATP1A2 polymorphisms in pooled DNA samples. Previous studies have shown 
that this method can be used to estimate allele frequencies with high precision (Mohlke et al. 
2002). For each SNP, 12 replicate PCRs and extension reactions were performed on a pool 
consisting of equimolar amounts of DNA from 132 Finnish individuals. Furthermore, four 
replicates on the Coriell NA16129 DNA pool sample consisting of 24 individuals were 
performed for each SNP. When pooled samples are used, it must be taken into account that 
the peak heights and areas of the two alleles are usually unequal. Thus we also genotyped 15 
individual samples, calculated the ratio of the peak areas of the two alleles in heterozygous 
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Figure 7. Principle of the Sequenom MassARRAY SNP genotyping system. 
individuals and used this information to correct the allele frequency estimations in the DNA 
pools.  
2.3 Sequencing 
PCR was performed using intronic primers under conditions optimized for each reaction. 
PCR-products were then purified enzymatically and sequenced in both sense and antisense 
directions using BigDye terminator chemistry (Applied Biosystems), a modification of the 
dideoxy chain termination method of Sanger (Sanger
 et al. 1977). After a sodium 
acetate/ethanol precipitation, sequencing reactions were run on an automated sequencer 
(ABI377 or ABI3700; Applied Biosystems). 
2.4 RNA analysis 
After identifying the CACNA1A splice site mutation in study V, we wanted to investigate the 
effect of this mutation on mRNA splicing. The normal and mutated CACNA1A sequences 
were analyzed using Splice Site Predictions, a neural network-based program 
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(http://www.fruitfly.org/seq-tools/splice.html). Furthermore, we aimed at studying the effect 
of this mutation using laboratory methods. Although CACNA1A is known to be expressed 
almost exclusively in the brain, we hypothesized that a minimal background expression in 
lymphocytes could make it possible to reverse transcribe and amplify the mRNA in question. 
We tested this using total RNA extracted from blood samples of healthy control individuals 
with the RNeasy kit (Qiagen, Hilden, Germany). RNA extracted from human fetal second 
trimester brain tissue samples (cerebellum/cerebrum) was also used to ensure the functioning 
of the reverse-transcriptase PCR (RT-PCR) procedure. The quality of the RNA samples was 
monitored using β-actin specific primers. RNA samples were transcribed to cDNA using the 
Titan One tube RT-PCR system (Roche, Basel, Switzerland), RNAquard RNase inhibitor 
(Amersham Biosciences) and a reverse primer annealing to exon 40 of CACNA1A. PCR was 
performed using the cDNA as a template with primers annealing to exons 35 and 39, and 
subsequently (nested-PCR), with inner primers using the first PCR product as a template. The 
RT-PCR and nested PCR products were evaluated by agarose gel electrophoresis, purified 
with the MinElute Gel Extraction Kit (Qiagen) and sequenced. 
2.5 Statistical methods 
2.5.1 Simulations and power calculations 
In studies II and V, it was essential to evaluate the informativeness of the sample size used. 
Simulations were performed to estimate whether the 72 pedigrees genotyped in study II were 
sufficient to detect linkage. The SLINK program was used to generate 500 data replicates (a 
marker with 5 alleles completely linked to the disease locus) that were then analyzed with the 
programs MSIM and ELODHET (Ott 1989, 1991; Weeks et al. 1994). The expected 
maximum LOD score (EMLOD), which is the average of the maximum LOD scores for each 
replicate, and power, the probability of rejecting the null hypothesis of no linkage when it is 
false, were evaluated. Power was defined as the proportion of replicates where the LOD score 
was equal to or greater than a given threshold, 3.3, and was calculated with variable proportions 
of unlinked families.  
In study III, the power of the case-control sample to replicate the association of MA to SNPs 
in candidate genes ESR1 and MTHFR was evaluated with the Genetic Power Calculator 
program (Purcell et al. 2003). The disease prevalence of MA was estimated to be 5%, the 
allele frequencies were as found in our material and the odds ratios (OR) for the at-risk 
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genotypes were assumed to be somewhat smaller than previously reported (Colson et al. 
2004; Lea et al. 2004). 
2.5.2 Linkage analysis 
Both in study I and II, parametric two-point linkage analysis (MLINK option of the 
LINKAGE package), nonparametric affected sib pair (ASP) analysis, family-based 
association analysis (TDT, HRR) and homogeneity testing (HOMOG) were performed for 
each marker with the help of the ANALYZE package (Penrose 1953; Lathrop and Lalouel 
1984; Ott 1991; Terwilliger 1995; Kuokkanen et al. 1996). Furthermore, another helper 
program, AUTOSCAN, enabling the analyses of all autosomal chromosomes in a single run 
was used (Hiekkalinna and Peltonen 1999). The parametric analyses were performed using a 
dominant mode of inheritance, a disease gene frequency of 0.001, penetrance of 0.9, and a 
phenocopy frequency of 0.024 (Hovatta et al. 1994). An affecteds-only strategy was used to 
circumvent problems of incomplete penetrance by coding only individuals with MA (stage I) 
and MA or MO (stage II) as affected. All other individuals were classified as unknown. The 
allele frequencies were estimated from all genotyped individuals using the DOWNFREQ 
program. For the region showing evidence of linkage in the genome-wide scan, multipoint 
parametric and nonparametric analyses were performed using the GENEHUNTER program 
(version 2.1) (Kruglyak et al. 1996). To enable the comparison of different results, the two-
point LOD scores were also converted to p-values (Chiano and Yates 1995; Nyholt 2000). In 
study II, nonparametric linkage (NPL) analysis was performed using statistics B (the 
maximum number of alleles among the affecteds descended from any one founder-allele; 
most powerful for dominant traits) and E (NPL_all statistic as implemented in 
GENEHUNTER) of the SimWalk2 program (version 2.82) (Sobel and Lange 1996). 
In studies IV and V, two-point LOD scores were calculated using the MLINK option of the 
LINKAGE package assuming autosomal dominant inheritance with incomplete penetrance 
(0.8) and a disease gene frequency of 0.0001. No phenocopies were allowed. Individuals with 
MO or headache other than migraine were considered unaffected while an unknown status 
was given to asymptomatic family members under the age of 20.  
2.5.3 Association analysis 
In study III, association of several MTHFR and ESR1 SNPs with migraine was studied. The 
pairwise LD of the genotyped markers and the haploblock structure of the genes in our study 
sample was determined with the Haploview program (Barrett
 et al. 2005b). The allele and 
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genotype frequencies of the SNPs were compared between cases and controls using standard 
χ2-analysis. Furthermore, logistic regression analysis was applied for five ESR1 SNPs 
showing nominal evidence of association to calculate the odds ratios for individuals with one 
and two copies of the minor allele (compared to those having none). Alternatively, subjects 
carrying two copies of the minor allele were compared with all the other subjects. These 
analyses were performed with the SPSS program. 
For the five ESR1 SNPs showing nominal evidence of association, haplotypes were estimated 
using both the Haploview and the PHASE programs and association analysis of these 
reconstructed haplotypes performed with the Haploview and the Haplo-assoc software 
(Stephens and Donnelly 2003; Barrett
 et al. 2005b). 
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RESULTS AND DISCUSSION 
1 GENOME-WIDE SCAN WITH 50 FINNISH MA FAMILIES 
In study I, we genotyped 350 microsatellite markers in 430 individuals belonging to 50 
multigenerational MA families with seemingly autosomal dominant inheritance. In two-point 
linkage analysis, 18 markers produced LOD or HLOD (LOD score under heterogeneity) 
scores above 1 (Table 18). The HLOD scores were always at least as high as the LOD scores 
assuming locus homogeneity but when converted to p-values, the LOD results at some 
markers were more significant than the HLOD results because the p-values of HLOD scores 
require more correction (Nyholt 2000). Results of this genome-wide scan are presented in a 
graphical form in Figure 8. 
Results of the nonparametric ASP analysis were almost invariably less significant than the 
results of parametric linkage analysis. The only markers showing LOD scores >1.0 in the ASP 
analysis but not in the parametric analysis were D14S1426, D17S1830, and D18S535 
producing LODs of 1.13, 1.44, and 1.41, respectively. 
 
 
Table 18. The markers with two-point LOD scores ≥ 1.0 in the genome-wide scan (study I).  
 
Under locus homogeneity Under locus heterogeneity 
 
 
Marker (Location) 
Position 
(cM) 
LOD 
Score 
Pointwise 
p-value 
θ 
  
HLOD 
Score 
Pointwise 
 p-value 
θ 
 
 D1S552 (1p36.13) 45 0.36 NS 0.28  1.08 0.020 0.00  
 D1S3462 (1q42.2) 247 0.70 0.036 0.30  1.66 0.0046 0.34  
 D4S1517 (4q13.3) 82 1.66 0.0029 0.26  1.66 0.0046 0.26  
 D4S3243 (4q21.2) 88 1.01 0.016 0.26  1.01 0.023 0.26  
 D4S2409 (4q22.1) 96 1.85 0.0018 0.20  1.89 0.0026 0.16  
 D4S2380 (4q22.3) 101 1.75 0.0023 0.22  2.26 0.0011 0.08  
 D4S1647 (4q24) 105 4.20 0.000006 0.18  4.20 0.000011 0.18  
 D4S3240 (4q25) 114 0.76 0.031 0.30  1.01 0.023 0.16  
 D4S2394 (4q28.2) 130 0.98 0.017 0.28  1.05 0.021 0.22  
 D4S1520 (4q31.1) 141 1.55 0.0038 0.20  1.55 0.0061 0.20  
 D5S2500 (5q12.1) 69 1.11 0.012 0.44  1.16 0.016 0.20  
 D15S659 (15q21.1) 43 0.05 NS 0.42  1.09 0.019 0.06  
 D15S655 (15q25.3) 83 0.70 0.036 0.24  1.38 0.0092 0.04  
 D16S753 (16p12.3) 58 0.004 NS 0.40  1.22 0.014 0.00  
 D17S945 (17p13.1) 21 0.96 0.018 0.30  1.01 0.023 0.24  
 D18S877 (18q12.1) 54 0.18 NS 0.40  1.00 0.024 0.00  
 D19S427 (19p13.2) 21 1.70 0.0026 0.22  1.70 0.0042 0.22  
 DXS9896 (Xp) 31 1.08 0.013 0.30  1.08 0.020 0.30  
 θ = recombination fraction at which maximum LOD was found   
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Figure 8. Plot of LOD scores from the genome-wide scan in 50 Finnish MA families (HLOD = LOD 
score under heterogeneity). 
1.1 Chromosome 4q21-24 locus 
Significant evidence of linkage was seen between MA and chromosome 4q. Marker D4S1647 
gave the largest LOD score, 4.20 (under homogeneity p = 0.000006; under heterogeneity p = 
0.000011), at θ = 0.18. Seven other adjacent markers within a 59 cM region on chromosome 
4q showed two-point maximum LOD scores ranging from 1.01 to 2.26 (Table 18). For the 
region showing the best two-point LOD scores, multipoint parametric and nonparametric 
analyses were performed with the GENEHUNTER program. The results are shown in Figure 
9 and Table 19. The highest HLOD, 4.45, was observed between markers D4S2409 and 
D4S2380 with a parametric test. At this location, the fraction of linked families (α) was 
estimated to be 50%. The maximum NPL score, obtained at the same position as the best 
parametric multipoint LOD, was 3.43. The 4q region showing evidence of linkage was at least 
30 cM wide. Although problematic in the restriction phase, this increased the reliability of our 
results even further since it has been suggested that true positive linkage peaks are generally 
longer than false positive peaks (Terwilliger et al. 1997). 
Figure 9. Multipoint 
linkage analyses of the 4q 
region (Wessman et al. 
2002). 
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Even more encouragingly, significant evidence of linkage to a very nearby chromosomal area 
was seen in a genome-wide scan performed by the Icelandic company deCODE Genetics 
(Björnsson et al. 2003). The company used their unique genealogical strategy for identifying 
117 families with altogether 351 affected individuals. In contrast to our strategy, they 
concentrated mainly on MO patients. Furthermore, slightly relaxed diagnostic criteria for MO 
were used to maximize the number of affected individuals. With this strategy, they observed 
linkage (LOD 2.87) to markers on chromosome 4q21. When only affected females were 
included in the analysis, marker D4S2409 produced a significant LOD score (4.08; p = 
0.0000072). This marker is located approximately 10 cM centromeric to our peak marker 
(D4S1647) and even closer to our multipoint peak. Since it has been shown that the variation 
of location estimates in complex disease linkage studies is substantial, with 95% confidence 
intervals covering tens of cM, it is likely that these 4q findings resulted from the same 
susceptibility locus (Roberts et al. 1999). 
It is rather surprising that these results providing a replication of our finding were obtained 
using a different phenotype, MO (including also patients not fulfilling all of the IHS criteria), 
and that the results were more significant when only females were analyzed. In our genome-
wide study, the results were also analyzed with both MA and MO patients as affected. 
However, when the 53 MO patients were included, the 4q area showed only suggestive 
evidence of linkage with a maximum LOD score of 2.48 for the D4S1647 marker (see Figure 
 Table 19. Multipoint linkage analysis results along the linked region on chromosome 4.  
 
Marker Map location (cM) HLOD α NPL-all p-value Information content  
 
D4S2409 96.16 3.66 0.45 3.41 0.0008 0.70 
 
 
 97.08 4.43 0.50 3.43 0.0007 0.65 
 
 
 98.00 4.45 0.50 3.43 0.0007 0.64 
 
 
 98.91 4.17 0.47 3.40 0.0008 0.66 
 
 
 99.80 3.65 0.42 3.35 0.0009 0.71 
 
 
D4S2380 100.75 2.73 0.34 3.27 0.001 0.81 
 
 
 101.59 2.75 0.34 3.23 0.001 0.76 
 
 
 102.43 2.74 0.34 3.19 0.001 0.74 
 
 
 103.26 2.69 0.34 3.15 0.002 0.74 
 
 
 104.10 2.61 0.33 3.12 0.002 0.75 
 
 
D4S1647 104.94 2.49 0.31 3.09 0.002 0.78 
 
 
 106.76 2.59 0.34 2.87 0.003 0.67 
 
 
 108.58 2.47 0.33 2.69 0.005 0.62 
 
 
 110.40 2.26 0.31 2.55 0.007 0.60 
 
 
 112.22 1.96 0.28 2.44 0.009 0.62 
 
 
D4S3240 114.04 1.50 0.23 2.36 0.01 0.68 
 
 α = Fraction of linked pedigrees at maximum HLOD  
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11, page 81). In conclusion, it seems possible that this locus contributes to both MA and MO 
susceptibility although in our study this region is only linked to the MA phenotype.  
After conducting the genome-wide scan, our group has concentrated on restricting and fine-
mapping the 4q21-24 locus (unpublished data). Sixteen of the 50 genotyped families were 
chosen for further genotyping based on location scores (directly comparable with multipoint 
LOD scores) of individual families calculated with SimWalk2 (criterion: location score 
>0.27). Furthermore, another set of 30 families has been studied for linkage to 4q. The 
maximum combined heterogeneity location score of SimWalk2 was, however, only 0.49 (with 
α = 0.15, nearest marker D4S2409) with this set of families. Although it was thus evident that 
most of these families are not linked to chromosome 4q, we were able to select 11 families for 
further studies using a similar criterion as above. It is possible that the heterogeneity of results 
is due to slightly different family selection criteria since the majority of the patients belonging 
to the 30 additional families had migraine with a very typical (as described in the literature) 
aura phase with spreading symptoms. Because of this, another whole-genome scan has been 
performed in this family set but the results are not yet available. 
Sixty microsatellite markers covering an approximately 30 cM region between markers 
D4S1517 (82.1 cM) and D4S3240 (114.0 cM) have been genotyped in the combined subset of 
27 families showing evidence of linkage to 4q21-24. Furthermore, 149 SNPs (located 
between microsatellite markers D4S2409 and D4S3240) have been genotyped in these same 
families. Both linkage and association analyses have been conducted. Using the subset of 16 
linked families selected from the 50 initially genotyped, we have been able to highlight a 6 
Mb region between markers D4S1578 (104.8 cM) and D4S1572 (108.0 cM) as the most likely 
location for variant(s) predisposing to MA (Figure 10a). Our two-point top marker D4S1647 
(104.9 cM) is located within this susceptibility region. Interestingly, the peak region of this 
multipoint curve is located more telomeric than our initial multi-point peak and thus further 
away from the area detected by deCODE (their top marker D4S2409; 96.2 cM). 
The chromosomal area covered by SNPs contains 32 known genes, some of which are shown 
in Figure 10b and Table 20. Some of the SNPs have shown nominal evidence of association 
with MA (Figure 10c-d). However, the mean distance between SNPs is ~110 kb and denser 
SNP coverage is clearly needed before the actual susceptibility variant can be identified. 
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Figure 10. A) “Conditional” parametric multipoint linkage analysis results. B) Examples of candidate 
genes located within the susceptibility area. C) Results of the haplotype analysis performed using the 
Transmit program. D) Model-based Pseudomarker results (LD given linkage) and global FBAT analysis 
results. 
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Table 20. Some interesting candidate genes in the chromosome 4q21-24 migraine susceptibility area. 
 
 Gene 
symbol Name Function Expression  
 
 GRID2 Glutamate receptor, 
ionotropic, delta 2  
Ionotropic glutamate receptor Cerebellar Purkinje 
cells 
 
 ATOH1 Atonal homolog 1 
(Drosophila) 
Involved in the development of the 
nervous system 
NA  
 UNC5C Unc-5 homolog C (C. 
elegans) 
Transmembrane member of the 
immunoglobulin superfamily, involved in 
cell migration during cerebellum 
development 
Ubiquitous  
 RAP1GDS1 RAP1, GTP-GDP 
dissociation stimulator 1 
Stimulatory GDP/GTP exchange protein 
with GTPase activity 
Ubiquitous  
 TM4SF9 Tetraspanin 5 Cell-surface protein, signal transduction Ubiquitous  
 ADH cluster  
(7 genes) 
Alcohol dehydrogenase Catalyzes the conversion of alcohols to 
aldehydes 
Some ubiquitous, 
some liver specific 
 
 PPP3A Protein phosphatase-3, 
catalytic subunit, alpha 
isoform (calcineurin A) 
Calmodulin dependent serine/threonine 
phosphatase 
Ubiquitous  
 NA = information not available  
 
  
1.2 Other regions of interest 
Statistically significant or suggestive linkage was not observed in any other chromosomal 
region although markers in nine other regions (1p, 1q, 5p, 15q, 16p, 17p, 18q, 19p, Xp) 
produced LODs >1.0 (Table 18, page 75). Of these, 1q, 19p, and the X-chromosome were 
especially interesting since these regions have previously been connected either to FHM or 
the common forms of migraine. The marker on chromosome 1q with a maximum HLOD 
score of 1.66 was, however, located on 1q42 while the FHM2 gene ATP1A2 localizes to 
1q21-23 and the other migraine susceptibility region to 1q31 (Ducros et al. 1997; Lea et al. 
2002). Similarly, the DXS9896 marker with a LOD of 1.08 is on Xp and no evidence of 
linkage to Xq24-28, the location of the susceptibility region in two Australian families, was 
observed in our study (Nyholt et al. 2000). The results concerning the chromosome 19p locus 
are discussed in more detail in the following chapter. When MO patients were also classified 
as affected, marker D18S877 on 18q showed suggestive evidence of linkage (LOD 2.32 
versus LOD 1.00 with MA affection criteria). Another region showing higher LODs with the 
broader phenotype was 3p25, with a maximum LOD of 1.83 (Figure 11). Interestingly, 
evidence of linkage to a locus on 3p21 was recently found in a large Dutch family with 
hereditary vascular retinopathy associated with migraine and Raynaud’s phenomenon (Ophoff 
et al. 2001). The distance between these two chromosome 3p loci is, however, approximately 
30 cM. 
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Figure 11. Two-
point LOD 
scores for those 
chromosomes 
where changing 
the affection 
criteria (only MA 
versus MA+MO 
patients affected) 
had the largest 
effect. 
 
 
 
 
 
 
 
 
After conducting this study, several other genome-wide scans and candidate locus studies on 
migraine have been performed. Loci on chromosomes 5q21, 6p12.2-21.1, 11q24, 14q21.2-
q22.3, and 15q11-q13 have been significantly linked to migraine (Carlsson
 et al. 2002; Cader 
et al. 2003; Soragna et al. 2003; Nyholt et al. 2005; Russo et al. 2005). Furthermore, in a 
recent study by the Australian migraine group suggestive evidence of linkage to loci on 18p11 
and 3q was found (Lea et al. 2005). The loci on 6p and 14q have been identified in a single 
multigenerational pedigree with mainly MO patients (Carlsson
 et al. 2002; Soragna et al. 
2003) while the Canadian and the Italian studies producing evidence of susceptibility loci on 
11q and 15q have both used a study design similar to ours and genotyped MA families (N= 43 
and N=10, respectively) chosen for an apparent autosomal dominant transmission pattern 
(Cader
 et al. 2003; Russo et al. 2005). Nevertheless, none of these other scans showed any 
evidence of linkage to 4q21-24. On the other hand, not even nominal evidence of linkage to 
any of these other susceptibility areas was seen in our study. Even the two markers on 
chromosome 15 producing LODs >1.0 in our sample are located on 15q21 (43 cM) and 15q25 
(83 cM), more than 30 and 70 cM away from the identified 15q11-q13 susceptibility locus 
(Russo
 et al. 2005).  
It is, however, worth mentioning that two of the reported less significant loci overlap with our 
findings (Table 21): in the Canadian study a LOD score of 2.22 was seen on 16p12 with 
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marker D16S769 (51 cM) (Cader et al. 2003) while we obtained a HLOD of 1.22 with marker 
D16S753 (58 cM). Furthermore, LODs ≥ 1.0 were obtained with marker D18S877 on 18q 
both in the deCODE study (Björnsson
 et al. 2003) and in our study (Wessman et al. 2002). 
Similarly, in the Australian study (Lea et al. 2005), a LOD >2 was obtained both on 14q22 
(the Italian locus, Soragna
 et al. 2003) and on 18p11, which is one of the minor loci (LOD 
1.6) observed by deCODE (Björnsson
 et al. 2003). Nevertheless, the susceptibility locus on 
4q identified in our genome-wide scan remains as the only significantly replicated migraine 
locus (Table 21). 
 Table 21. Possible overlap in the migraine susceptibility loci identified using genome-wide scans.  
   Locus Marker Location 
(cM)* 
LOD Population Phenotype Reference  
 D1S2878 178 1.58 Australian LCA-severe Lea et al. 2005  
 
1q21-23 
D1S1679 171 1.53 Australian LCA-migraine Nyholt et al. 2005  
 D4S1647 105 4.20 Finnish MA Wessman et al. 2003  
 
4q21-24 
D4S2409 96 4.08 Icelandic MO (women) Björnsson et al. 2003  
 D14S978 53 3.70 Italian MO Soragna et al. 2003   
 
14q21-22 
D14S258 76 2.06 Australian LCA-severe Lea et al. 2005  
 D16S753 58 1.22 Finnish MA Wessman et al. 2003  
 
16p12 
D16S769 51 2.22 Canadian MA Cader et al. 2003  
 D18S453 43 1.57 Icelandic MO Björnsson et al. 2003  
 
18p11 
D18S53 41 2.30 Australian LCA-severe Lea et al. 2005  
 D18S877 54 1.00 Finnish MA Wessman et al. 2003  
 
18q12 
D18S877 54 1.50 Icelandic MO Björnsson et al. 2003  
 * according to the Marshfield map; data from UCSC genome browser (http://genome.ucsc.edu/)  
 
1.3 Are MA and MO distinct traits? 
In spite of replication of the linkage to 4q21-24 locus, the lack of consensus between migraine 
susceptibility loci identified in genome-wide scans is considerable and probably an indication 
of heterogeneity. This situation is, however, more a rule than an exception when studying 
complex traits with incomplete penetrance, phenocopies and locus heterogeneity (Altmuller et 
al. 2001). When designing our genome-wide scan, our aim was to diminish the genetic 
heterogeneity as much as possible. Given that all our migraine families are of Finnish origin, 
the advantages of using a founder population apply to our study although we did not 
concentrate on any specific subisolate (Varilo and Peltonen 2004). Even more importantly, we 
decided to concentrate on clinically well-defined families ascertained for MA since: 1) most 
MA patients have very typical visual aura symptoms that precede the headache and thus the 
questionnaire-based differential diagnosis of MA can be regarded as even more reliable than 
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the diagnosis of MO and 2) family-based data suggest that genetic factors are more important 
in susceptibility to MA than to MO (Russell and Olesen 1995).  
However, it is still unknown whether MO and MA are genetically distinct disorders or if there 
are some genetic variants that predispose to migraine in general. A continuum-severity model 
of headache disorders, where tension-type headache represents the mild end and MA the 
severe end, has also been suggested (Featherstone 1985). Many clinicians support the view 
that MA and MO are variants of the same disorder, mainly based on frequent co-occurrence 
of both types of attacks in the same individual and on observations where migraine type has 
converted from one to another at some stage of life (Blau 1995). Some clinical differences 
between MA and MO exist, but since most of the attack features are similar (Russell
 et al. 
1996; Kallela
 et al. 2001b) one would assume some liability genes to be shared. However, a 
Danish twin study showed that co-occurrence of MA and MO in twin pairs does not occur 
more frequently than expected by chance and thus suggested MA and MO to be distinct 
disorders (Russell et al. 2002). On the other hand, results of a recent Australian twin study 
utilizing LCA and identifying subgroups of migraine patients based on their patterns of 
symptoms do not support the distinct disorder hypothesis (Nyholt et al. 2004). Two successful 
Australian genome-wide scans have been performed based on this phenotype classification, 
thus providing further evidence of the usefulness of this approach (Lea
 et al. 2005; Nyholt et 
al. 2005). 
1.4 Choosing the best model 
Both parametric and NPL analysis methods were applied in this study. In parametric linkage 
analysis, the mode of inheritance must be specified while nonparametric methods examine the 
extent of marker allele sharing among affected family members without specifying the 
underlying genetic model. On the other hand, the drawback of nonparametric methods is their 
lower power compared to traditional linkage analysis (Abreu et al. 1999). The genome-wide 
scan was performed assuming an autosomal dominant mode of inheritance. This was 
reasonable, since in the families selected for this study migraine segregated as a seemingly 
autosomal dominant trait. In addition, a classic form of NPL analysis, affected sib-pair 
analysis, was performed for each marker. The ASP results were, however, almost invariably 
less significant than the parametric linkage analysis results. This is not surprising, since some 
power is inevitably lost when large pedigrees are split into nuclear families. After identifying 
the susceptibility locus on chromosome 4q, NPL analysis for this region was conducted with 
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GENEHUNTER but these results were also less significant than those produced by the 
parametric analysis. Thus it seems that, at least for this set of migraine families, the 
parametric method was more powerful than the nonparametric method. 
Other parametric migraine linkage studies have also used a dominant inheritance model, while 
the other parameters have differed markedly between these studies. With current knowledge, 
it is impossible to judge which model is the most correct. It is likely that multiple genetic 
and/or environmental risk factors are needed before migraine becomes manifested and thus a 
significant proportion of individuals carrying any given susceptibility factor can be expected 
to be healthy. A method in which multiple liability classes are used to account for age-
dependent variability in the penetrance has been applied in two of the genome-wide scans in 
migraine (Carlsson et al. 2002; Cader et al. 2003). Furthermore, since migraine is 2-3 times 
more common in women than in men, the disease penetrance of men can be assumed to be 
lower than that of women. Due to these complicating factors, we decided to use the affecteds-
only approach and thus the penetrance model used had less significance. The disadvantage of 
this method is, however, that similar to NPL analysis, some power is lost because linkage 
information coming from the healthy family members is not used. 
2 ANALYSING CANDIDATE LOCI AND GENES 
Two different candidate gene approaches were applied in this thesis. In study II, the role of 
candidate locus 19p13 in MA susceptibility was investigated using a linkage approach while 
in study III, several SNPs in candidate genes ESR1 and MTHFR and their association with 
MA were examined. Of these, the role of the 19p13 locus that surrounds the CACNA1A 
(FHM1) gene (Table 10, page 42) as well as the role of the MTHFR gene (Table 23, page 88) 
has been relatively extensively studied. The power of these previous studies has, however, 
been rather limited due to small sample sizes and thus the results have been inconclusive. 
Therefore the basic idea of studies II and III was to use a sample size large enough to be able 
to provide conclusive results of whether these loci/genes contain variants predisposing to MA. 
2.1 Candidate locus on 19p13 
The migraine candidate locus on 19p13 contains two genes associated with migraine: the 
CACNA1A (FHM1) gene and the nearby insulin receptor INSR gene (Ophoff et al. 1996a; 
Jones
 et al. 2001). In our genome-wide scan (study I), the D19S1150 marker, an intragenic 
marker of the CACNA1A gene, showed no evidence of linkage to migraine (HLOD 0.00). 
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However, marker D19S427, located approximately 20 cM distal to D19S1150 and near the 
INSR gene, produced a maximum LOD score of 1.70 (θ = 0.22). Thus we felt that this 
chromosomal region was worth studying further and genotyped eight polymorphic 
microsatellite markers surrounding the INSR and CACNA1A genes (Figure 1 of study II) for 
757 individuals belonging to 72 families. This family sample was the largest used so far for 
studying chromosome 19. Furthermore, we performed simulation studies to confirm that with 
this set of families, it should be possible to detect linkage even if only a minority of them 
(~30%) are linked to this region (Figure 12). 
Figure 12. 
Simulation of the 
linkage in the 72 
studied MA families. 
The x-axis shows the 
proportion of linked 
families (α) from 0.1 
to 0.7. At α = 0.6, 
the power of 1 is 
reached. 
 
 
 
 
 
 
Both parametric and NPL analyses with the affecteds-only model were performed. In 
summary, none of the studied markers covering a 34 cM region showed any evidence of 
linkage to MA either under locus homogeneity or heterogeneity (Table 22). Furthermore, 
neither the results of ASP analysis nor the results of NPL analysis performed using SimWalk2 
supported linkage. Similarly, the results obtained using the broader affection criteria with MO 
patients also coded as affected were non-significant (maximum LOD and HLOD 0.13). 
One of the main reasons why we were interested in conducting study II was the report 
published in 2001 of an MA susceptibility locus on 19p13 nearby but distinct from CACNA1A 
and the subsequently reported association of migraine with the INSR gene (Jones et al. 2001; 
McCarthy et al. 2001). We expected to find some evidence of linkage to the INSR region 
considering that the proportion of linked families was very high in the original study 
performed in 16 North American families of mainly western or northern European descent 
(Jones et al. 2001). Furthermore, the nominal LOD score of 1.70 obtained with marker 
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D19S427 (flanking the INSR gene) in our genome-wide screen suggested linkage (Table 18, 
page 75). 
However, in study II, the HLODs of the two INSR flanking markers, D19S427 and D19S592, 
were practically zero (Table 22) thus producing no evidence of a migraine susceptibility locus 
in this region. It is likely that the LOD score obtained in the genome-wide scan was a false 
positive, as is often the case when only weak evidence of linkage is found. Although 50 of the 
72 families were the same in both studies, the information provided by the 22 additional 
families and the fact that the marker D19S427 was genotyped again in all of the samples 
using another genotyping system (LI-COR versus ABI) are probable explanations for the 
observed LOD score drop (from 1.70 to 0.07). No other reports either replicating or excluding 
linkage or association to the INSR region have been published since. Furthermore, none of the 
published genome-wide scans has obtained a linkage peak in this area. 
The CACNA1A area has been speculated to play a role in susceptibility to the common forms 
of migraine for more than ten years. Our group tested this hypothesis in 1994 using four 
Finnish MA/MO families and saw no evidence of linkage to 19p13 (Hovatta
 et al. 1994). 
However, after conducting that study, it has become evident that much larger family sets are 
required to detect complex disease loci. Thus, in addition to INSR markers, we wanted to 
genotype and test markers covering the CACNA1A region in our sample of 72 families. The 
linkage results for these CACNA1A markers were clearly negative and, most convincingly, the 
intragenic marker D19S1150 produced a HLOD score of 0.00 (Table 22). This was in 
accordance with the results of our genome-wide scan (study I). Many other research groups 
 
Table 22. Two-point LOD scores and NPL scores for the 19p13 markers and the location of the INSR and 
CACNA1A genes. 
 
 Position on 
chromosome 19 
Under locus 
homogeneity 
Under locus 
heterogeneity 
NPL-all 
(SimWalk stat E) 
 
Marker 
cM* Mb* 
 
Max 
LOD θ 
LOD at 
θ = .00 
 
Max 
HLOD θ 
 
-log (P) 
p-
value 
 
 D19S247 9.8 3.1  0.00 - -45.24  .00 -  0.27 0.54  
 D19S427 20.8 6.1  0.00 - -26.86  .07 .00  0.63 0.23  
 INSR gene 7.1 – 7.2    
 D19S592 NA 7.3  0.00 - -38.71  .00 -  0.71 0.19  
 D19S391 28.8 8.5  0.03 .46 -39.86  .03 .46  0.52 0.30  
 D19S394 34.3 10.6  0.00 - -43.80  .16 .14  0.79 0.16  
 D19S221 36.2 12.6  0.00 - -44.38  .00 -  0.36 0.44  
 CACNA1A gene  13.2-13.5   
 D19S1150 NA 13.3  0.00 - -44.65  .00 -  0.44 0.36  
 D19S226 42.3 14.5  0.00 - -46.06  .00 -  0.39 0.41  
 NA = not available; * from p-tel 
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have also studied the role of CACNA1A in migraine (Table 10, page 42). Some of these 
studies have reported suggestive linkage to this region, mainly based on ASP analysis (May
 et 
al. 1995; Nyholt et al. 1998a; Terwindt et al. 2001). However, results of all of the published 
linkage studies with larger sample sizes are negative and thus in accordance with ours (Lea
 et 
al. 2001b; Noble-Topham et al. 2002). Furthermore, none of the genome-wide scans have 
provided evidence of linkage to this region.  
Although evidence against CACNA1A as a predisposing locus for common forms of migraine 
is now mounting, some families may still have high penetrance susceptibility alleles in this 
gene. Interestingly, sequencing of all CACNA1A exons in two Australian patients belonging to 
a MA family with suggestive linkage to this region showed no mutations (Lea
 et al. 2001b). 
This result is in accordance with our data (unpublished). We studied nine families with 2-5 
patients having migraine attacks accompanied by hemiparetic or hemisensory symptoms for 
linkage to 19p13 (Kaunisto 1999). Three of these families showed LOD scores above 1 and 
the haplotype analysis showed that all MA patients with hemisensory or hemiparetic 
symptoms carried the same haplotype within the families. The pedigree structure and the 
19p13 haplotypes of the most representative of these families are shown in Figure 13. Every 
CACNA1A exon was sequenced in six patients belonging to these three families but no 
mutations were found. Thus it seems that mutations in the coding regions of CACNA1A are 
not found even in those few migraine families showing linkage to the region. However, it is 
still possible that the 
variant(s) predisposing to 
common types of migraine 
reside in the promoter region, 
introns or still unidentified 
exons and are thus more 
difficult to detect. 
 
 
Figure 13. Pedigree and 
haplotypes of a Finnish MA 
family showing linkage to 19p13. 
The susceptibility haplotype 
cosegregating with FHM is 
shown by a black bar. 
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2.2 Candidate gene studies 
2.2.1 The role of MTHFR and ESR1 genes in MA susceptibility  
In study III, we aimed at selecting the most promising candidate genes previously reported to 
be associated with migraine and to evaluate their contribution in a substantially larger case-
control sample set than used in the original studies. Although a considerable number of 
association studies on migraine have been published, only very few of the initial positive 
results have been replicated using an independent sample. Among these are polymorphisms in 
the methylenetetrahydrofolate reductase (MTHFR) and estrogen receptor (ESR1) genes 
located on chromosomal areas 1p36 and 6q25, respectively. 
The association of a functional C677T variant of the MTHRF gene with migraine was 
originally described in Japanese patients and subsequently replicated in Turkish, Australian, 
and Spanish populations (Kowa et al. 2000; Kara et al. 2003; Lea et al. 2004; Oterino et al. 
2004). These studies have consistently shown that the homozygous carriers of this variant 
have an increased risk for migraine, especially MA. However, the number of MA patients 
investigated in these studies has been very small, 22-170 (Table 23). Before our study, the 
G2014A variant of ESR1 had only been studied in the Australian population (224 migraine 
patients) (Colson et al. 2004). The association of this variant with migraine susceptibility was, 
 
Table 23. Results of association studies concerning the role of the MTHFR gene on migraine. 
 
 Population 
(reference) 
Japanese  
(Kowa et al. 2000) 
Turkish 
 (Kara et al. 2003) 
Australian 
 (Lea et al. 2004) 
Spanish 
 (Oterino et al. 2004) 
Finnish  
(study III) 
 
Patients (N) 121 102 270 230 898  
MA 22 23 170 78 898  
MO 52 70 100 152 -  
HA 47 9 - - -  
 Controls (N) 261 136 270 204 900  
 T637 allele frequency    
MA 0.64 0.26 0.40 0.42 0.24  
MIG All 0.48 0.34 0.38 0.33 (MO: 0.29)  -  
Controls 0.35 0.25 0.33 0.36 0.24  
p-value < 0.01 0.027* 0.017 0.006# 0.84  
 T677T genotype frequency   
MA 0.41 0.04 0.19 0.18 0.05  
MIG All 0.20 0.08 0.15 0.12 (MO: 0.09) -  
Controls 0.10 0.02 0.09  0.13  0.06  
p-value <0.0001 0.015* 0.006 0.03# 0.83  
OR¤ 6.5 5.7* 2.5 2.3# 0.89  
MA = migraine with aura; MO = migraine without aura; HA = headache; * all cases compared to controls; 
 # MA cases compared to MO cases; ¤ for the TT genotype compared to others 
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however, replicated by the same group in an independent case-control sample of 260 patients 
(Colson et al. 2004). Since multiple subgroup testing and small sample sizes can easily 
produce associations significant at the 5% level by chance alone, there is a possibility that 
these results are false positives. Nevertheless, the MTHFR and ESR1 genes are good candidate 
genes for migraine due to their function. Methylenetetrahydrofolate reductase catalyses the 
reduction of 5,10-methylenetetrahydrofolate to 5-methylenetetrahydrofolate and reduced 
activity of this enzyme leads to mild hyperhomocysteinemia (Frosst et al. 1995). On the other 
hand, the role of hormone receptors in migraine susceptibility has been suggested because the 
female preponderance among migraine patients could be due to the additional trigger of 
fluctuating female hormone levels during the menstrual cycle (Bousser 2004).  
Based on the information summarized above, we selected the MTHFR and ESR1 genes to be 
genotyped in our candidate gene study. In the previous positive studies concerning these 
genes only 1-2 SNPs were tested. This type of study design is not, however, suitable for 
evaluating the potential role of the studied gene in migraine susceptibility. Although the 
polymorphisms tested have been assumed to be functional, the observed association signal 
could as well be due to some other variant within the gene that is in partial LD with the 
studied SNP. To avoid this problem, we aimed at covering the whole genes with SNPs. 
Genotyping results were obtained from 6 MTHFR SNPs (gene size 19 kb) and from 24 ESR1 
SNPs (gene size >200 kb) with a mean distance of 3.8 kb in MTHFR and 13.6 kb in ESR1 
(Table 2 of study III). The SNPs had a minor allele frequency of 10-45% in our population. 
Since ~1800 samples were tested, more than 53,000 genotypes were produced with an 
average success rate of 98.6%. Based on the lack of discrepant genotypes among the duplicate 
samples the quality of our genotype data was considered to be high. The genotype 
distributions of all but two of the SNPs, rs746432 and rs3853248 located within the first exon 
and intron of the ESR1 gene, were in Hardy-Weinberg equilibrium (HWE). Interestingly, the 
genotype distributions of these two SNPs violated HWE only among patient samples. 
Although a careful examination of the genotyping results revealed no genotyping errors, we 
noticed that due to weak allele signals several potentially heterozygous genotypes had been 
rejected, providing a possible explanation for the observed HWE violation. On the other hand, 
a small number of HWE failures can be due to chance alone. Most of the genotyped MTHFR 
SNPs were in high LD (Figure 1 of study III) and thus produced redundant information. 
Several blocks of high LD were also identified in the ESR1 gene (Figure 1 of study III).  
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The main result of this study was that we were unable to replicate the previous association 
findings connecting the MTHFR C677T variant and the ESR1 G2014A variant with migraine. 
The genotype and allele frequencies of these SNPs did not differ between cases and controls 
in our population (Tables 23 and 24). Similarly, no association with the other MTHFR SNPs 
was seen. 
On the other hand, the minor alleles of five ESR1 SNPs located approximately 150-220 kb 
from the G2014A variant were slightly more common among cases than controls: the allele 
frequency comparison produced p-values of 0.008-0.067 (OR 1.15-1.21) and the genotype 
distribution comparison p-values of 0.007-0.034 (Table 25). Logistic regression analysis 
provided no evidence of an additive genetic model (OR for heterozygous individuals ~1) 
while the disease risk for individuals having two minor alleles was increased (Table 25). 
Haplotype association analysis was also performed and the overall haplotype distribution 
comparison with PHASE produced a p-value of 0.01. The haplotype formed by the minor 
alleles was found to be over-represented among cases while the haplotype formed by the 
major alleles was under-represented (Table 5 of study III). These results were, however, less 
significant than the single SNP association p-values. 
 
Table 24. Results of the MTHFR and ESR1 SNPs previously associated with migraine. 
 
  MAF (%)  p- OR (confidence Genotype frequencies (%) p-  
 SNP controls cases  value interval) controls  cases value  
       11 12 22  11 12 22   
 MTHFR 
C677T 
24 24  0.84 0.98  
(0.84-1.15) 
58 36 6  58 37 5 0.830  
 ESR1  
G2014A 
19 20  0.50 1.06  
(0.90-1.25) 
66 30 4  63 33 4 0.548  
                
 
Table 25. Results of the five ESR1 SNPs showing nominal association with MA.   
 Genotypes (N) 
 
ESR1 SNP  
MAF 
(%) 
p-
value OR 1 1 1 2 2 2 
p- 
value 
OR- 
Het* 
OR-
Hom# 
 rs6557170  cases 0.28 0.014 1.21 470 345 78 0.007 1.062 1.851 
  controls 0.24   502 347 45     
 rs2347867  cases 0.37 0.020 1.18 367 388 130 0.034 1.071 1.489  
  controls 0.33   391 386 93     
 
 rs6557171  cases 0.34 0.008 1.2 390 387 107 0.023 1.146 1.558  
   controls 0.30   426 369 75     
  rs4870062  cases 0.34 0.008 1.21 391 385 111 0.024 1.143 1.54  
   controls 0.30   434 374 80     
  rs1801132  cases 0.26 0.067 1.15 499 330 67 0.016 1.007 1.813  
   controls 0.23   513 337 38     
  * individuals with 1 2 genotype compared to those with 1 1 genotype; 
#  individuals with 2 2 genotype compared to those with 1 1 genotype 
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Since polymorphisms in the estrogen receptor could be specifically associated with migraine 
susceptibility in females, the association analysis was also performed for females and males 
separately. These subgroup analyses had, however, only a negligible effect on the results. 
Furthermore, since 114 out of 898 migraine patients studied did not fulfil all the IHS criteria 
for MA, a subgroup analysis excluding these individuals was conducted but this had no effect 
on the results either. 
2.2.2 Problems concerning candidate gene studies 
The aim of the genome-wide linkage analysis method used in study I is to localize a disease 
susceptibility locus somewhere in the genome without prior assumption of its location. In 
studies II and III, a different approach i.e. candidate locus/gene strategy was applied. This 
type of study setting is based on a hypothesis about the possible role of a gene in the 
pathophysiology of the disease. The drawback of this method is that the disease mechanism is 
only rarely so well understood that selecting the correct gene from the estimated 25,000 in the 
human genome would be easy. In this thesis, the studied genes were selected because of 
previous evidence connecting them with migraine. 
Other main issues concerning the experimental design of association studies are the selection 
of individuals and the SNPs to be genotyped. We used the distance between the SNPs as the 
selection criteria. An alternative approach could have been to use the so called htSNPs of the 
HapMap project (http://www.hapmap.org). However, there is only limited evidence of the 
usefulness of this approach in different populations.  
A poorly matched control group can produce spurious associations. In this study, neither the 
cases nor the controls originated from a particular part of Finland but rather represented the 
Finnish population as a whole. Thus, population stratification should not be a problem in this 
case-control sample. Furthermore, a lot of effort was put into selecting control individuals that 
matched the cases for both age and sex. Although these variables should not affect the allele 
frequency distributions, they might have an effect on the disease penetrance. It is possible, for 
example, that a higher proportion of healthy males than females carries the risk allele 
assuming that the penetrance of the allele is higher in females because of hormonal or other 
factors. By selecting patients so that most had a strong family history of migraine and all had 
at least one affected family member, we aimed at increasing the amount of genetic 
susceptibility factors among cases. Furthermore, only controls without a family history of 
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migraine were included in the study. This selection criteria should be optimal for providing 
evidence of association.  
3 ATP1A2 MUTATION IN THE FHM2 FAMILY 
3.1 Linkage analysis 
In study IV, we identified a three-generation Finnish pedigree with 11 affected FHM family 
members. At the time this project was started, the second locus for FHM had been assigned to 
chromosome 1q but contradictory results existed as to whether the correct area is 1q21-23 or 
1q25-31 (Ducros et al. 1997; Gardner et al. 1997). Furthermore, the FHM2 gene ATP1A2 had 
not then been identified. Thus our first aim was to study this family for linkage to the known 
FHM susceptibility regions on 19p13 and 1q21-31 (Joutel et al. 1993; Ducros et al. 1997; 
Gardner et al. 1997). The two-point LOD scores for chromosome 19p13 markers were clearly 
negative, suggesting a lack of involvement of this locus, whereas significant evidence of 
linkage was found at the 1q21-23 locus. The maximum two-point LOD scores for 
chromosome 1q markers are shown in Table 26. The highest two-point LOD score, 3.37, was 
obtained at four nearby markers D1S2343, D1S2635, D1S1679, and D1S2844 at θ = 0.00 
using a model in which the two family members with MO were considered as unaffected. The 
 
Table 26. Locations and two-point LOD scores for markers on 1q21-32.  
 Marker (location) Position (cM) LOD Score θ  
 D1S514 (1p12) 152.45 1.27 0.00 
 
 D1S2343 (1q21.3) 155.89 3.37 0.00 
 
 D1S2346 (1q21.3) 158.75 3.15 0.00 
 
 D1S305 (1q21.3) 155.89 2.60 0.00 
 
 D1S2635 (1q23.2) 158.75 3.37 0.00 
 
 D1S2707 (1q23.2) 168.52 3.07 0.00 
 
 D1S2705 (1q23.3) 170.84 0.69 0.00 
 
 D1S1679 (1q23.3) 170.84 3.37 0.00 
 
 D1S2768 (1q23.3) 172.93 0.90 0.00 
 
 D1S2844 (1q23.3) 175.03 3.37 0.00 
 
 D1S426 (1q23.3) 177.86 1.09 0.10 
 
 D1S433 (1q24.2) 184.21 1.09 0.10 
 
 D1S2815 (1q24.3) 188.85 1.87 0.08 
 
 D1S215 (1q25.2) 194.89 1.09 0.10 
 
 D1S422 (1q31.2) 205.40 0.37 0.22 
 
 D1S2745 (1q31.3) 212.44 0.37 0.22 
 
 D1S2655 (1q32.1) 216.82 0.07 0.30 
 
 D1S249 (1q32.1) 220.65 0.61 0.20 
 
 D1S2782 (1q32.2) 222.84 0.07 0.30 
 
 D1S2703 (1q32.3) 231.67 0.14 0.30 
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markers covering the 1q31-32 locus produced only slightly positive LOD scores (Table 26). 
Unfortunately, the haplotype shared by all affected individuals of this pedigree extended from 
the most proximal marker studied, D1S514, to marker D1S2844 thus spanning at least 23 cM. 
As a result we were unable to refine the 1q21-23 FHM2 candidate region. 
3.2 Mutation screening 
The 1q21-23 area contained several potential candidate genes. We decided to screen one of 
them, KCNN3, coding for a small-conductance calcium-activated potassium channel SK3, for 
mutations. Small-conductance calcium-activated potassium channels (SK channels) modulate 
excitability in many cell types, including neurons, where they contribute to the after-
hyperpolarizations that dynamically control the frequency of spontaneous rhythmic action 
potentials. Furthermore, these channels have been shown to be selectively coupled to the 
Cav2.1 channels, mutations of which cause FHM1 (Womack et al. 2004). Four mammalian 
SK channels (SK1-4, encoded by KCNN1-4) have been cloned, of which KCNN3 is expressed 
in brain, striated muscle and lymphoid tissues (Kohler et al. 1996; Joiner et al. 1997). This 
gene
 
consists of eight exons spanning over 163 kb and contains two intragenic N-terminal 
CAG-repeats of which the second is longer and highly variable in humans, similar in size and 
variability to that of the CACNA1A gene (Chandy et al. 1998; Sun et al. 2001). However, no 
potential mutations were detected in the promoter region or in the exons of this gene and only 
common, short alleles at the polymorphic CAG repeat were observed. 
After the Italian migraine group observed that ATP1A2 mutations are the cause of FHM2 (De 
Fusco et al. 2003), we screened this gene and identified a heterozygous single nucleotide 
change A1033G in exon 9 leading to a T345A missense mutation. None of the studied 132 
Finnish control individuals had this A1033G change. In addition to this disease-associated 
mutation, 11 other polymorphisms, ten of which were intronic and one a synonymous exonic 
nucleotide change, were identified in the proband (Table 1 of study IV). Allele frequency 
information of only one of these sequence variants was available from the dbSNP database 
(http://www.ncbi.nlm.nih.gov/projects/SNP). Thus, to make certain that none of the other 
variants represented the actual disease-causing mutation, the allele frequencies of these 
polymorphisms were estimated using pooled DNA samples of the 132 control individuals. All 
the nucleotide changes were relatively common (minor allele frequencies 7-44%) and thus 
could not be regarded as potential mutations in a Mendelian trait. 
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3.3 Genotype-phenotype comparison 
The T345A missense mutation was detected in 12 family members, ten of which had FHM 
attacks while two (aged 19 and 10) were asymptomatic at the time of this study (Figure 14). 
Recently, however, the younger of these two individuals has started having attacks. 
Figure 14. Pedigree of the FHM2 family. + = Presence of mutation; - = absence of mutation. 
 
It has been suggested that FHM could be seen as a model for studying MA and MO although 
the FHM attacks are clearly more severe than the attacks of these more common forms of 
migraine (Ophoff et al. 1994). On the other hand, FHM families often include patients with 
MO and MA and FHM patients can also have attacks classified as non-hemiplegic migraine 
(Ophoff
 et al. 1994; Ophoff et al. 1996a). The occurrence of MA and MO in FHM probands 
and their first degree relatives has been investigated (Thomsen et al. 2003). The relative risk 
of MA was found to be about 7-fold both among FHM probands and their affected relatives 
and about 2-fold in non-FHM-affected relatives. No increased risk of MO was found and the 
authors concluded that sharing of genetic predisposing factors between FHM and MO is 
unlikely (Thomsen et al. 2003). In accordance with these results, three patients belonging to 
the FHM family investigated in study IV had MO but were not ATP1A2 mutation carriers. 
3.4 Pathophysiology of FHM 
The structure of the Na+,K+-ATPase α2 subunit and the thus far identified mutations are 
presented in Figure 5 (page 60). The T345A mutation, like most FHM2 mutations, is located 
in the large intracellular M4-5 loop that is critical for the correct function of the ATPase. At 
the cytosolic border of the transmembrane region M4 there is a characteristic amino acid 
sequence PEGL involved in energy transduction followed by a highly conserved 40 amino 
acids long sequence and a phosphorylation motif DKTGTLT (Figure 2 of study IV) (Moller et 
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al. 1996). The threonine 345 is situated in the middle of this conserved 40 amino acid 
connecting sequence.  
The functional consequences of the first two published FHM2 mutations, L764P and W887R 
were evaluated using a robust in vitro cell growth phenotype test (De Fusco et al. 2003). 
Since Na+,K+-ATPase activity is essential for cell viability, blocking of the endogenous 
enzyme in cells transfected with the mutant ATPase leads to cell death if the mutant indeed 
abolishes the enzyme function. The L764P and W887R mutant enzymes did not support the 
growth of cultured cells and thus a haploinsufficiency effect caused by loss of function of the 
mutated Na+,K+-ATPase was suggested to be the disease mechanism of FHM2 (De Fusco et 
al. 2003).  
We have studied the functional effects of the T345A mutation identified in this thesis in 
collaboration with a research group from the University of Montreal, Canada (Segall et al. 
2004). Interestingly, the total loss of function suggested by the Italian group was not seen 
with this mutation. On the contrary, growth of the mutated cells was normal and the enzyme 
was shown to be fully active. However, detailed kinetic analysis revealed differences between 
the wild type and T345A mutation containing enzymes. Most importantly, the affinity of the 
mutant enzyme for extracellular K+ was decreased ~2-fold (Segall et al. 2004). It has been 
shown that the N-terminal half of the M4-M5 loop has an important role in cation selectivity 
although the actual cation binding sites are located in the transmembrane regions (Blostein
 et 
al. 1999). The increased hydrophobicity created by the T345A mutation, located near the 
cytosolic border of the transmembrane region M4, affects the cation-binding pocket of the 
enzyme thus explaining the lowered affinity for extracellular K+ (Segall
 et al. 2005). 
Very recently, our collaborators published a kinetic analysis of two other FHM2 mutations 
(Segall
 et al. 2005). Similarly to the T345A mutation identified in this thesis, the mutations 
R689Q and M731T originally identified by the Dutch migraine group (Vanmolkot
 et al. 2003) 
were shown to lead to functional but kinetically altered Na+,K+-ATPase subunits. In the case 
of these mutations, the reduced enzyme activity was, however, due to decreased catalytic 
turnover of the Na+,K+-ATPase (Segall
 et al. 2005).  
Since the first FHM2 mutations were identified, it has been speculated as to how mutations in 
the CACNA1A and ATP1A2 genes, expressed in distinct cell types (neurons and astrocytes), 
can lead to practically identical FHM phenotypes. It is clear that increased Ca2+ influx through 
mutant Cav2.1 channels (FHM1) might lead to hyperexcitability due to increased release of 
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the excitatory neurotransmitter, glutamate (Turner et al. 1992; Moskowitz et al. 2004). On the 
other hand, astrocytes are known to have an important role in the termination of synaptic 
activity by removing glutamate and K+ from the synaptic cleft with the help of the Na+,K+-
ATPase (FHM2). It is likely that the ATP1A2 mutations slow the removal of K+ from the 
extracellular space. An increased extracellular K+ concentration can either directly make the 
brain more susceptible to CSD or slow down the Na+ gradient-driven glutamate transporter 
(Moskowitz et al. 2004; Segall et al. 2004). Indeed, blocking of Na+,K+-ATPases has been 
shown to induce spreading depression-like depolarization in rat hippocampus (Balestrino et 
al. 1999). The recently identified FHM3 gene, the neuronal voltage-gated sodium channel 
SCN1A (Dichgans et al. 2005), and the finding of a mutation in the glutamate transporter 
EAAT1 gene SLC1A3 in a patient with a complex neurological phenotype (Jen et al. 2005) fit 
well into this idea of FHM pathophysiology. The SCN1A mutation identified was shown to be 
of gain of function type and thus lead to excessive firing of neurons while the SLC1A3 
mutation markedly decreased the glutamate uptake capacity. 
Interestingly, Na+,K+-ATPase α2 isoforms are specifically localized in plasma membrane 
microdomains that overlie endoplasmic reticulum (Juhaszova and Blaustein 1997). Thus they 
seem to have a role in the regulation of local intracellular Ca2+ concentration via Na+/Ca2+ 
exchangers that are also localized in these microdomains (Golovina et al. 2003). 
Consequently, reduced Na+,K+-ATPase α2 activity might elevate local Na+ concentration, 
promote Ca2+ entry via Na+/Ca2+ exchangers and thus amplify Ca2+ signalling. This 
alternative FHM2 disease mechanism is, however, less likely because ATP1A2 expression 
within the nervous system seems to be astrocyte-specific in adults (Moseley et al. 2003).  
4 THE CACNA1A MUTATION CAUSING EA-2 IN A FINNISH FAMILY  
4.1 Identifying the CACNA1A mutation  
In study V, we identified a multi-generation Finnish family with several individuals having 
symptoms characteristic of EA-2. All available family members were genotyped at three 
microsatellite markers flanking the CACNA1A region. As significant evidence of linkage to 
this area was obtained (maximum two-point LOD 4.48), CACNA1A was sequenced. We 
identified a heterozygous A to G nucleotide change at the 3’ acceptor splice site of intron 36 
(IVS36-2A>G substitution) in the proband and her affected mother and demonstrated that the 
mutation segregated with the EA-2 phenotype in the family (Figure 15). No other potential 
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disease-causing mutations were found. There were no carriers of this nucleotide change 
among 132 control individuals, further supporting its role as a pathogenic mutation. 
We have subsequently identified three other Finnish EA-2 patients unrelated to the family 
segregating the IVS36-2A>G mutation. These patients are either sporadic or have only one 
affected family member, and are thus unsuitable for linkage analysis. These patients do not 
carry the IVS36-2A>G mutation and thus this mutation does not seem to represent a founder-
mutation, as might be expected. Although no systematic study aimed at identifying all Finnish 
EA-2 patients has been carried out, the number of patients that we are aware of is smaller than 
could be assumed. This is a typical situation for many recessive traits frequent in Caucasian 
populations, although for dominant traits the situation is less evident. 
4.2 Genotype-phenotype comparison 
In total, 22 mutation carriers were identified in the extended family (Figure 15). Of these, 17 
were affected, two had extreme alcohol sensitivity as their only symptom and three were 
asymptomatic at-risk subjects, aged 8, 15, and 65. The oldest of these mutation carriers was 
telephone interviewed for a second time but no history of any episodic or permanent 
neurologic dysfunction was disclosed. This is, however, not surprising since incomplete 
penetrance of EA-2 has been previously demonstrated (Denier et al. 1999). The other two 
healthy mutation carriers are still too young to draw any conclusions concerning their future 
affection status. Interestingly, among the more distant family members one described 
symptoms indistinguishable from the affected individuals but did not have the mutation. It is 
possible, although unlikely, that this phenocopy carries some other predisposing genetic 
variant. Alternatively, the social environment, i.e. witnessing the attacks of other family 
members, might somehow predispose her to imagining symptoms that mimic the disease. 
The clinical features of patients with different types of CACNA1A mutations are widely 
overlapping. Both EA-2 and FHM patients may develop progressive ataxia and EA-2 patients 
often have concomitant symptoms that fulfill the diagnostic criteria for migraine. In 
accordance with this, six EA-2 patients of the family studied by us were diagnosed as having 
MO as well. However, in these individuals migraine headache was not part of the EA-2 
attacks. One additional patient had symptoms fulfilling the criteria for basilar migraine during 
the EA-2 attack. Furthermore, two healthy family members were also diagnosed as having 
MO and thus migraine appeared to segregate independently of the CACNA1A mutation in this 
family. 
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Figure 15. Pedigree of the EA-2 family. +  = Presence of mutation; -  = absence of mutation.  
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4.3 Disease mechanism 
The IVS36-2A>G mutation destroys the highly conserved AG acceptor splice site consensus 
sequence of intron 36. It has been estimated that 99.24% of all mammalian splice site pairs 
are GT-AG and practically all of the other possible pairs also contain A in the -2 position 
(Burset et al. 2000). Several other CACNA1A splice site mutations have been published, but 
all of them affect the donor splice site (Table 13, page 52). In principle, splice site mutations 
most often lead either to skipping of an exon or to cryptic splice site usage (Krawczak 1992). 
Splice site prediction programs can be used to predict such effects. We utilized this approach 
to determine whether the DNA sequence around the IVS36-2A>G variant included any 
potential cryptic splice sites and, indeed, a cryptic acceptor splice site was found 65 bp 
downstream of the mutation site in exon 37 (Figure 16). This cryptic splice site produced a 
splice site score of 0.81, while the wild type has a score of 0.98 and the mutated site was not 
recognized at all. Based on these results, one likely consequence of the IVS36-2A>G 
mutation is the utilization of this cryptic splice site and a subsequent frameshift producing a 
premature STOP-codon at nucleotides 5891-5893 of CACNA1A (Figure 16). 
Figure 16. Predicted effect of the IVS36-2A>G mutation on CACNA1A mRNA splicing. 
On the other hand, altered mRNA splicing should also be confirmed experimentally. Brain 
tissue samples of deceased patients would be ideal for this purpose, but since these are not 
available, we attempted to investigate the mutated CACNA1A mRNA using RNA isolated 
from lymphocytes. Although we were able to reverse transcribe and amplify the CACNA1A 
mRNA from peripheral blood lymphocytes of control individuals, the results were 
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inconsistent. The nested PCR amplification of the blood samples with inner primers specific 
for exons 35 and 39 resulted in several amplification products of different sizes that were 
verified by sequencing. In one product, all the exons 35 through 39 were present, in one 
product exon 37 was missing and in one product both exons 36 and 37 were missing. The 
number of splice variants varied between individuals and between samples from the same 
individual. This is likely to reflect stochastic differences in the amplification of a very low 
number of target molecules. Since the results of healthy individuals were so conflicting we 
concluded that comparing these with those of patients would not be reasonable. Thus the 
consequences of this as well as most of the other described EA-2 splice site mutations are 
currently unclear. However, after conducting this study, minigene constructs have been 
successfully used in determining the splicing defect from two intronic EA-2 mutations (Wan
 
et al. 2005a). It would be interesting to apply this same method to the IVS36-2A>G mutation. 
We can conclude that the IVS36-2A>G mutation most probably produces a truncated or 
aberrant Cav2.1 α1 subunit, like the majority of previously identified EA-2 mutations. Based 
on electrophysiological studies it is likely that all EA-2 mutations, regardless of their type, 
lead to either complete or considerably reduced Ca2+ current density or channel activity 
(Guida et al. 2001; Jen et al. 2001; Wappl et al. 2002; Imbrici et al. 2004; Spacey et al. 
2004). Thus a loss of function of Cav2.1 channels can be considered as the underlying disease-
causing mechanism but the details of this are still unknown. In principle, either a simple 
haploinsufficiency of functional channels or a dominant-negative effect could be the primary 
cause. Since the pore-forming part of Ca2+ channels consist of only one protein subunit, the 
dominant negative effect is not as likely as in the case of K+ channels, which are tetramers. 
Competition for auxiliary subunits or regulatory proteins could be hypothesized although 
recent results propose a mechanism mediated by misfolding of the full-length channel 
proteins due to interaction with the truncated channels (Page et al. 2004). However, this is 
still controversial since most of the other EA-2 mutations studied do not seem to affect 
transcription and translation processes or to cause degradation of the truncated proteins 
(Guida et al. 2001; Jen et al. 2001; Wappl et al. 2002). Thus, if haploinsufficiency is the 
underlying disease mechanism it is more likely to be due to either impaired channel function 
or inefficient targeting to the cell membrane than to reduced production of channels.  
The IVS36-2A>G mutation is located in the part of the gene that codes for the intracellular C-
terminus of the Cav2.1 channel while most of the previously published CACNA1A truncation 
mutations are predicted to prevent formation of at least one of the transmembrane regions of 
RESULTS AND DISCUSSION 
 
 101
the Cav2.1 subunit. Since no evidence of differences between the disease phenotype produced 
by these C-terminal truncations and the disease phenotype caused by more prematurely 
truncating mutations exists, the C-terminus must have an important role in the correct 
function of the Cav2.1 channel if the truncated proteins truly are stable and correctly targeted 
to the plasma membrane. The C-terminal part of the channel contains several important 
regulatory sites, including a β subunit interaction domain, a G-protein interaction site, an EF-
hand-like domain, an IQ-like motif and a calmodulin binding domain, the three latter of which 
are involved in Ca2+-dependent inactivation and facilitation of the channel (Catterall 2000; 
Lee et al. 2003; Chaudhuri et al. 2004). 
Making things even more complicated, at least seven sites for alternative splicing have been 
identified in CACNA1A and one of them involves splicing of exon 37 (Soong et al. 2002). 
There are two mutually exclusive alternatives of this exon (exons 37A and 37B) coding for 
72% homologous amino acid strands and thus producing two variants of the EF-hand motif 
(Trettel et al. 2000). These channel splice variants have different functional properties, the 
distribution of which is variable across brain regions (Chaudhuri et al. 2004). Furthermore, 
expression of these splice variants also seems to be developmentally regulated since >90% of 
the Cav2.1 channels in fetal brain contain the EF-B variant while the distribution is nearly 
equal in adulthood (Chaudhuri et al. 2004). It is possible that the IVS36-2A>G mutation does 
not lead to an aberrant splicing in the CACNA1A transcripts that contain exon 37B, which 
would mean that less than 50% of the channels produced are abnormal in mutation carriers. 
Interestingly, a similar situation is expected in two recently identified families with mutations 
in exon 37A producing a premature STOP-codon Y1845X within this exon (Kors 2004).  
5 MIGRAINE PATIENTS AND THEIR CLASSIFICATION 
A careful diagnosing and subclassification procedure is essential for genetic studies of 
complex diseases and can be especially demanding when no laboratory or other diagnostic 
test is available as is the case with migraine. This thesis work is part of the larger “Finnish 
Migraine Project” in which the main emphasis has been in collecting families segregating 
migraine with aura. Because of the large number of families and patients needed for complex 
disease studies, the cost-effectiveness of the recruitment and diagnosing procedures has been 
especially important. Most of the index cases have been recruited by neurologists working in 
clinics specialized for headache disorders. The diagnoses of the other family members have 
mainly been based on questionnaires and could thus be regarded as less reliable. However, the 
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questionnaire used has been validated by comparing the agreement between questionnaire-
based and interview-based diagnoses of 200 individuals and was shown to have a sensitivity 
of 99% and a specificity of 96% for migraine in general (Kallela
 et al. 2001a). The response 
rate has also been good despite the extensiveness of the questionnaire. Since the recruitment 
of the index cases has been clinic-based, this patient sample does not represent the whole 
population of migraine patients, but rather the more severe end of the spectrum. Furthermore, 
we have concentrated on collecting families with several affected individuals. Although not 
very suitable for epidemiological studies, this is, however, exactly what is needed for genetic 
analyses. 
The International Headache Society has provided a set of diagnostic criteria based on which 
diagnosing headache patients, at least for scientific purposes, is performed (Headache 
Classification Committee of the International Headache Society 2004). This has been shown 
to work well with most of our patients. However, in real life there are always patients that are 
difficult to classify. In the Finnish Migraine Project, the use of an additional category called 
“migraine with unclassified aura” has been found to be practical. This category comprises 
patients that, at least based on the questionnaire, do not completely fulfill the criteria for aura 
symptoms while definitely have migraine. According to the IHS criteria, these patients should 
be classified as having migraine without aura. This could, however, lead to potential wasting 
of useful genetic information if at least some of the underlying susceptibility loci are shared.  
Another practical problem is the diagnosing of patients with hemiplegic migraine. The IHS 
criteria (2004) for hemiplegic migraine demand that the aura phase must include motor aura 
consisting of unilateral motor weakness or paralysis. It is relatively common that one or a few 
patients within large MA families fulfill these criteria and should thus be classified as having 
sporadic hemiplegic migraine. However, is has been consistently shown that these sporadic 
patients very rarely have mutations in the FHM genes CACNA1A and ATP1A2 (Terwindt et 
al. 2002; Jen et al. 2004b). Similarly, we were unable to identify mutations when we 
sequenced the CACNA1A in index cases of families with hemisensory and/or motoric 
symptoms showing nominal evidence of linkage to chromosome 19. On the other hand, the 
phenotype of the FHM2 family studied in this thesis was clearly more severe with several 
patients that had been hospitalized during their attacks. Thus, for a geneticist, it seems that the 
FHM patients worth screening are those that belong to families where most of the migraine-
affected individuals have hemiplegic symptoms. However, these kind of families seem to be 
very rare in Finland as well as in other countries.  
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CONCLUDING REMARKS AND FUTURE PROSPECTS 
Unraveling the genetic susceptibility factors of complex diseases has become the major goal 
of human genetic research but progress in this field has been relatively slow thus far. 
However, now it seems that convincing examples of polymorphisms implicated in the 
etiology of common diseases are starting to gradually mount. Compared with many other 
diseases with complex inheritance, the molecular genetics of migraine has been studied for a 
relatively short time. Furthermore, there are only a handful of research groups worldwide that 
are trying to tackle the genetics of this debilitating headache disorder. Therefore, it is not 
surprising that genetic susceptibility factors for the common forms of migraine have not yet 
been identified. 
The main achievement of this thesis was the identification of the susceptibility locus for MA 
on chromosome 4q. The genome-wide scan we conducted was the first of its kind on 
migraine. Since then, several other whole genome linkage analyses have been performed, and, 
encouragingly, the 4q locus has been replicated in the Icelandic population. In spite of this 
replication and the truly significant evidence of linkage we saw, narrowing of the critical 
susceptibility region and identification of the causative gene variant(s) has turned out to be 
extremely challenging. Consequently, alternative approaches have been used in this thesis. 
One of the central ideas has been to utilize our exceptionally large migraine family and patient 
samples to investigate the role of susceptibility loci and genes previously associated with 
migraine. Using this approach it became obvious that the chromosome 19p13 locus important 
in FHM does not seem to be a major player in the susceptibility of common forms of 
migraine. This is a noteworthy finding, especially in view of the considerable previous 
controversy surrounding this subject. 
Candidate gene studies have become popular in complex disease research. However, the 
presumably small increase in disease risk due to the at-risk genotype has to be taken account 
when planning these studies and thus large case-control sample sets are needed. In most of the 
candidate gene studies on migraine, only a couple of hundred patients have been studied. 
Thus planning and carrying out the case-control project comprising 1798 individuals can be 
regarded as a further achievement of this thesis, particularly since this sample will be used in 
the future for several other purposes.  
It is possible that our limited understanding of the etiology of migraine is the main problem in 
these genetic studies. The patient is diagnosed as having migraine if an adequate number of 
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symptoms listed in the IHS criteria are present. Some of these criteria are, however, optional 
and only rarely do the patients fulfil all of them. For these reasons, we have hypothesized that 
it might be possible to define the phenotype by investigating these symptoms one at a time 
instead of using the end-point migraine diagnosis as the affection status. This trait component 
analysis using the genotypes of our original genome-wide scan is currently in progress and it 
seems that new susceptibility loci can be identified using this approach. 
The pathophysiology of migraine is still very poorly understood. Identification of even one 
susceptibility gene might open up totally new perspectives on the cellular processes involved 
in this complex disease and thus facilitate the development of more effective treatments and 
more precise diagnostic applications. The quest for migraine genes has only just started but 
hopefully the genetic approach and this thesis itself will be useful in revealing the primary 
pathways of this debilitating disease. 
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